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SUMMARY 
INTRODUCTION 
Approximately 9% of all new malignant diagnoses in the UK are due to 
haematological malignancies. The acute and chronic leukaemias constitute 
2.5 % of all cancers and leukaemia is the 12th most common cancer 
registered in the UK. Approximately 7 000 people are diagnosed with the 
disease and more than 4 300 people die from leukaemia in the UK each 
year. As such, they have an important impact on the health of the public and 
represent a significant cost to the health care budget. 
AIMS AND OBJECTIVES 
The research presented in this thesis firstly aimed to quantify the incidence of 
and mortality from the acute and chronic leukaemias in the UK, and to define 
their associations with gender, age, socioeconomic class, calendar time, and 
geographic region of residence. A further aim was to determine whether the 
use of non-steroidal anti-inflammatory drugs (NSAIDs) had a protective effect 
on the incidence of and mortality from these leukaemias, as has been shown 
to be the case for a number of other cancers. Finally, the impact of alcohol 
consumption on leukaemia incidence and mortality was investigated. A 
surprising result from the incidence and mortality studies was that survival in 
AML, but not other leukaemias, was worse with increasing socioeconomic 
III 
deprivation. This generated an additional hypothesis surrounding potential 
class bias in bone marrow transplantation in these patients, a new area that 
was also investigated, in addition to the original aims and objectives of the 
research. 
METHODS 
Both general practice and hospital data were used to conduct these 
population-based studies. 'The Health Improvement Network' (THIN) general 
practice dataset was used to conduct the cohort studies of incidence and 
mortality, as well the case-control studies investigating non-steroidal anti-
inflammatory drug use and alcohol consumption, as potential risk factors for 
leukaemia. Hospital Episode Statistics (HES) data were used to investigate 
the additional hypothesis generated by results of the incidence and mortality 
studies, which showed that mortality in AML patients worsens with increasing 
socioeconomic deprivation. 
RESULTS 
A total of 4162 cases of leukaemia were identified, 2314 (56%) of whom were 
male. The overall incidence of leukaemia is 11.25 per 100 000 person-years 
and is independent of socioeconomic class. Median survival from leukaemia 
is 6.58 years and mortality increases with increasing age at diagnosis. The 
prognosis in AML is dismal and worsens with increasing socioeconomic 
deprivation, a phenomenon not seen in other leukaemias. 
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Bone marrow transplantation declines with increasing socioeconomic 
deprivation (p for trend <0.01). Patients with AMl in the most deprived 
socioeconomic quintile are 40% less likely to have a bone marrow 
transplantation than those in the most advantaged socioeconomic class (OR 
0.60, p<0.01, 95% C.I. 0.49 - 0.73), even after adjusting for gender, age at 
diagnosis, year of bone marrow transplantation and co-morbidity. 
The risk of leukaemia overall appears to increase marginally with increased 
use of NSAIOs prior to diagnosis. This is not seen when individual leukaemia 
subtypes are examined, however, except perhaps in Cll where patients who 
had received 2-5 prescriptions/year were 29% more likely to be diagnosed 
with Cll than those who had not had any NSAIO prescriptions (O.R. 1.29, 
p=0.05, 95% C.I. 1.00 - 1.67). There is no statistically significant association 
between exposure to NSAIOs prior to leukaemia diagnosis, and survival. 
There is no statistically significant association between alcohol consumption 
and risk of developing leukaemia overall, nor with any of the leukaemia 
subtypes studied here. Alcohol consumption is associated with a lower risk of 
death in leukaemia overall (HR 0.83, p=0.04, 95% C.I. 0.69 - 0.99), as well 
as in All (HR 0.14, p<0.01, 95% C.I. 0.04 - 0.44) and Cll (HR 0.71, p=0.02, 
95% C.1. 0.53 - 0.96), when compared to those who had not consumed any 
alcohol. 
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CONCLUSIONS 
The age and gender patterns of leukaemia incidence and mortality in the 
subtypes studied here are consistent with the published literature. Time 
trends in incidence and mortality must be interpreted with caution due to 
changes in case ascertainment and classification of leukaemia subtypes over 
time. The increase in incidence of All, Cll and AMl over the past 20 years 
has not been accompanied by improvements in mortality with time. Whether 
the increase in incidence over time is real or due to better recording, or both, 
remains unclear. 
Similar mortality across socioeconomic gradients in the leukaemias studied 
here suggests equal access to and uptake of services. The exception to this 
is in AMl, where poorer survival among AMl patients from lower 
socioeconomic classes is seen. AMl patients from lower socioeconomic 
classes are less likely to undergo bone marrow transplantation than their 
better off counter-parts and this phenomenon is independent of co-existing 
illness. 
The use of NSAIDs does not reduce the risk of developing leukaemia, nor do 
they improve survival. This research found no statistically significant 
association between alcohol consumption and incident leukaemia, although 
alcohol consumption was found to be associated with a reduced risk of death 
from leukaemia overall, All and ClL. Better recording of alcohol 
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consumption in THIN will enhance its value in investigating associations of 
alcohol consumption and disease or other outcomes. 
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1 INTRODUCTION 
Approximately 9% of all new malignant diagnoses in the UK are due to 
haematological malignancies 1. The acute and chronic leukaemias constitute 
2.5 % of all cancers and leukaemia is the 12th most common cancer 
registered in the UK1. Approximately 7 000 people are diagnosed with the 
disease and more than 4 300 people die from leukaemia in the UK each 
year1. As such, they have an important impact on the health of the public and 
represent a significant cost to the health care budget. 
This introductory chapter firstly summarizes the clinical features of the acute 
and chronic leukaemias. A literature review then follows discussing what is 
already known about the epidemiology of leukaemia as it pertains to gender, 
age, geographical region, socioeconomic class and trends over time. The 
associations of these factors with both the incidence of and mortality from 
leukaemia are discussed. The available literature on aetiological factors 
implicated in leukaemia incidence and mortality is then reviewed. The aims 
and rationale of this project are then presented, and the chapter concludes 
with an outline of the contents of subsequent chapters. 
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1.1 CLINICAL FEATURES 
1.1.1 Acute Lymphoblastic Leukaemia (ALL) 
Pathogenesis. ALL results from a clonal proliferation of B or T blast cells, in 
the earliest stages of lymphoid maturation. Blast cells infiltrate the bone 
marrow and are also present in the peripheral blood2. Normal cell 
differentiation is shown in Figure 1.1 and a normal peripheral blood film is 
shown in Figure 1.2. 
Clinical findings. Clinical manifestations are mainly those of bone marrow 
failure secondary to bone marrow infiltration. The symptoms include: 
tiredness; bruising and bleeding; bacterial infections; bone pain; enlarged 
lymph nodes; headache and vomiting. Physical findings include: pallor; 
purpura and bruising; lymphadenopathy; hepatosplenomagaly; bone 
tenderness and fever. 
Laboratory features. Anaemia; leucopaenia; thrombocytopaenia; circulating 
blast cells on blood film (marked with '1' in Figure 1.3) and bone marrow 
infiltration with blast cells are common laboratory findings. Cytogenetic 
analyses are also conducted as this provides important prognostic 
information upon which treatment regimes are based. 
12 
Treatment. ALL treatment regimes used in adults and children depend on 
risk stratification, which incorporates an assessment of several prognostic 
factors in each case. Chemotherapy is the mainstay of treatment and is 
carried out in 4 phases: (1) induction, which clears the bone marrow of blast 
cells and replaces them with normal cells; (2) consolidation, which further 
reduces the leukaemia cell burden; (3) Central Nervous Systems (eNS) 
prophylaxis, which aims to prevent CNS involvement; and (4) maintenance 
therapy, which is given over 2-3 years. Patients who are deemed to be in 
poor risk categories at presentation, as well as those who relapse, are 
considered for allogeneic bone marrow transplantation2 . 
Figure 1.3: ALL Peripheral Blood Film 
1 
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1.1.2 Chronic lymphocytic leukaemia (Cll) 
Pathogenesis. Cll is characterised by the accumulation of small mature B 
lymphocytes in the peripheral blood, bone marrow and secondary lymphoid 
organs3 . 
Clinical features. While most patients are asymptomatic at diagnosis, those 
with symptoms may present with: tiredness; bleeding and bruising; bacterial 
infections; night sweats; and/or fever and weight loss. lymphadenopathy and 
splenomegaly are the main physical findings. Patients may have associated 
autoimmune conditions such as autoimmune haemolytic anaemia (AIHA) and 
autoimmune thrombocytopenic purpura (ATP)2. 
Laboratory features. These include monoclonal lymphocytosis; anaemia; 
thrombocytopaenia; bone marrow infiltration and hypogammaglobulinaemia. 
Peripheral blood film shows small mature lymphocytes with fragile 
membranes to the extent that they are damaged during the preparation of 
slides, leading to their appearance as 'smudge cells', as seen in Figure 1.43 . 
Cytogenetic investigations are also undertaken and provide some prognostiC 
information2. 
Treatment. While asymptomatic patients do not require treatment, 
progressive disease is treated with chemotherapy. Antibody therapy is 
14 
sometimes combined with chemotherapy, and bone marrow transplantation 
is sometimes undertaken in younger patients2. 
Figure 1.4: ell Peripheral Blood Film 
© commons.wikimedia.org 
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1.1.3 Acute Myeloid Leukaemia (AML) 
Pathogenesis. AML is a clonal disorder of myeloid precursor cells that leads 
to infiltration of the bone marrow with immature cells. This, in turn, results in 
impaired neutrophil, platelet and red cell production. Blast cells also appear 
in the peripheral blood2 . 
Clinical features. Again, symptoms and signs of bone marrow failure, as 
described above, occur. Blast cell infiltration of other organs can also occur, 
causing gum hypertrophy, skin lesions, lymphadenopathy and splenomegaly. 
Laboratory features. Anaemia, thrombocytopaenia, disseminated 
intravascular coagulopathy (DIC), leucocytosis, leucopaenia and blast cells in 
the bone marrow (large, darkly stained cells seen in the centre of Figure 1.5) 
are among the laboratory features. Cytogenetic features may again provide 
prognostic information. 
Treatment. There are 3 main components to treatment: (1) intensive 
chemotherapy to induce remission; (2) supportive care, which is inevitably 
required to manage the neutropaenia and mucosal inflammation that follows 
chemotherapy; and (3) bone marrow transplantation for patients in poor risk 
disease groups and for those who have relapsed2 . 
16 
Figure 1.5: AML Bone Marrow 
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1.1.4 Chronic Myeloid Leukaemia (CML) 
Pathogenesis. CML is a clonal disease in which a genetically altered stem 
cell proliferates, generating a population of differentiated cells that gradually 
replaces normal haemopoesis and expands the total myeloid mass4 . 
Clinical features. Symptoms include: fatigue; weight loss; sweats and 
anorexia, while pallor and splenomegaly are the most common physical 
findings. 
Laboratory features. Laboratory findings include: anaemia; leucocytosis; 
abnormal platelet counts; myelocytes, metamyelocytes and basophils in the 
peripheral blood (see Figure 1.6); and hypercellular bone marrow with 
increased white blood cell production. 
Treatment. Treatment entails chemotherapy, which reduces the white cell 
count to normal; a-interferon which also controls the blood count; and bone 
marrow transplantation, which is the only known curative therapy for CML2. 
18 
Figure 1.6: CML Blood Film 
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1.2 LITERATURE REVIEW 
1.2.1 Search Strategy 
A search of the available peer-reviewed literature was conducted at the start 
of this project to identify publications examining the epidemiology of 
leukaemia. The following three databases were searched as far back as 
1950: CINAHL, EMBASE and MEDLINE. The electronic resource 'eLibrary 
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Gateway' of the University of Nottingham Library was used to access 
publications. The search terms '(Ieuk$ AND epidemiology) were used, 
producing 361 results. Publications were then limited to those in English, and 
those applicable to humans, leaving 242 publications. After removing 
duplicates, 164 remained for review. An additional search using the terms 
'(poverty AND leuk$), was also conducted, and limited in the same way. This 
produced an additional 95 publications. Finally a third search, of the terms 
'((socioeconomic AND deprivation) AND leuk$)' was conducted. This search 
was also limited to English language publications and applicability to 
humans, and produced 4 additional results once duplicates were removed. A 
total of 263 publications were therefore reviewed and the relevant ones are 
summarised below. 
Publications reporting the associations of gender, age, socioeconomic class, 
trends over time and geographic region, with incidence and mortality are 
discussed first, and these are presented by leukaemia sub-type. A summary 
of the literature as it pertains to a range of environmental factors suspected 
of being of aetiological importance in leukaemia then follows. 
1.2.2 Results 
1.2.2.1 ALL 
INCIDENCE. ALL is the commonest childhood cancer, but it may present at 
any age2 . Incident ALL is believed to show a slight male preponderance and 
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there is wide regional variation in its incidence across the world5 6. Although a 
registry-based study specifically examining sex ratios and risks of 
haematological malignancies, found no gender differences in children under 
10 yrs, the overall incidence of ALL in the UK was greater in men than 
women
7
. Another later UK study of children aged 0-14 years also found a 
male excess in ALL incidence, although the statistical significance of the 
gender difference was not tested8 . A recent study of ALL incidence among 
teenagers and young adults in England found neither an association with 
socioeconomic class, nor significant regional variation in incidence within the 
UK9. This was consistent with findings from a case-control study of 0 to 14 
year olds in the UK, which also showed no association with socioeconomic 
class 10. Reported trends over time suggest that annual increases until about 
two decades ago were followed by a subsequent plateau in incidence in 
children6 11. 
MORTALITY. The prognosis of ALL is better in girls than boys, and better in 
children than adults, with around 70% of children and 40% of adults surviving 
long-term 12. A review of children treated in UK ALL trials from 1972 to 1990, 
found that although results of treatment have improved over time, survival 
was significantly better in girls than boys, independent of age and white cell 
count at presentation 13. A similar survival advantage was seen over time, and 
in girls, in a European study, although this study did not adjust for white cell 
count at presentation 14. Studies also demonstrated significant inter-country 
variation in survival within Europe 1415 with better survival in Nordic countries 
than in eastern Europe, but there was no statistically significant regional 
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variation in 1- or 5-year survival between regions within the UK in the period 
1986 to 199016. A UK study examining survival in childhood All diagnosed 
between 1971 and 1990, using national cancer registry data, found no 
statistically significant socioeconomic class gradient in survival16. 
1.2.2.2 ell 
INCIDENCE. Cll is the most common leukaemia in the Western world and 
mainly affects people aged over 50 years2. Cll is believed to be twice as 
common in men as in women at any given age 17, and its incidence is known 
to increase with age3. In the UK, a recent registry-based study confirmed a 
male excess specific to people in the 5th and ih decade7 . There is also large 
regional variation in incidence, being rare in China and Korea, and virtually 
absent in Japan3. Regional variation in incidence in the UK has also been 
noted in a study conducted in the mid 1980s 17. The incidence appears to be 
increasing as measured by registration rates6, although an earlier review 
found incidence rates increased between 1945 and 1957 and then showed a 
declining trend since 196811 . The association of socioeconomic class with 
Cll has not been investigated in the UK. 
MORTALITY. While the natural history is very variable, the majority of 
patients survive without symptoms or progression, such that more than half 
die of unrelated causes 17. A recent review estimates survival ranges from 
months to decades, with a median survival of 7.5 years3. Age per se is not a 
22 
prognostic factor, since the clinical course of the disease is identical in 
younger and older patients. The causes of death are Cll-related in the 
younger patients, and related to second malignancies or are unrelated in the 
elderly3. Better rates of remission have been achieved over recent years, but 
it is not clear whether overall survival has improved3. Two reviews found no 
trend in survival over time6 11. Associations between survival in Cll and 
socioeconomic class, and UK region have not been investigated. 
1.2.2.3 AML 
INCIDENCE. While AMl can occur at any age, it becomes increasingly 
common with increasing age 18 and is the most common form of leukaemia in 
adults2. A male excess in AMl incidence has been noted in the UK, 
particularly after the age of 55? 18, as well as in an earlier Finnish studi 9 . A 
registry based UK study found no association between socioeconomic class 
and AMl incidence?, consistent with the findings of another UK study of 
teenagers and young adults which also found no socioeconomic class trend 
in AMl incidence9. There was, however, regional variation within the UK after 
adjusting for socio-economic class, with the highest incidence noted in the 
south-east and the lowest incidence in the east of England. Regional 
variation in AMl incidence was also found in Finland in an earlier study19. 
The incidence of AMl in the UK is believed to have increased between 1961 
and 1978, but not between 1984 and 19886. 
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MORTALITY. Survival declines with increasing age2 18, and survival beyond 1 
year is rare in those aged over 702. A UK study of adults with AML found no 
significant gender differences in 1- and 3-year survival18. In a study 
examining the effect of gender and age on survival in European children with 
AML, girls had better survival than boys overall, but there was no gender 
difference in survival under the age of 5 years20. These findings with regard 
to gender were similar across most of the European countries studied. The 
same study also found that survival varied from one country to another, being 
worse in Eastern and Southern Europe, and better in Western Europe, and 
that survival improved considerably over the time-period of the study (1978-
1989). A subsequent study examining survival in children diagnosed between 
1990 and 1994 showed that survival had continued to improve across 
Europe, but that the earlier pattern of inter-country variation remained 15. 
1.2.2.4 CML 
INCIDENCE. The incidence of CML increases with increasing age and is rare 
in children2. A greater incidence in males than females is a consistent finding 
within the UK, and worldwide4 718. In a study of teenagers and young adults, 
the incidence of CML was found to increase with increasing socioeconomic 
deprivation9. This study also found regional variation in incidence with higher 
rates in London and the southwest than elsewhere in the UK. The incidence 
of CML is believed to have remained stable between 1943 and 1977 in 
Denmark6 . In the UK, however, registrations have declined in the period 1984 
to 19986. 
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MORTALITY. The median survival is around 4 to 5 years and depends on the 
response to initial treatment4. In a study of adults with CMl in the south east 
of England, survival was better in those under the age 65 than in older 
patients, with no survival difference between men and women 18. A registry-
based study investigating survival among European children with CMl found 
survival in girls was significantly better than in boys20. This study also found 
that regional variation in survival exists across Europe, and that survival has 
improved over the period of the study (1978-1989). Mortality has also been 
shown to have declined in both men and women in a review covering the 
period between 1970 and 200011 . 
1.2.2.5 AETIOLOGICAL FACTORS 
A number of environmental and lifestyle factors have been implicated in the 
aetiology of leukaemia, but results of research have been inconclusive for 
many of them. 
IONISING RADIATION. A review of the associations between environmental 
factors and a number of leukaemias confirmed that exposure to ionising 
radiation is a well documented risk factor for acute non-lymphocytic 
leukaemia (ANll)21. The same review also concl'uded that while exposure to 
high doses of ionising radiation may precede the development of CMl, no 
such association exists with ClL. Another recent review similarly concluded 
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that exposure to ionising radiation is strongly associated with AML 22 . ALL in 
children has been associated with in-utero exposure to ionising radiation21 . 
ELECTROMAGNETIC FIELDS. Exposure to strong electro-magnetic fields 
has also been implicated in the development of ANLL, although the difficulty 
in quantifying such exposure makes any firm conclusions impossible21 22. 
ORGANIC SOLVENTS. Occupational handling of benzene and other organic 
solvents has been implicated in the aetiology of leukaemia. A strong 
association has been noted between occupational exposure to benzene and 
AML22 and ANLL23, for example. The biological mechanisms are believed to 
surround chromosomal aberrations seen in leukaemic cells of patients who 
have been exposed to these organic solvents. These aberrations are 
believed to playa role in activation of oncogenes, with consequent 
malignancy. A latency period of 10 years or more appears to exist between 
the start of exposure to these compounds and a diagnosis of ANLL23. In 
contrast, in a study examining the occupations of AML patients, organic 
solvents were not found to be associated with AML 19. This study utilised 
Finnish cancer registry data, and compared the exposure of AML cases with 
that of registry patients with other cancers. An important weakness of this 
study in exploring associations with exposure to solvents and other 
chemicals was that occupation at the time of AML diagnosis was used. Given 
the latency period between exposure and leukaemia diagnosis found by 
others, it is likely that positive associations may have been missed as a result 
of using this approach. 
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While studies have shown an unusually high incidence of CLL among 
farmers in the USA, this was not seen in Scandinavian farmers21 . Reasons 
for this difference may include differences in the specific chemicals farmers 
are exposed to, difficulty in adequately measuring, and then comparing the 
levels of exposure within and between studies, as well as differences in study 
design and methodology. There is no strong evidence to suggest CML is 
related to exposure to organic solvents, although they may increase the risk 
of other haematological malignancies such as Non-Hodgkin's Lymphoma, 
Hodgkin's disease and myeloma. These associations will not be explored 
further as they are not relevant to the research presented here. 
ALCOHOL. The relationship between alcohol consumption and leukaemia 
has been examined before, but results have been inconsistent. 
In a case-control study of 578 white men with leukaemia, alcohol 
consumption was positively associated with ALL, but not leukaemia overall or 
CML 24. Odds ratios for ALL did not reach statistical significance, however, 
nor did investigators find a dose response gradient with the quantity of 
alcohol consumed, a pattern which may have suggested causality, had it 
been found. 
In another case-control study of 164 case-control pairs, Pogoda et al. found 
that alcohol consumption was associated with a decreased risk of AML in 
adults, but results did not reach statistical significance25 . The authors 
27 
acknowledged that alcohol consumption in their study population was related 
to higher socioeconomic class, and that their controls were also of higher 
socioeconomic class than their cases. This represents an important potential 
source of bias in their results. As only education was controlled for in the 
analYSis, this combination of factors may have resulted in residual 
confounding with respect to socioeconomic class and consequently produced 
spuriously low odds ratios. 
In another case-control study of 765 incident cases of acute de novo 
leukaemia in adults and 618 controls, regular drinkers had a reduced relative 
risk of leukaemia compared to non-drinkers26. When consumption patterns 
and different types of alcohol were examined, light and moderate beer intake 
was associated with a reduced risk of leukaemia that was statistically 
significant, while moderate or heavy wine intake was associated with an 
increased relative risk of leukaemia, although results for the latter did not 
reach statistical significance. As in the study by Pagoda et a1. 25 , alcohol 
consumption was more prevalent among controls than cases and education 
was the only marker of socioeconomic class adjusted for. Again this may 
have resulted in downwardly biased odds ratios if the controls were of higher 
socioeconomic class than the cases in this study. Unfortunately, the similarity 
or otherwise of cases and controls with respect to socioeconomic class is not 
reported in the paper. Selection bias related to social class may also explain 
the inverse association found with beer if, for example, beer intake is 
inversely associated with socioeconomic class and controls were of lower 
socioeconomic class than cases. 
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A more recent multi-centre case-control study exploring the associations of 
alcohol intake with a number of leukaemia subtypes was also inconclusive27 . 
In this study of 649 cases and 1771 controls, any alcohol intake was found to 
be associated with a reduced risk of leukaemia overall, All and Cll, 
compared to those who never drank alcohol. The contrary was true for AMl 
and CML. None of these odds ratios reached statistical significance, 
however. This study also examined the type and quantity of alcohol 
consumed and found an inverse association with leukaemia overall and 
moderate intake of all alcohol, wine, beer and spirits. Similar inverse 
associations were seen in All, Cll and AMl with all alcohol. A positive 
association with leukaemia overall was found for high-level consumption of 
all alcohol, wine and beer. Again, results did not reach statistical significance. 
CMl was positively associated with alcohol consumption at all levels, but 
odds ratios again did not reach statistical significance. 
A review examining the evidence for an association between alcohol 
consumption and leukaemia, as well as other cancers, concluded that there 
were insufficient studies of appropriate size to draw any firm conclusions with 
I k . 28 regard to eu aemla . 
SMOKING. A number of studies have shown an association between 
smoking and AMl and ANll, but not for all leukaemias. Results are not 
consistent, however, and have often been confounded by social class29-33 . 
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DIET. Animal studies and ecological studies of leukaemia in humans have 
suggested that diet may influence the risk of leukaemia, but this has not been 
confirmed in studies directly examining this association. A large study 
compared leukaemia incidence as recorded in cancer registry data from 24 
countries with international food supply data34. A positive correlation, which 
was stronger in men than women, was found between total calorie-intake and 
lymphoid as well as total leukaemia. No such correlation was seen for 
myeloid leukaemias. 
PERINATAL AND REPRODUCTIVE FACTORS. As part of a large childhood 
cancer study in the UK, a number of perinatal factors and their associations 
with childhood leukaemia were examined35 . Hyperemesis was associated 
with all leukaemias, and polyhydramnios and anaemia with AML. Although 
babies who developed leukaemia were heavier at birth, these results were of 
borderline statistical significance. Babies who developed common B-cell 
precursor ALL were more likely to have been born to mothers who had had a 
previous molar pregnancy. Down's Syndrome was also shown to be strongly 
associated with ALL and AML, consistent with earlier reports. 
Maternal medication use during pregnancy has also been examined as a 
potential aetiological factor in infant leukaemia. A case-control study 
examined medications used by 243 mothers of infants diagnosed with 
leukaemia36 . Controls were selected from mothers whose children did not 
have leukaemia. Their use of 27 specific drugs (including several antibiotics, 
clomiphene and levothyroxine) as recorded in their medical records was then 
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compared. None of the associations seen reached statistical significance. 
Possible reasons for this include the small numbers of cases with each 
leukaemia sub-type and/or the large number of drugs examined. 
PRESCRIPTION MEDICATION. The use of non-steroidal anti-inflammatory 
drugs (NSAIDs) has been investigated in both epidemiological studies and 
clinical trials as potentially reducing the risk of several malignancies. Few 
studies have explored the association of NSAI D use and risk of leukaemia. A 
case-control study of 412 AMl cases found NSAIDs had a protective effect 
on the risk of one AMl subtype (M2), but results did not reach statistical 
significance37. Another study of 81 post-menopausal women with leukaemia 
(including 35 cases of Cll, 28 of AMl and 5 of CMl) found a statistically 
significant protective effect with NSAID use in leukaemia overall, as well as 
with aspirin use in leukaemia overall, AMl and Cll38 . However, both these 
studies relied on self-reported drug histories (in the former, subjects were 
required to recall their drug intake up to 10 years prior to their diagnosis) 
subjecting results to recall bias. 
While chemotherapy is an established risk factor for AMl, other prescription 
drugs as a potential aetiological factor in the development of leukaemia have 
not been investigated to any great extent. long-term benzodiazepine use has 
been implicated in the incidence of AMl of the M4 subtype, but results did 
not reach statistical significance37. Studies have also suggested that the use 
of hormone replacement therapy (HRT) may be associated with certain 
cancers as a result of oestrogen receptor stimulation. Given that 
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haemopoetic cells also express oestrogen receptors, HRT use has also been 
investigated as a risk factor for leukaemia. Only 2 studies were identified in 
the peer-reviewed literature. A US study, linking data from a cohort of women 
in Iowa to population-based registry data identified 63 cases of ell over a 
13-year follow-up period39 . No association with ell risk was found. A later 
study, using the same study population, but followed up for a longer time 
period, identified 201 cases of leukaemia, including 87 ell cases and 74 
cases of AMl40. Again, no association was seen between current or previous 
HRT use and leukaemia overall, AMl, or elL. 
1.3 PROJECT AIMS AND RATIONALE 
less is known about the acute and chronic leukaemias compared to other 
cancers, such as lung or breast cancer, for example. This is particularly the 
case with regard to the UK burden of disease and aetiology. As illustrated by 
the review above, specific aspects of the epidemiology of leukaemias in the 
UK, such as associations with socioeconomic class, have not been 
investigated before for many of the leukaemia subtypes. This gap in our 
knowledge, with respect to both incidence and mortality, can be addressed 
using general practice data. Hence the quantification of the incidence of and 
mortality with the acute and chronic leukaemias in the UK, producing up-to-
date incidence and mortality figures for these diseases, forms the basis of 
this research project. 
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By using computerised general practice data a number of risk factors for 
these malignancies are also examined, including gender, age, socio-
economic class, calendar time and geographical location. These initial 
incidence and mortality studies generated hypotheses surrounding access to 
treatment in certain groups, and these are examined in greater detail using 
hospital data. 
The aetiological factors investigated here were chosen to reflect both the 
gaps in knowledge that currently exist, as well those research questions that 
could be answered using the data sources available to me. The role of 
alcohol consumption and smoking, for example, where published studies are 
limited in number, small and/or have produced inconclusive results, was 
chosen because it was possible to answer these questions using these data. 
Furthermore, general practice data have not been used to examine these 
factors before. 
Factors such as exposure to ionising radiation, proximity to electromagnetic 
fields, occupational exposure to organic solvents, and diet, on the other 
hand, cannot be investigated using these data, and hence this was not 
undertaken. 
Although it is possible to investigate the association between leukaemia and 
the use of many drugs, NSAIDs were chosen as they have been 
demonstrated to be protective in other cancers, and published studies 
investigating their role in the leukaemias have thus far been small, 
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underpowered and inconclusive. This research project therefore represented 
an opportunity to definitively answer this question. 
While the over-arching aim of this research was to assess the usefulness of 
'THIN' data for haematology epidemiology research, a number of questions 
surrounding the natural history, aetiology, and uptake of certain health 
services have been answered. 
Results from these studies will not only to inform the planning of health care 
services by providing up-to-date stratified incidence and mortality figures, but 
also provide new aetiological insights into these conditions and identify areas 
for further research. 
1.4 OUTLINE OF SUBSEQUENT CHAPTERS 
The next chapter discusses several aspects of the methodology employed in 
the studies presented here. Chapter 3 then reports the incidence of and 
mortality from leukaemias overall in the UK, stratified by gender, age at 
diagnosis, Townsend Score of socioeconomic deprivation, year of diagnosis 
and geographical region. Chapter 4 reports the incidence of and mortality 
from several leukaemia subtypes in a similar way. In the light of findings from 
this study, bone marrow transplantation across socioeconomic class strata 
was then investigated using hospital data, and results of this study are 
reported in Chapter 5. Chapter 6 describes the findings of a case-control 
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study examining the use of non-steroidal anti-inflammatory drugs and their 
association with leukaemia incidence and mortality. This is followed by 
another case-control study presented in Chapter 7, which investigates the 
association of alcohol consumption and leukaemia incidence and mortality. 
The existing literature will be discussed in greater depth within the context of 
the individual studies reported in each chapter. 
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2 METHODOLOGY 
This chapter discusses key aspects of the methodology specific to the 
research presented in this thesis. These include: available general practice 
datasets and more specifically, 'The Health Improvement Network' (THIN); 
Hospital Episode Statistics (HES), the Townsend Score of material 
deprivation, and the Charlson Co-morbidity Index (CCI). 
2.1 GENERAL PRACTICE DATA 
Commercial companies have long recognised the potential of collating 
patient data held in UK general practices into large databases for the 
purpose of medical research 41 . In the 1980s companies encouraged the use 
of computers in general practice by publicising practice management 
software as well as by offering financial incentives to adopt computerisation. 
In the 1990s government facilitated the funding of primary care computers, 
and also established service targets that were financially rewarded. The 
evidence practices were required to produce in order to demonstrate that 
targets had been met was most easily obtained by interrogating practice 
computer systems. These factors accelerated computerisation and a 
concomitant increase in data collection in general practice. Databases 
containing anonymised patient records obtained from general practice 
systems now represent a hugely important medical research resource, and 
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have been widely used in epidemiological research42 . More than 97% of 
people in the UK are registered with a general practitioner, which makes 
general practice databases an excellent source of data for this type of 
research. 
2.1.1 THIN data 
The dataset used for this research is 'The Health Improvement Network' 
(THIN) dataset which comprises data from over 330 general practices and 
includes 5.7 million patients, 2.5 million of whom are actively contributing 
data and can be prospectively followed. Prospective data collection started in 
September 2002, but data from practices that have held electronic records 
from as early as 1987 have also been included43. The total number of usable 
patients in the dataset is 5 395 612, with 2 592 133 actively contributing data 
on 1 st July 2007 when data for these studies were extracted. Data recorded 
from 1987 to July 2007 have been used in these studies. 
Over 35 million person-years of data are contained in the dataset and data 
include patient demographics, such as date of birth, gender, household size 
and period in database. All diagnoses made, along with referrals to hospitals 
and emergency visits are included, as are details of all drugs prescribed in 
primary care. Additional health data such as height, weight, alcohol 
consumption, smoking habits and blood pressure are also held. The 
Townsend score, a measure of socioeconomic deprivation, is also held for 
each patient, as are markers of pollution to which they may be exposed. 
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The number of patients in the dataset at mid-year compared to the UK 
population are shown below for previous years (1998 to 2006)43. 
Table 2.1: THIN Population 
Year UK Population THIN Population 0/0 Coverage 
1988 57 165777 1 307 398 2.3 
1989 57364985 1 435486 2.5 
1990 57567259 1 533 168 2.7 
1991 57438700 1 653 748 2.9 
1992 57563100 1 740605 3.0 
1993 57672500 1 848 102 3.2 
1994 57797400 1 979507 3.4 
1995 57928000 2076790 3.6 
1996 58043000 2 163589 3.7 
1997 58 167200 2231 958 3.8 
1998 58305300 2286916 3.9 
1999 58481 100 2319774 4.0 
2000 58643200 2348228 4.0 
2001 58789 194 2 374474 4.0 
2002 59207000 2404968 4.1 
2003 59554000 2437720 4.1 
2004 59834300 2435264 4.1 
2005 60209500 2446248 4.1 
2006 60533000 2426358 4.0 
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THIN data therefore currently represent around 4% of the UK population. 
Since only general practices which use particular IT systems contribute data 
to THIN, and greater use of these particular IT systems occurs in the south-
east of England, contributing practices are potentially more likely to serve 
patients from higher social classes than those practices that do not contribute 
to THIN. This has the potential to introduce a social class bias into studies 
that use these data. Matching for general practice in the design of case-
control studies and/or adjusting for social class in analyses can minimise this 
potential bias. Both of these approaches have been used in this project. 
THIN data are organised into 6 files: patient; medical; therapy; additional 
health data (AHD) data file, which contains information on preventative 
healthcare, tests and immunisations; postcode variable indicators (PVI); and 
dosage. A patient identifier links the patient data files to each other43 . 
STRENGTHS AND LIMITATIONS: 
Data are collected in an automated way during the routine activities of a 
general practice, thus not interfering in the delivery of care to patients. This 
also means that the data recorded reflect 'real life' practice. Since information 
is continually up-dated, investigations can be conduced into newly marketed 
drugs or recently adopted diagnostic tests or other health technologies used 
in general practice, for example. Access to these established data also 
allows for the rapid conduct of a range of study designs. Furthermore, the 
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selection of population controls at the same time as cases in the conduct of 
case-control studies is also facilitated. 
A complete computerised record of a patient's healthcare is built up over the 
time they are registered with their GP. If a general practice becomes 
computerised after a patient has registered, events considered medically 
important by the GP are entered onto the electronic system from the paper 
notes. Similarly, if a patient transfers from a practice that does not contribute 
to THIN to one that does, only medically important events are likely to be 
recorded in the electronic record at the new practice. As such, a patient will 
typically only have a complete electronic record in THIN for a part of their life. 
Data are recorded for the purposes of patient and practice management 
rather than for research, and hence will reflect those data that are considered 
relevant to the patient's care. 
THIN data also include the dates a patient registers and leaves a practice, 
which allows follow-up period to be taken into account in study designs. In 
terms of demographic information, THIN data are anonymised to the extent 
that names, addresses, NHS numbers and exact dates of birth are excluded. 
Gender and age are, however, included. A unique household identifier links 
patients who live at the same address, or who are members of the same 
family, provided they are registered at the same general practice. 
Medical conditions and symptoms reported to the GP are recorded 
electronically during the consultation. A hierarchical system of codes (Read 
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Clinical Classification version 2) that can be cross-referenced to the 
International Classification of Disease (ICD) is used for this purpose. 
Referrals to secondary care are also recorded. Information from secondary 
care and other information received by the practice is transcribed and 
entered retrospectively. Where information is entered retrospectively, only 
those aspects considered significant and relevant are likely to be entered, 
which represents a potential source of weakness with regard to 
completeness of the patient's electronic record. Symptoms are more likely to 
be recorded if a prescription is issued as a result of the consultation. 
Furthermore, illnesses such as common colds and headaches, which are not 
routinely consulted for will not be recorded in THIN (or other general practice 
databases) and hence prevalence estimates of these conditions based on 
such data will be spuriously low. 
The diagnostic validity of general practice data has been demonstrated for a 
range of malignant diseases, including breast cancer and non-melanoma 
skin cancer44-46. The validity of non-malignant diagnoses, including 
gastrointestinal disease, liver disease, autism, venous thromboembolism, as 
well as chronic obstructive pulmonary disease (COPD), has also been 
demonstrated4447-50. The quality of prescription data within these databases 
has also been the subject of investigation, and have been shown to be 
accurate51 52. These validation studies used direct observation of medical 
records as well as questionnaires sent to GPs to assess validity. 
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Two popular methods of testing validity, namely direct observation of records 
and 'face validity', have both been used to assess the validity of THIN data. 
The former method was used in a study that specifically examined the validity 
of non-melanoma skin cancer (NMSC) diagnoses in THIN46. Patients with 
this diagnosis were firstly identified in THIN. Questionnaires were then sent 
to the GPs of a random sample of 40 of these patients asking how their 
diagnoses were confirmed. 37/40 (93%) had had their diagnoses confirmed 
by a letter from the hospital or a pathology report, and 2 had left the practice 
before the diagnosis could be confirmed. Gribbon et.al. have used the 'face 
validity' method in an incidence and mortality study of idiopathic pulmonary 
fibrosis and sarcoidosis in the UK53. They demonstrated that incidence and 
mortality rates in THIN were consistent with what previous studies, using 
alternative data sources, had found. 
While the other published studies of diagnostic validity in general practice 
databases tended to use the GPRD, the similarities between these datasets 
in terms of the data collection methods and quality control standards 
employed, can be expected to result in similar levels of data accuracy. This 
has in fact been tested in a series of case-control studies examining several 
disease-disease and disease-drug associations in both THIN and the GPRD. 
This examination of 'face validity' concluded that THIN data were as valid as 
Prescriptions issued in general practice are generated electronically and a 
copy is issued to patients who have them filled by a pharmacist. As a result, 
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prescriptions are well recorded in THIN. Prescriptions for controlled drugs, 
immunisations and those issued on home visits, however, are not done 
electronically, and so need to be recorded onto computer systems 
retrospectively. This has the potential to result in under-recording of 
prescriptions for drugs issued under these circumstances. 
Similarly, drugs prescribed in secondary care will not be recorded in THIN 
unless further prescriptions need to be issued by the general practitioner, or 
they are of sufficient relevance to the GP's management of the patient so as 
to be recorded retrospectively. Psychiatry patients may obtain their 
medication from community mental health teams, while contraception may be 
obtained from family-planning clinics, increasing the likelihood that these 
medications are also under-recorded in THIN. While these are potential 
weaknesses of all general practice databases, they are not likely to have 
impacted on the studies presented here, as they do not involve such 
prescriptions. 
Non-prescription drugs (i.e. those obtained 'over the counter') are also not 
recorded in GP prescription databases. Children, people over the age of 65, 
and certain subgroups of patients such as pregnant women and diabetics, 
are entitled to free prescriptions, however, and so there exists a financial 
incentive to obtain drugs that can be bought 'over the counter', on 
prescription instead. Results of studies of these patient groups are therefore 
less likely to be biased by this weakness. This potential under-recording is 
relevant to one of the studies presented here involving non-steroidal anti-
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inflammatory drug (NSAID) use, and will be discussed in greater detail in the 
relevant chapter. Prescription data held in THIN reflects prescriptions issued, 
not those filled, nor whether the prescribed medication has actually been 
taken by patients or not. This weakness is common to all general practice 
databases. 
2.1.2 GPRD 
The GPRD is a similar dataset to THIN in origin, content and format. The 
GPRD contains data from around 500 practices and represents about 5.5% 
of the UK population54. There are over 4 million patients currently actively 
contributing to the dataset, which contains 63 million person-years of data. 
This dataset is also reported to be broadly representative of the UK 
population. Published data in terms of gender, at least, supports this 
assertion (see Figure 2.1 below), although the distribution by geographic 
region and social class compared to that of the UK population, for example, 
is less clear. 
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Figure 2.1: GPRD Population 
GPRD population population distribution by age and gender: GPRD vs UK population 
(UK population source : ONS mid year population estimates 2007 
GPRD version : August 2009) 
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Although linkage of the GPRD to socioeconomic class (as well as to Office 
of National Statistics data, cancer registry data, and Hospital Episode 
Statistics) is currently being undertaken, less than half of contributing 
practices are being linked in this way [personal communication]. This 
represents a significant disadvantage of this dataset compared to THIN , in 
the conduct of research such as that presented here where the focus is on 
socioeconomic class. 
2.1.3 Qresearch 
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Over 600 UK practices that use the EMIS clinical computer system contribute 
data to the Qresearch database55 • As with the above datasets, data from 
both actively contributing patients are included along with historical patient 
data. Data are reported to date back to the early 1990s. Again, the limitations 
of this database are in keeping with those of other general practice datasets. 
Information made publicly available by Qresearch gives no indication as to 
the distribution of these practices across the UK, or how representative of the 
UK population with regard to demography the data are. 
2.1.4 Registry Data 
While registry data make a valuable contribution to our knowledge, there are 
areas where these data are incomplete. Although post-code data are 
included in registry data, the socioeconomic class of patients is not held. 
While this limitation can be overcome by mapping post-codes to 
socioeconomic class, other limitations make registry data unsuitable for the 
range of studies presented here. Information on co-morbid illness is not held, 
for example, making adjustment for co-morbidity difficult without linking 
registry data to other datasets. Registry data also do not incorporate other 
health data, such as smoking and alcohol consumption, which limit their use 
in aetiological studies that require these lifestyle factors to be taken into 
account. The absence of prescription data, for example, limits its value in the 
pharmaco-epidemiological aspects of this research. While linkage of various 
UK data sources are currently underway, these are far from complete. The 
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GPRD is currently being linked to HES data, ONS data as well as registry 
data, but fewer than 50% of the English practices that contribute data to 
GPRD, have thus far consented to having their data linked to these other 
data sources [personal communication]. Once this linkage is complete, the 
resulting dataset would be a hugely valuable resource to epidemiological 
research. It is not at all clear when this project will be completed though, or 
what the likely extent of the eventual coverage achieved will be. 
There is therefore a need to utilize the best currently available datasets that 
do include this additional information to conduct epidemiological research 
quickly, cheaply, and efficiently in the meantime. 
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2.2 HOSPITAL EPISODE STATISTICS 
Since bone marrow transplantation is undertaken in hospitals, hospital data 
were deemed more appropriate than general practice data for the study of 
bone marrow transplantation in AML, which is reported in Chapter 5. 
Hospital Episode Statistics (HES) were introduced in 1986 and measure all 
hospital inpatient and day surgery activity56. HES data cover over 50 million 
people and all NHS hospitals, encapsulating 90 to 95% of all in-patient care. 
These are record-level data administered by The NHS Information Centre for 
Health and Social Care, on behalf of the Secretary of State for Health. Data 
are extracted from routine data flows between healthcare providers and 
commissioners and used to populate the 3 main HES datasets (admitted 
patient care, outpatient and Accident and Emergency datasets). 
The admitted patient dataset, which includes inpatient and day-case records, 
was used in anonymous form for this research. Cumulative data are 
extracted quarterly for this dataset and it is updated annually, in addition. 
There are approximately 16 million records in this dataset for each financial 
year. Data from the 1989/90 financial-year are available, although the 
records of individual patients have only been linked since 1997/98 onwards. 
Data held include patients' demographic information such as date of birth, 
gender and region of residence, details of diagnoses and treatments 
received, as well as administrative details such as admission and discharge 
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dates, along with the place they were treated (NHS Trust or independent 
sector hospital, for example). 
HES data are provided in tables, each of which represent one financial year, 
and contain all hospital episodes for that year. The contents of the tables 
provided are determined by the specific fields that have been requested (and 
paid for) by researchers. For the purposes of this research only those 
patients and fields that were required to address the specific research 
question were purchased. Data for all patients with a diagnosis of AML (as 
defined by specific ICD-9 and 10 codes provided to the data supplier) 
recorded in HES were requested. The data fields requested were age, month 
and year of birth, a patient identification number specific to HES (HESID), 
start and end dates of each hospital episode, all recorded diagnoses and 
procedures for each of these episodes, the health authority of residence of 
the patient, and the Lower Super Output Area (a measure of socio-economic 
deprivation) of the patient. 
STRENGTHS AND LIMITATIONS: 
HES data are anonymised and contain no patient names. Furthermore, 
access to GP and consultant codes is restricted to preserve anonymity where 
the small size of sub-sets of data, for example, may result in the identification 
of people. This limitation had no bearing on the results presented here. 
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As with all healthcare datasets, changes in geographical boundaries may 
contribute to fluctuations in data. While this may have affected data used in 
this research, the impact will have been random and is therefore unlikely to 
have biased results. 
Unlike general practice data, HES data do not include a denominator 
population. This presented no problems since those aspects of this research 
using HES data did not require a general denominator population. 
Inaccuracies with respect to coding are a further potential problem with all 
databases. While this is likely to have affected this research, errors were 
again likely to be random, occurring across all socioeconomic classes and so 
are not likely to have biased these results. 
HES data provided to researchers are reported to have a lag time of between 
9 and 12 months, representing the time taken for data to be extracted from 
hospital systems, cleaned by The NHS Information Centre, and then 
provided to researchers. 
Non-return of data is a further potential limitation of HES data. While the NHS 
Information Centre liases closely with the more than 300 NHS organisations 
and treatment centres to encourage them to submit complete and valid data, 
submitted data are then also subject to 'cleaning' processes to minimise the 
effect of missing and invalid data. Although data have improved over time, 
some inaccuracies are bound to remain. 
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The diagnostic validity of HES data has not been investigated to nearly the 
extent that general practice datasets have been. There is, however, some 
evidence that the accuracy of three-digit ICD-9 codes are between 86 and 
91 % for well-recognised acute conditions, and that the accuracy of procedure 
codes (first 2 digits of OPCS-4) is also very good57. Diagnostic codes were 
also found to be improving over time as the incentives for collecting accurate 
data change and hospital information systems become more sophisticated57. 
Another study found that procedures recorded in HES were consistent with 
those recorded in clinical datasets for several cardiovascular and colorectal 
cancer surgical procedures58. 
2.3 TOWNSEND SCORE 
Townsend Score of material deprivation is the measure of socioeconomic 
status recorded in THIN, and hence used in these studies. The score is 
based on a combination of four variables namely: unemployment; car 
ownership; home ownership and overcrowding, which produce a ranking of a 
particular sma" geographic area (of about 150 homes, called a Lower Super 
Output Area) relative to others59. The data used to calculate the Townsend 
Score are derived from the 1991 census. Unemployment is determined by 
the percentage of economically active residents aged 16-59/64 who is 
unemployed. Car ownership and home ownership are defined as the 
percentage of private households who do not possess a car, and are not 
owner-occupied, respectively. Overcrowding is defined by the percentage of 
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private households with more than one person per room. The Townsend 
Score is the summation of the standardized scores (z scores) for each 
variable. The greater the Townsend Score the greater the degree of 
deprivation in the area. Although the Townsend Score assigned to an 
individual in the dataset is not an assessment of that individual's own socio-
economic circumstances, it represents the sma" homogenous socio-
geographic area, comprising about 150 homes, in which they live. 
2.4 CHARLSON CO-MORBIDITY INDEX 
Co-morbid illnesses not only influence the diagnosis and management of 
cancers, they also predict survival in several malignancies60. Studies 
presented here have utilised the Charlson Co-morbidity Index (CCI) when 
adjusting for patients' co-existing medical conditions. 
The Charlson I ndex was developed about 20 years ago and was based on 
the 1-year mortality of medical patients admitted to a North American 
hospital. The scoring takes into account the presence of 19 different medical 
disease groups, each of which carries a weight ranging from 1 to 6, 
depending on the relative risk of death within 12 months associated with the 
presence of the particular disease group. The disease groups utilised and 
their weights are shown in Table 2.2. 
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Table 2.2: Charlson Co-morbidity Scoring 
CONDITION WEIGHT 
Myocardial infarct 1 
Congestive cardiac failure 1 
Peripheral vascular disease 1 
Cerebrovascular disease 1 
Dementia 1 
Chronic pulmonary disease 1 
Connective tissue disease 1 
Ulcer disease 1 
Mild liver disease 1 
Diabetes 1 
Hemiplegia 2 
Moderate or severe renal disease 2 
Diabetes with end-organ damage 2 
Any tumour 2 
Leukaemia 2 
Lymphoma 2 
Moderate or severe liver disease 3 
Metastatic solid tumour 6 
AIDS 6 
While the Charlson Co-morbidity Index was initially validated in breast 
cancer, it has since been validated in a range of malignancies, and for 
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predicting mortality over periods of time longer than just 12 months60. The 
Charlson Co-morbidity Index has been found to have good reliability and to 
correlate well with mortality and progression-free survival outcomes. It can 
also be easily modified to account for age, for example. Limitations of the 
index include: co-morbid conditions taken into account are limited to 19 
medical disease groups; non-malignant haematological conditions, such as 
anaemia, for example, are excluded; and its ability to predict outcomes within 
6 months is reduced. 
For these studies, all the diagnoses within each of the 19 groups utilised by 
the CCI were compared to the medical histories of the patients recorded in 
THIN. A co-morbidity score was then calculated for each patient and for each 
of the controls. 
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3 INCIDENCE AND MORTALITY OVERALL 
3.1 ABSTRACT 
Introduction: Although leukaemia constitutes 2.5% of all newly diagnosed 
malignancies in the UK, there is a paucity of accurate up-to-date data on the 
variation of its incidence with gender, age, socioeconomic status, calendar 
time and geographical region. General practice data were used to study this 
as it offered several advantages over cancer registry data. Aims and 
Objectives: The quantification of the incidence of and mortality from 
leukaemia in the UK and its variation with gender, age, socioeconomic 
status, year of diagnosis, and geographical region. Methods: General 
practice data from 'The Health Improvement Network' (THIN) dataset was 
used. A list of READ codes was used to identify cases of leukaemia in the 
dataset and steps were taken to ensure only incident, rather than prevalent 
cases were included in the analysis. Denominator data were also derived 
from THIN. Variables of interest were age at diagnosis, gender, Townsend 
Score, year of diagnosis and health authority. Crude incidence rates, as well 
as incidence rate ratios stratified by the variables of interest were calculated. 
The median survival and hazard ratios for death with leukaemia were 
calculated. All analyses were conducted using STAT Av9. Results: 4 162 
cases of leukaemia were identified, 2 314 (56%) of whom were male. 267 
(6.4%) cases were diagnosed in children aged under 20, of whom 147 (55%) 
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were male. The overall incidence of leukaemia is 11.25 per 100 000 person-
years, and 3.22 per 100 000 person-years in children aged under 20yrs. The 
age at which leukaemia is diagnosed shows a bimodal distribution with a 
peak in incidence in children aged 5 and under, and a further peak in the 8th 
decade of life. The relative risk (RR) of leukaemia in women is 0.66 (p<0.01 , 
95% C.1. 0.62-0.70) compared to men, when adjusted for age-category, 
Townsend score, health authority and year of diagnosis, but there is no 
gender difference in those under the age of 20yrs.The RR of leukaemia 
increases with increasing age (p for trend<0.01), but is independent of 
Townsend Score. The overall incidence of leukaemia has increased over 
time (p for trend<0.01), when mutually adjusted for all other variables of 
interest, but has decreased in the sub-group aged under 20yrs (p for 
trend<0.01). The median survival from leukaemia is 6.58 years. The risk of 
death is lower in women than men when adjusted for age at diagnosis, 
Townsend score, year of diagnosis and health authority (HR 0.88, p=0.01, 
95% C.1. 0.79 - 0.97), and greater with increasing age at diagnosis (p for 
trend<0.01). The increased risk of death with lower socioeconomic class is of 
borderline statistical significance (p for trend=0.05). Mortality has remained 
stable over time, while some geographical variation in both incidence and 
mortality were found. Mortality in the sub-group of children is independent of 
all the variables of interest. Discussion: Greater mortality in lower socio-
economic classes may reflect a greater incidence of those leukaemia 
subtypes with a poorer prognosis in these groups; more co-morbidity in these 
groups; and/or a class bias in access to and up-take of treatment. These 
factors will be investigated in greater depth in subsequent chapters. 
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3.2 INTRODUCTION 
Leukaemia constitutes 2.5 % of all cancers and is the 12th most common 
cancer registered in the UK1. Approximately 7000 people are diagnosed with 
the disease and more than 4 300 people die from leukaemia in the UK each 
year1. Although statistics available through the Office of National Statistics, 
cancer charities and cancer registries in the UK shed some light on the 
variation in incidence of leukaemia by gender and age, as well as trends over 
time, there is a paucity of data on its association with patients' socioeconomic 
circumstances. 
3.3 AIMS AND OBJECTIVES 
This study set out to quantify the incidence of and mortality from leukaemia 
overall in the UK, as well as its variation with gender, age, socioeconomic 
status, calendar time and geographical region. Children, as a sub-group of 
the study population were also of interest. 
3.4 METHODS 
Data source: 'The Health Improvement Network' (THIN) dataset was used. 
The total number of usable patients in the dataset was 5 395 612, with 2 592 
133 actively contributing data on 1 st July 2007 when data for this study was 
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extracted. Data recorded from 1987 to July 2007 have been used in this 
study. 
Case ascertainment: A list of READ codes was used to identify all cases with 
a diagnosis of leukaemia in the dataset (see Appendix 8). I compiled this list 
by collating the descriptions of all ICD-10 diagnostic codes that apply to 
leukaemia and identifying the applicable READ codes from the READ code 
dictionary accompanying THIN data. Many retrospective diagnoses are 
entered into patient records at the time someone first joins a practice, or 
when a practice first starts to use diagnostic software. For this reason, cases 
were only included in these studies if their first ever recording of a diagnosis 
of leukaemia occurred at least 12 months after their general practice records 
were computerised. This ensured that only incident, rather than prevalent 
cases were identified for inclusion in the study. 
Data management for cases: As mentioned in Chapter 2,THIN data are 
organised into 6 files: patient; medical; therapy; additional health data (AHD) 
data file, which contains information on preventative healthcare, tests and 
immunisations; postcode variable indicators (PVI) and dosage. A patient 
identifier links the patient data files to each other. Data for the leukaemia 
cases used in these studies were provided to me in the form of 6 files as 
mentioned above, and all subsequent data management and statistical 
analyses were performed by me. The files were linked to each other using 
the unique patient identifier included in THIN data. 
58 
The specific variables of interest required for these analyses were then 
created as follows: Age at diagnosis was calculated as the age at which a 
leukaemia diagnosis was first recorded in a given patient's record in the 
dataset. This was then grouped into 19, 5-year age categories with category 
1 being those aged 0-5yrs and category 19 representing those aged over 90. 
To further enhance statistical power, age at diagnosis was further grouped 
into 20-year age-bands, and year of diagnosis into 5-year bands for the 
purposes of calculating adjusted incidence and mortality rates. Age and 
year-band were then included in the analysis as categorical variables, as 
were gender, Townsend Score and health authority. Male gender was used 
as the baseline in gender analyses. The 13 health authorities are those 10 
defined for England by the Department of Health in July 200661 , in addition to 
Scotland, Wales and Northern Ireland. 
Denominator data: In order to calculate incidence and mortality rates the 
THIN mid-year population (1 st July 2007) were used as denominator data. 
These were provided to me as aggregate data stratified by gender, age, 
Townsend score and health authority, and contained over 37 million person-
years of data. This method was used in order to reduce the volume of data 
that would have to be handled. Processing individual person-time data would 
have exceeded the capacity of available computing resources. 
Analysis: Crude incidence rates for leukaemia, stratified by gender, age at 
diagnosis, Townsend score, year of diagnosis and health authority, were 
calculated. Poisson Regression was then used to determine incidence rate 
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ratios independently for gender, age, Townsend Score, year of diagnosis and 
health authority. Incident rate ratios mutually adjusted for all the variables of 
interest were then calculated. Incidence rate ratios were then calculated in 
the same way for children under the age of 20 years at the time of diagnosis. 
The median survival from leukaemia was determined, and as well as the risk 
of death (Hazard Ratios) stratified by age, gender, Townsend Score, year of 
diagnosis and health authority. All analyses were conducted using STAT Av9. 
Ethics: Ethical approval for study was obtained from the Nottingham 
Research Ethics Committee. 
3.5 RESULTS 
3.5.1 Incidence 
A total of 4 162 cases of leukaemia were identified, of whom over half were 
male. Over 6% of all cases were diagnosed in children aged less than 20 
years, of whom over half were male (Table 3.1). 
Table 3.1: Gender Distribution of Leukaemia Cases 
MALES FEMALES TOTAL 
N 0/0 N 0/0 
All Cases 2314 55.60 1 848 44.40 4 162 
Under 20yrs 147 55.06 120 44.94 267 
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The overall incidence of leukaemia in this study population is 11.25 per 
100 000 person-years, and 3.22 per 100 000 person-years in children aged 
less than 20 years. Crude incidence rates stratified by gender, age category, 
Townsend Score, year of diagnosis and health authority are shown in Table 
3.2 to Table 3.8. 
Table 3.2: Crude Incidence Rates by Gender 
Cases Person-years I. R. * 95% Cont. Interval 
Overall 
Male 
Female 
4162 
2314 
1 848 
36 982 494 11 .25 
18278041 12.66 
18 704 453 9.88 
*Incidence Rates per hundred thousand person-years 
10.91 - 11.60 
12.15 -13.18 
9.44 - 10.34 
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Table 3.3: Crude Incidence Rates by Age at Diagnosis 
Age Cases Person-years LR.* 950/0 Conf. Interval 
<6 131 2282229 5.74 4.84 - 6.81 
6-10 66 2 129032 3.10 2.43- 3.94 
11-15 38 2010582 1.89 1.37 - 2.59 
16-20 40 1 851 851 2.16 1.58 - 2.93 
21-25 34 2537313 1.34 0.96 - 1.87 
26-30 32 2500000 1.28 0.90 - 1.81 
31-35 53 2746 113 1.93 1.47 - 2.52 
36-40 66 2784810 2.37 1.86 - 3.02 
41-45 103 3179012 3.24 2.67 - 3.93 
46-50 142 2431 506 5.84 4.95 - 6.88 
51-55 199 2271 689 8.76 7.62 - 10.06 
56-60 311 2 114208 14.71 13. 17 - 1 6.44 
61-65 391 2 195395 17.81 16.13-19.67 
66-70 506 1 630679 31.03 28.44 - 33.85 
71-75 590 1 444308 40.85 37.69 - 44.29 
76-80 593 1 192679 49.72 45.87 - 53.89 
81-85 460 996708 46.15 42.12 - 50.57 
86-90 279 433901 64.30 57.18 - 72.31 
>90 128 237499 53.90 45.32 - 64.09 
*Incidence Rates per hundred thousand person-years 
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Table 3.4: Crude Incidence Rates by 20-year Age Bands 
Age Cases Person-years I .R.* 950/0 Conf. Interval 
<20 267 8291 925 3.22 2.86 - 3.63 
20-39 193 10604395 1.82 1.58 - 2.10 
40-59 755 10000000 7.55 7.03 - 8.11 
60-79 2080 6463642 32.18 30.83 - 33.60 
80+ 867 1 667949 51.98 48.63 - 55.55 
*Incidence Rates per hundred thousand person-years 
Table 3.5: Crude Incidence Rates by Townsend Score 
Townsend Score Cases Person-years I.R.* 95% Cont. Interval 
1 946 8423864 11.23 10.54 - 11.97 
2 922 7 180685 12.84 12.04-13.70 
3 784 6950354 11.28 10.51 - 12.09 
4 695 6222023 11.17 10.37 - 12.04 
5 446 4486921 9.94 9.06 - 10.90 
No Record 369 3731 041 9.89 8.93 - 10.96 
*Incidence Rates per hundred thousand person-years 
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Table 3.6: Crude Incidence Rates by Year of Diagnosis 
Year Cases Person-years LR.* 950/0 Cont. Interval 
1987 1 41 778 2.39 0.34 - 16.99 
1988 2 286755 0.70 0.17 - 2.79 
1989 20 503 119 3.98 2.57 - 6.16 
1990 74 1 112 781 6.65 5.29 - 8.35 
1991 116 1 379310 8.41 7.01 - 10.09 
1992 126 1 494661 8.43 7.08 - 10.04 
1993 147 1 644295 8.94 7.60 - 10.51 
1994 188 1 787072 10.52 9.11 - 12.13 
1995 197 1 921 951 10.25 8.91 - 11.79 
1996 185 2095 130 8.83 7.64 - 10.20 
1997 198 2229729 8.88 7.72 - 10.20 
1998 243 2316491 10.49 9.25 - 11.90 
1999 236 2 381 432 9.91 8.72 - 11.26 
2000 260 2418604 10.75 9.52 - 12.14 
2001 307 2467845 12.44 11.12 - 13.91 
2002 362 2 520 891 14.36 12.96 - 15.92 
2003 317 2 568 881 12.34 11.05 - 13.77 
2004 356 2 581 580 13.79 12.43 - 15.30 
2005 305 2618025 11.65 10.42 - 13.04 
2006 350 2617801 13.37 12.04 - 14.84 
*Incidence Rates per hundred thousand person-years 
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Table 3.7: Crude Incidence Rates by Year-band of Diagnosis 
Year Cases Person-years I.R.* 95% Conf. Interval 
1987-1991 213 3322932 6.41 5.60 - 7.33 
1992-1996 843 8949044 9.42 8.81 - 10.08 
1997-2001 1 244 11 813 865 10.53 9.96 - 11.13 
2002-2006 1 690 12910618 13.09 12.48 - 13.73 
*Incidence Rates per hundred thousand person-years 
Table 3.8: Crude Incidence Rates by Health Authority 
Health Authority Cases Person-years I.R. * 95% Conf. Interval 
London 400 4 415 011 9.06 8.21 - 9.99 
East of England 339 3228571 10.50 9.44 - 11.68 
East Midlands 213 1 797468 11.85 10.36 - 13.55 
North East 156 1 258064 12.40 10.60 - 14.51 
North West 466 4000000 11.65 10.63 - 12.75 
Northern Ireland 82 1 156558 7.09 5.71 - 8.80 
Scotland 261 2242268 11.64 10.31 -13.14 
South Central 476 4 103448 11.60 10.60 - 12.69 
South East Coast 424 3424878 12.38 11.26 - 13.62 
South West 485 3733641 12.99 11.89 - 14.20 
Wales 234 1 908646 12.26 10.78 - 13.93 
West Midlands 358 3520157 10.17 9.17 - 11.28 
Yorkshire & Humber 268 2200328 12.18 10.80 - 13.73 
*Incidence Rates per hundred thousand person-years 
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The results of Poisson regression showing incidence rate ratios 
independently for gender, age category, Townsend Score, year of diagnosis 
and health authority are shown in Table 3.9 to Table 3.15. Incidence rate 
ratios mutually adjusted for all the variables of interest are shown in Table 
3.16 and Table 3.17. 
With regard to gender, the unadjusted risk of leukaemia in women is 11 % 
lower than in men (IRR 0.79, p<0.01, 95% C.I. 0.74-0.84). When adjusted for 
age-category at diagnosis, Townsend Score, year of diagnosis and health 
authority, however, the risk is 34% lower in women than men (IRR 0.66, 
p<0.01, 95% C.I. 0.62-0.70). 
Table 3.9: Incidence Rate Ratios by Gender 
Gender IRR Std. Err. P>z 95% Cont. Interval 
Males 1 
Females 0.79 0.03 <0.01 0.74 - 0.84 
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The bimodal distribution of age at time of diagnosis is shown in Figure 3.1 . 
Figure 3.1: Distribution of Age at Diagnosis 
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The risk of leukaemia in those aged between 20 and 40 is only 56% that of 
those aged less than 20 years (IRR 0.56, p<0.01, 95% C.I. 0.47-0.68), when 
adjusted for gender, Townsend Score, year of diagnosis and health authority. 
After the age of 40 the RR of leukaemia rises, reaching as much as 17 times 
that of the under 20's in those aged 80 and over (IRR 17.03, p<0.01 , 95% 
C.I. 14.81-19.57), when similarly adjusted (p for trend<0.01) . 
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Table 3.10: Incidence Rate Ratios by Age at Diagnosis 
Age IRR Std. Err. p>z 95% Conf. Interval 
<6 1 
6 - 10 0.55 0.08 <0.01 0.41 - 0.74 
11 - 15 0.34 0.06 <0.01 0.23 - 0.48 
16 - 20 0.37 0.07 <0.01 0.26 - 0.54 
21 - 25 0.24 0.05 <0.01 0.16 - 0.35 
26 - 30 0.20 0.04 <0.01 0.13 - 0.23 
31 - 35 0.32 0.05 <0.01 0.23 - 0.45 
36 - 40 0.42 0.06 <0.01 0.31 - 0.56 
41 - 45 0.56 0.07 <0.01 0.43- 0.72 
46 - 50 0.99 0.12 0.93 0.78 - 1.26 
51 - 55 1.52 0.17 <0.01 1.22 - 1.90 
56 - 60 2.51 0.27 <0.01 2.04 - 3.09 
61 - 65 3.01 0.31 <0.01 2.47- 3.68 
66 -70 5.25 0.52 <0.01 4.32 - 6.38 
71 - 75 7.01 0.69 <0.01 5.79 - 8.50 
76 - 80 8.36 0.82 <0.01 6.90 - 10.13 
81 - 85 7.94 0.80 <0.01 6.52 - 9.67 
86 - 90 11.10 1.19 <0.01 8.99 - 13.69 
> 90 9.31 1.17 <0.01 7.27-11.92 
68 
Table 3.11: Incidence Rate Ratios by 20-year Age-bands 
Age IRR Std. Err. p>z 95% Cenf. Interval 
<20 1 
20-39 0.55 0.05 <0.01 0.46- 0.67 
40-59 2.29 0.16 <0.01 1.99 - 2.64 
60-79 9.65 0.63 <0.01 8.48 - 10.97 
80+ 15.83 1.12 <0.01 13.78-18.18 
The incidence of leukaemia increases more sharply in men than women after 
the age of 40 years (Figure 3.2). 
Figure 3.2: Incidence by Age at Diagnosis and Gender 
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In terms of socioeconomic deprivation, the relative risk of leukaemia tends to 
decrease with increasing Townsend Score (i.e. increasing deprivation), 
although the test for trend did not reach statistical significance (p for trend = 
0.08 across Townsend Scores 1 to 5) in multivariate analyses. 
Table 3.12: Incidence Rate Ratios by Townsend Score 
Townsend Score IRR Std. Err. p>z 95% Cont. Interval 
1 1 
2 1.13 0.05 0.01 1.03 - 1.24 
3 0.99 0.05 0.82 0.90 - 1.09 
4 0.99 0.05 0.81 0.89 - 1.09 
5 0.87 0.51 0.02 0.78 - 0.98 
No Record 0.89 0.06 0.05 0.78 - 1.00 
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Table 3.13: Incidence Rate Ratio by Year of Diagnosis 
Year IRR Std. Err p>z 95% Conf. Interval 
1987 1 
1988 0.29 0.36 0.31 0.03 - 3.21 
1989 1.66 1.70 0.62 0.22 - 12.37 
1990 2.78 2.80 0.31 0.39 - 19.98 
1991 3.51 3.53 0.21 0.49 - 25.15 
1992 3.52 3.53 0.21 0.49-25.19 
1993 3.73 3.75 0.19 0.52 - 26.68 
1994 4.39 4.40 0.14 0.62 - 31.34 
1995 4.28 4.29 0.15 0.60 - 30.55 
1996 3.69 3.70 0.19 0.52 - 26.32 
1997 3.71 3.72 0.19 0.52 - 26.45 
1998 4.38 4.39 0.14 0.61 - 31.24 
1999 4.14 4.15 0.16 0.58 - 29.50 
2000 4.49 4.50 0.13 0.63 - 31.98 
2001 5.20 5.20 0.10 0.73 - 37.00 
2002 6.00 6.01 0.07 0.84 - 42.70 
2003 5.15 5.16 0.10 0.72 - 36.70 
2004 5.76 5.77 0.08 0.81 - 41.01 
2005 4.87 4.88 0.11 0.68 - 34.67 
2006 5.58 5.59 0.09 0.78 - 39.74 
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Table 3.14: Incidence Rate Ratio by Year-band of Diagnosis 
Year- band IRR Std. Err. P>z 95% Cont Interval 
1987-1991 1 
1992-1996 
1997-2001 
2002-2006 
1.47 
1.64 
2.04 
0.11 
0.12 
0.15 
<0.01 
<0.01 
<0.01 
1.27 - 1.71 
1.42 - 1.90 
1.77 - 2.36 
The incidence of leukaemia has increased over calendar time. The relative 
risk of leukaemia in 2002-2006 was nearly twice that of the period 1987-
1991, when adjusted for gender, age-category, Townsend Score and health 
authority (p for trend<0.01). When only data for the past decade is analysed, 
the incidence has remained stable, however (p for trend= 0.09). 
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The relative risk of leukaemia does not vary significantly by health authority 
compared to London, when adjusted for gender, age-category, Townsend 
Score and year of diagnosis. The exception to this is in Northern Ireland 
where the risk is 23% lower than London (IRR 0.77, p=0.04, 95% C.1. 0.61-
0.98), when adjusted for gender, age-category, Townsend Score and year of 
diagnosis. 
Table 3.15: Incidence Rate Ratio by Health Authority 
Health Authority IRR Std. Err. p>z 95% Conf. Interval 
London 1 
East of England 1.18 0.09 0.02 1.02 - 1.37 
East Midlands 1.27 0.11 0.01 1.07 - 1.51 
North East 1.36 0.13 <0.01 1.13 - 1.65 
North West 1.26 0.09 <0.01 1.10- 1.45 
Northern Ireland 0.79 0.10 0.06 0.62 - 1.01 
Scotland 1.28 0.10 <0.01 1.09 - 1.50 
South Central 1.26 0.09 <0.01 1.10- 1.44 
South East Coast 1.36 0.10 <0.01 1.19 -1.57 
South West 1.42 0.10 <0.01 1.24 - 1.62 
Wales 1.33 0.11 <0.01 1.13 - 1.57 
West Midlands 1.14 0.08 0.07 0.99 -1.32 
Yorkshire & Humber 1.32 0.11 <0.01 1.12 - 1.54 
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Table 3.16: Mutually Adjusted Incident Rate Ratios 
IRR** Std. Err. p>z 95% Cont. Interval 
Gender 
Males 1 
Females 0.66 0.02 <0.01 0.62 - 0.70 
Age at Diagnosis 
<20 1 
20-39 0.56 0.05 <0.01 0.47 - 0.68 
40-59 2.28 0.16 <0.01 1.98 - 2.63 
60-79 9.85 0.65 <0.01 8.66 - 11.20 
80+ 17.03 1.21 <0.01 *p<0.01 14.81 - 19.57 
Townsend Score 
1 1 
2 1.05 0.05 0.30 0.96 - 1.15 
3 0.97 0.05 0.55 0.88 - 1.07 
4 0.98 0.05 0.76 0.89 - 1.09 
5 0.90 0.05 0.09 *p=0.08 0.80 - 1.02 
No record 0.93 0.06 0.26 0.82 - 1.06 
Year of Diagnosis 
1987-1991 1 
1992-1996 1.44 0.11 <0.01 1.24 - 1.67 
1997-2001 1.59 0.12 <0.01 1.38 - 1.84 
2002-2006 1.95 0.14 <0.01 *p<0.01 1.69 - 2.25 
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Table 3.17: Mutually Adjusted Incident Rate Ratios (Cont.) 
Health Authority 
London 1 
East of England 1.01 0.08 0.91 0.87 - 1.17 
East Midlands 1.12 0.10 0.20 0.94 - 1.33 
North East 1.19 0.12 0.07 0.99 - 1.44 
North West 1.12 0.08 0.10 0.98 - 1.29 
Northern Ireland 0.77 0.10 0.04 0.61 - 0.98 
Scotland 1.17 0.09 0.06 0.99 - 1.37 
South Central 1.00 0.07 0.97 0.87 - 1.15 
South East Coast 1.12 0.08 0.12 0.97 - 1.29 
South West 1.09 0.08 0.21 0.95 - 1.25 
Wales 1.12 0.10 0.19 0.95 - 1.32 
West Midlands 1.03 0.08 0.74 0.89 - 1.19 
Yorkshire & Humber 1.09 0.09 0.29 0.93 - 1.28 
** AlIlRRs are adjusted for all other variables in the table. 
*p = test for trend across ordered categories. 
Cases for whom there is no record of Townsend Score were excluded from 
the trend analysis of Townsend Score. 
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Children aged less than 20yrs: In the analysis of this sub-group of 267 
children, the overall incidence of leukaemia is 3.22 per hundred thousand 
person-years. The risk of leukaemia is similar in males and females, when 
adjusted for gender, Townsend Score, year of diagnosis and health authority. 
Furthermore, multivariate analysis reveals an increasing trend in incidence 
with increasing Townsend Score (Le. increasing deprivation), although this 
does not reach statistical significance (p for trend=O.07). A statistically 
significant decreasing trend over calendar time is also seen in multivariate 
analysis (p for trend<O.01). There was some variation in incidence by 
geographic region, with higher incidence rates in the Midlands, the North 
East, Northern Ireland and Wales, compared to London. (See Table 3.18 and 
Table 3.19) 
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Table 3.18: Mutually Adjusted Incident Rate Ratios « 20 years) 
IRR** Std. Err. p>z 95% Cont. Interval 
Gender 
Males 1 
Females 0.97 0.13 0.84 0.76 - 1.25 
Townsend Score 
1 1 
2 1.39 0.28 0.10 0.94 - 2.05 
3 1.31 0.26 0.17 0.89 - 1.93 
4 1.50 0.31 0.05 0.99 - 2.25 
5 1.53 0.38 0.09 *p=0.07 0.94 - 2.47 
No record 1.43 0.43 0.24 0.79 - 2.59 
Year ot Diagnosis 
1987-1991 1 
1992-1996 0.45 0.12 <0.01 0.27 - 0.78 
1997-2001 0.35 0.10 <0.01 0.20 - 0.59 
2002-2006 0.35 0.09 <0.01 *<0.01 0.21 - 0.58 
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Table 3.19: Mutually Adjusted Incident Rate Ratios ( < 20 years) (Cont.) 
Health Authority 
London 1 
East of England 1.23 0.37 0.48 0.68 - 2.23 
East Midlands 2.94 1.12 0.01 1.39 - 6.22 
North East 2.37 1.01 0.04 1.03 - 5.45 
North West 1.15 0.28 0.58 0.71 - 1.85 
Northern Ireland 2.44 1.03 0.04 1.06 - 5.58 
Scotland 1.73 0.52 0.07 0.95 - 3.12 
South Central 1.05 0.30 0.87 0.60 - 1.82 
South East Coast 0.93 0.27 0.80 0.53 - 1.64 
South West 1.15 0.33 0.62 0.66 - 2.03 
Wales 1.88 0.55 0.03 1.06 - 3.34 
West Midlands 1.15 0.32 0.61 0.67 - 1.99 
Yorkshire & Humber 1.63 0.51 0.12 0.88 - 3.00 
** AlllRRs are adjusted for all other variables in the table. 
*p = test for trend across ordered categories. 
Cases for whom there is no record of Townsend Score were excluded from 
the trend analysis of Townsend Score. 
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3.5.2 Mortality 
The median survival from leukaemia is 6.58 years, and is more than a year 
longer in women than men. See Table 3.20. 
Table 3.20: Median Survival by Gender 
Gender 
Men 
Women 
Overall 
Cases Median Survival (years) 
2293 6.08 
1 829 7.12 
4 122 6.58 
Std. Err. 95% C. I. 
0.25 5.42 - 6.86 
0.35 6.14 - 8.62 
0.32 6.00 - 7.05 
Mutually adjusted hazard ratios for the risk of death from leukaemia are 
presented in Table 3.21 and Table 3.22. The risk of death from leukaemia is 
11 % lower in women than men when adjusted for age, Townsend Score, 
year of diagnosis and health authority (HR 0.89, p=0.02, 95% C.1. 0.81-0.98), 
and increases with increasing age at diagnosis (p for trend <0.01). The risk 
of death increases with increasing Townsend Score (p for trend=0.05), but 
there has been no significant change in mortality over time. The risk of death 
from leukaemia is greater in the East Midlands, North East, North West, 
South West, West Midlands and Yorkshire & Humber, compared to London 
as baseline, when adjusted for gender, age at diagnosis, Townsend Score 
and year of diagnosis. 
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Table 3.21: Mutually Adjusted Hazard Ratios 
HR** Std. Err. p>z 95% c. I. 
Gender 
Males 1 
Females 0.89 0.04 0.02 0.81 - 0.98 
Age at Diagnosis 
<20 1 
20-39 1.94 0.40 <0.01 1.29 - 2.91 
40-59 2.16 0.36 <0.01 1.56 - 2.99 
60-79 3.97 0.62 <0.01 2.93 - 5.38 
80+ 7.32 1.16 <0.01 *p<0.01 5.36 - 9.99 
Townsend Score 
1 1 
2 1.08 0.08 0.31 0.93 - 1.25 
3 1.31 0.10 <0.01 1.13 - 1.52 
4 1.17 0.09 0.04 1.00 - 1.37 
5 1.13 0.11 0.20 *p=0.05 0.94 - 1.36 
No record 1.44 0.14 <0.01 1.19 -1.75 
Year of Diagnosis 
1987-1991 1 
1992-1996 0.91 0.09 0.32 0.74-1.10 
1997-2001 0.93 0.09 0.47 0.76-1.13 
2002-2006 0.92 0.09 0.39 *p=0.98 0.75-1.12 
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Table 3.22: Mutually Adjusted Hazard Ratios (Cont.) 
Health Authority 
London 1 
East of England 1.26 0.15 0.06 
East Midlands 1.32 0.18 0.04 
North East 1.61 0.22 <0.01 
North West 1.55 0.17 <0.01 
Northern Ireland 0.94 0.21 0.77 
Scotland 0.87 0.12 0.34 
South Central 1.22 0.14 0.08 
South East Coast 1.19 0.14 0.14 
South West 1.38 0.15 <0.01 
Wales 1.25 0.17 0.09 
West Midlands 1.36 0.16 0.01 
Yorkshire & Humber 1.30 0.17 0.04 
** All HRs are adjusted for all other variables in the table. 
*p = test for trend across ordered categories. 
0.99 - 1.59 
1.01 - 1.72 
1.23 - 2.11 
1.25 - 1.92 
0.60 - 1.46 
0.66-1.15 
0.98 - 1.53 
0.94 - 1.50 
1.11 - 1.72 
0.96 -1.63 
1.07 - 1.72 
1.01 - 1.67 
Cases for whom there is no record of Townsend Score were excluded from 
trend analysis of Townsend Score. 
Children aged less than 20yrs. The risk of death from leukaemia in this 
group is independent of gender, Townsend Score and year of diagnosis. 
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3.6 DISCUSSION 
The overall incidence of leukaemia in this study is 11.25 per 100 000 person 
years. Men are more commonly affected than women overall, but the risk of 
leukaemia under the age of 40 years is similar in men and women. The age 
at which leukaemia is diagnosed shows a bimodal distribution with a peak in 
incidence in children aged 5 years and under, and a further peak in the 8th 
decade of life. The incidence of leukaemia is independent of socioeconomic 
deprivation. There is an increase in the incidence of leukaemia over calendar 
time, and some variation in incidence with geographical region. 
The median survival from leukaemia is 6 years and 7 months in this study. 
Mortality is greater in men than in women, and increases with increasing age 
at diagnosis. Increasing mortality (of borderline significance) is seen with 
increasing deprivation. Mortality has remained stable over time, but varies 
with geographic region. 
In the subgroup of children, however, leukaemia incidence is independent of 
gender and socioeconomic class, but has decreased over calendar time. 
Again there is some variation by geographical region. Leukaemia mortality in 
children is independent of gender, Townsend Score and year of diagnosis. 
The overall incidence of leukaemia found in this study is consistent with the 
crude incidence rate of 11.7 per 100 000 population published by Cancer 
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Research UK for 20041. The overall protective effect of the female gender on 
the relative risk of leukaemia, despite a similar risk until the age of 40 years, 
is explained by a sharper increase in incidence in men compared to women 
after the age of 40 (Figure 3.2). This pattern of divergence in incidence has 
been noted in other developed countries6. An infectious aetiology for 
leukaemia is supported by this difference in that there are known gender 
differences in susceptibility to infections such as polio and herpes simplex, 
for example. The role of hormonal influences such as the use of HRT in 
women is also an area for further exploration. Two previous studies that 
investigated HRT as a risk factor for leukaemia were inconclusive 3940. Both 
studies contained only small numbers of leukaemia cases, however. The 
finding here of a poorer prognosis in men than women with leukaemia is also 
consistent with other published data 1 62. 
Studies of leukaemia and social class prior to the 1980's have mainly found 
higher incidences of leukaemia in higher social classes6 63 64, in both adults 
and children. Since the 1980's, however, studies have consistently reported 
inverse associations with socioeconomic class65 . This apparent change in 
direction of the association may be due to differences in study design and 
measures of socioeconomic deprivation that have been used over time, 
however. Most studies conducted prior to the 1980's were ecological and 
these tended to show a positive association of leukaemia with higher social 
class. In contrast, after 1980 most studies were case-control studies and 
used individual-level measures of income and education, rather than 
ecological-level indicators of socio-economic status65 . This study has now 
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shown a lack of association of leukaemia incidence with socioeconomic 
class, but an impact on mortality when small-area measures of socio-
economic status, such as Townsend Score, are used. 
Except for Northern Ireland, this study showed no significant differences in 
incidence among health authorities compared to London when adjusted for 
gender, age-category, deprivation and year of diagnosis. Significant regional 
differences in mortality consistent with a 'north-south divide' are evident, 
however, even when adjusted for socioeconomic deprivation. A study 
examining nearly 4 000 cases of leukaemia in teenagers and young adults 
between 1979-2001, found statistically significant variation in leukaemia 
incidence by English region 9• In contrast to this study though, the highest 
incidences of leukaemia were found in London and the south of England 
when adjusted for Townsend score, but results were not adjusted for gender 
or year of diagnosis. This difference may reflect a real change in the pattern 
of incident leukaemia since that study was done, or differences in study 
design. Regional mortality rates published by the Office of National Statistics 
(ONS) also show wide regional variation, but because the denominator 
population used by the ONS was based on 1996 UK population estimates, 
figures between that study and this one cannot be directly compared62 . 
The initial increase in incidence over calendar time followed by a stable 
incidence over the last decade found in this study is consistent with those 
trends published by Cancer Research UK, which shows an increase in 
incidence until the mid 1990s followed a subsequent plateau 1. While the 
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initial increasing trend may represent a true increase in leukaemia incidence, 
it is more likely to represent a combination of the latter with demographical 
changes in the population over that time, improvements in diagnostic 
accuracy, and improvements in cancer data recording and collation. Given 
that the diagnosis of leukaemia increases with age, the expansion in the 
elderly population over the time period in question would have contributed to 
an increase in the number of cases over time. Improvements in specialist 
medical care for the elderly would also have resulted in greater case 
ascertainment in this group as more asymptomatic and/or milder disease was 
detected by the increased use of routine blood testing. Furthermore, once 
blood tests have shown abnormalities, more invasive diagnostic 
investigations are more likely to have been carried out in this age group in 
recent years than in the past. With the advent of cancer registries and the 
development of regional specialist cancer services, there has also been 
better recording, collection and collation of data over time. In terms of 
mortality, an analysis of nearly 57 000 patients with leukaemia in the UK 
found that 5-year survival increased for men diagnosed over the period 1986-
1999, but not for women66. A study reporting age-specific mortality rates for 
leukaemia covering the period 1910 to 1997, showed that in children under 5, 
mortality increased until the 1950 ls and then declined steadily since 11. For 
those aged over 65 years, however, an increase in mortality rates was again 
seen until the 19501s, but the subsequent decline only continued until the 
19801s. This was then followed by plateau in mortality rates. 
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The main strength of this study is that the large size of the study population 
has allowed precise estimates of the incidence and mortality of leukaemia in 
the UK to be calculated. By using THIN data, access to a number of variables 
of interest by which to stratify results has been possible, which would not 
have been the case had registry data been utilised. A further strength is that 
the denominator population was obtained from the same dataset as the 
cases, which has enabled accurate stratified incidence rate and hazard ratios 
to be determined. The methodology employed here to minimise the inclusion 
of prevalent cases means that incidence rates are not spuriously elevated. 
The risk of masking any trends over time has also been minimised by 
excluding prevalent cases in this way. 
A further strength of this study is its design. The vast majority of previous 
studies have been case-control studies, with most requiring the involvement 
of patients and/or carers in completing interviews and/or questionnaires65 . 
Case-control studies like these, while efficient for studying rare diseases, are 
prone to bias, including socioeconomic class bias, in the selection of cases 
and controls. This potentially results in disproportionately more people from 
higher social classes participating in studies. Using general practice data has 
minimised this type of selection bias, while addressing the difficulty of 
studying a rare disease by using appropriate statistical techniques, i.e. 
Poisson regression. 
A potential weakness of this study is the issue of diagnostiC validity in the 
dataset. This is unlikely to have impacted on these results given that 
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leukaemia is a secondary care diagnosis made only after confirmatory 
pathological tests. General practitioners are therefore unlikely to record this 
diagnosis in patients' records in error. The similarity of the disease incidence 
, 
gender distribution and trends over time presented here, with those published 
from registry data, provides some evidence of the 'face validity' of leukaemia 
in THIN. Direct examination of patients' medical records to confirm leukaemia 
diagnoses is possible, but this is time-consuming and expensive. Due to the 
limited resources available, it was not possible to examine individual patient 
records in this way for this project. 
In summary, the incidence of leukaemia in the UK is independent of 
socioeconomic class, but mortality appears to be worse with increasing 
deprivation. One explanation for this may be that those leukaemia subtypes 
with worse prognoses are more common among people from lower 
socioeconomic classes. This issue is addressed in the following chapter, 
which examines the incidence of and mortality from a number of leukaemia 
subtypes. While different subtypes are known to have different peak ages of 
onset and different mortality patterns, the next study will determine whether 
these patterns are consistent across the spectrum of socioeconomic class. 
Greater co-morbidity in patients from lower socioeconomic classes, and/or a 
class bias in access to treatments such bone marrow transplantation are 
other possible reasons for finding greater mortality rates among leukaemia 
patients from lower socioeconomic classes. This will also be examined in 
subsequent studies. 
87 
Although the incidence of leukaemia has remained relatively stable over the 
past decade, the number of people affected will continue to rise as the 
population ages. This has significant implications for the planning of future 
health care services. 
This study has demonstrated the value of general practice data in leukaemia 
research, adding to the growing evidence of the value of such data in 
epidemiological research. 
MAIN FINDINGS 
• THIN data are a valuable resource for leukaemia research. 
• Mortality in leukaemia patients from lower socioeconomic 
classes is worse than among the better off. 
QUESTIONS ARISING 
• Are leukaemia subtypes with poorer prognoses more common In 
people from lower socioeconomic classes? 
• Does a socioeconomic class gradient in mortality exist for all 
leukaemia subtypes? 
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4 INCIDENCE AND MORTALITY BY LEUKAEMIA 
SUBTYPE 
4.1 ABSTRACT 
Introduction: The previous study showed that while the incidence of 
leukaemia overall was independent of social class, mortality was worse with 
increasing socioeconomic deprivation. This study will determine whether 
these trends hold true for all leukaemia subtypes. Aims and Objectives: The 
quantification of the incidence of and mortality from leukaemia subtypes in 
the UK and their variation with gender, age, socioeconomic status, 
geographical region, and year of diagnosis. Methods: General practice data 
from 'The Health Improvement Network' (THIN) dataset were used as before. 
Incident cases of 6 leukaemia subtypes of interest were identified from READ 
codes and denominator data were again derived from THIN. Crude incidence 
rates, incidence rate ratios, as well as the median survival and hazard ratios 
for risk of death from these leukaemia subtypes were calculated as before. 
Results: 3 226 (78%) of the 4 162 leukaemia cases were identified as falling 
into one of the 6 subtypes of interest. Cll is the most common and All the 
least common subtype. Cll, AMl and unspecified lymphocytic leukaemia 
are more common in men. The incidence of all leukaemia subtypes increases 
with increasing age at diagnosis, and the incidence of all subtypes studied 
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are independent of socioeconomic class. All subtypes, except unspecified 
Lymphocytic Leukaemia and CML, show an increasing trend in incidence 
over time. Median survival is best in ALL and worst in AML. The prognosis for 
women with CLL and unspecified Lymphocytic Leukaemia is better than for 
men. The risk of death increases with increasing age at diagnosis (p for 
trend<0.01) for all subtypes. Mortality in AML increases with increasing 
socioeconomic deprivation (p for trend=0.01), but is independent of 
deprivation in all other subtypes. Mortality is independent of the year of 
diagnosis. There is some regional variation in both incidence and mortality. 
Discussion: Similar mortality from most leukaemia subtypes across 
socioeconomic gradients and geographical locations suggests that on the 
whole, access to and uptake of diagnostic services is equal across these 
strata. However, poorer survival in AML patients from lower socioeconomic 
classes, despite no socioeconomic class gradient in incidence warrants 
further exploration. 
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4.2 INTRODUCTION 
The previous study showed that while the incidence of leukaemia overall was 
independent of socioeconomic class, survival appears to worsen with 
increasing socioeconomic deprivation. Furthermore, despite little regional 
variation in incidence, there is wide regional variation in survival even when 
socioeconomic deprivation is adjusted for. This study will examine whether 
these findings hold true for all leukaemia subtypes. 
4.3 AIMS AND OBJECTIVES 
To quantify the incidence of and mortality from leukaemia subtypes in the 
UK, and their variation with gender, age, socioeconomic status, calendar time 
and geographic region. 
4.4 METHODS 
The data source and case ascertainment methods used were the same as in 
the previous study. Again, I did all data management and statistical analyses 
myself. 
Data management of cases: The following leukaemia subtypes were 
identified from the same list of READ codes described before (See Appendix 
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8): Acute Lymphocytic Leukaemia (ALL), Chronic Lymphocytic Leukaemia 
(CLL), unspecified Lymphocytic or Lymphoid Leukaemia, Acute Myelocytic 
Leukaemia (AML), Chronic Myelocytic Leukaemia (CML), and unspecified 
Myeloid Leukaemia. Cases that were described as lymphoid or myeloid, but 
which could not be identified as either acute or chronic were categorised as 
'unspecified' lymphoid or myeloid leukaemia, respectively. These are not, 
therefore, discrete disease entities. Each case was assigned the most 
specific diagnosis in their THIN record. This ensured that even if the first 
recoding of a leukaemia diagnosis for a given patient was non-specific, but 
subsequent records were more specific because bone marrow biopsy results 
had became available in the interim, for example, then the more specific 
diagnosis was captured. 
Denominator data: These were derived and used as before. 
Variables of interest: Age at diagnosis was calculated as before, and was 
grouped into 5, 20-year age categories with category 1 being those aged 
<20yrs and category 5 representing those aged 80yrs and above. Year of 
diagnosis was grouped into 4, 5-year bands with 1987-1991 being the first 
year-band and 2002-2006 the most recent. As before, age and year of 
diagnosiS were then included in the analysis as categorical variables, along 
with gender, Townsend Score and health authority. Male gender was again 
used as the baseline in gender analyses. 
92 
Analysis: The 6 different subtypes described above were analysed 
separately. Crude incidence rates for leukaemia subtypes, stratified by 
gender, age at diagnosis, Townsend Score, year of diagnosis and health 
authority, were calculated. Poisson Regression was then used to determine 
incidence rate ratios, both independently and mutually adjusted for gender, 
age, Townsend Score, year of diagnosis and health authority. The median 
survival for each of the leukaemia subtypes was then calculated. Hazard 
ratios for the risk of death, adjusted for gender, age-category, Townsend 
Score, year of diagnosis and health authority, was then determined by Cox 
Regression. All analyses were conducted using STATAv9. 
Ethics: Ethical approval for study was obtained from the Nottingham 
Research Ethics Committee. 
4.5 RESULTS 
3 226 (78%) of the 4 162 leukaemia cases were identified as falling into one 
of the 6 subtypes of interest. The 936 cases that did not have a sufficiently 
specific diagnosiS to be further categorised were broadly representative of 
the overall study population. 
With respect to gender, for example, 56% of them were male and 44% were 
female. The age at diagnosis of the uncategorized cases showed a bimodal 
distribution (Figure 4.1) consistent with that of the overall population, as seen 
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in Figure 4.2. In terms of socioeconomic class, the number of uncategorized 
cases decline with increasing Townsend Score (i.e. with increasing 
socioeconomic deprivation) (see Figure 4.3 below) as is seen with the overall 
leukaemia population studied (see Figure 4.4 below and Table 3.5). The 
increase in the number of cases recorded over time in this group between 
1987 -1991 and 1997-2001 follows a similar pattern to the overall leukaemia 
population as is shown in Table 4.1. The number of uncategorized cases 
then fell in the period 2002-2006. The uncategorized cases as a proportion of 
all leukaemia diagnoses fell from 1992-1996 through 2002-2006, which 
suggests that the recording of leukaemia diagnoses in general practice data 
has improved over time. This is probably the result of a combination of more 
specific diagnoses being made, and then reported to GPs from secondary 
care, and/or more specific diagnoses being recorded in the general practice 
computer systems. The health authorities in which these patients reside also 
reflect those of the leukaemia cases overall, with more cases from the South 
Central and fewest cases from Northern Ireland (see Figure 4.5 and Figure 
4.6). Excluding these 936 cases in subsequent analyses is therefore unlikely 
to have introduced important bias into the results that follow. 
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Figure 4.1: Age Distribution of Unclassified Cases 
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Figure 4.2: Age Distribution of All Leukaemia Cases 
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Figure 4.3: Townsend Score Distribution of Unclassified Cases 
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Figure 4.4: Townsend Score Distribution of All Leukaemia Cases 
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Table 4.1: Uncategorized vs All Leukaemia Cases by Year of Diagnosis 
Year of Diagnosis All Leukaemia Cases Uncategorized Cases 
Number Number % Of all leukaemia cases 
1987-1991 213 62 29 
1992-1996 843 283 34 
1997-2001 1 244 310 25 
2002-2006 1 690 257 15 
Total 4162 936 22 
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Figure 4.5: Health Authority Distribution of Unclassified Cases 
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Figure 4.6: Health Authority Distribution of All Leukaemia Cases 
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4.5.1 Incidence 
The crude incidence rates are shown in Table 4.2 and Table 4.3. ell is the 
most common subtype and All the least common, with crude incidence 
rates of 4.20 and 0.49 per hundred thousand person years, respectively. 
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Table 4.2: Crude Incidence Rates Per 100 000 Person-years 
! All Cll Unsp. lymph. AML CML Unsp. Myel. Person-years 
Cases I IR Cases 1 IR Cases I IR Cases I IR Cases I IR Cases I IR 
Overall: 36993338 182 0.49 1 554 4.20 356 0.96 602 1.63 265 0.72 257 0.70 
Gender: Male 18284784 89 0.49 914 5.00 203 1.11 319 1.74 138 0.75 118 0.65 
Female 18708554 93 0.50 640 3.42 153 0.82 283 1.51 137 0.73 139 0.74 
Age at Diagnosis: 
<20 8288518 116 1.40 1 0.01 20 0.24 30 0.36 5 0.06 7 0.08 
20-39 10600000 23 0.22 6 0.06 10 0.09 54 0.51 23 0.22 18 0.17 
40-59 9995 140 18 0.18 251 2.51 68 0.68 123 1.23 66 0.66 58 0.58 
60-79 6462905 14 0.22 927 14.34 185 2.86 296 4.58 120 1.86 115 1.78 
80+ 1 668 108 1 1 0.66 369 22.12 73 4.38 99 5.93 61 3.66 59 3.54 
Townsend Score: 
1 8421 428 45 0.53 356 4.22 85 1.01 138 1.64 65 0.77 54 0.64 
2 7 179869 35 0.49 335 4.67 82 1.14 145 2.02 51 0.71 66 0.92 
3 6 952 931 36 0.52 293 4.21 64 0.92 111 1.60 61 0.88 47 0.68 
4 6220650 27 0.43 269 4.32 65 1.04 103 1.66 40 0.64 40 0.64 
5 4488547 19 0.42 174 3.89 35 0.78 53 1.18 32 0.71 31 0.69 
No Record 3729913 20 0.54 127 3.40 25 0.67 52 1.39 26 0.70 19 0.51 
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Table 4.3: Crude Incidence Rates Per 100 000 Person-years (Cont.) 
Year of Diagnosis: 
1987-1991 3323812 10 0.30 62 1.87 29 0.87 21 0.63 16 0.48 13 0.39 
1992-1996 8945 190 31 0.35 230 2.57 102 1.14 82 0.92 66 0.74 49 0.55 
1997-2001 11 800000 54 0.46 449 3.80 104 0.88 164 1.39 75 0.63 88 0.74 
2002-2006 12900000 81 0.63 733 5.68 113 0.88 295 2.29 108 0.84 103 0.80 
Health Authority: 
London 4417 180 25 0.57 162 3.67 31 0.70 63 1.43 28 0.63 15 0.34 
East of England 3227730 14 0.43 120 3.72 31 0.96 53 1.64 26 0.81 17 0.53 
East Midlands 1 798239 6 0.33 84 4.67 16 0.89 25 1.39 15 0.83 17 0.95 
North East 1 257649 5 0.40 52 4.13 16 1.27 28 2.23 16 1.27 4 0.32 
North West 4001 708 24 0.60 171 4.27 34 0.85 67 1.67 29 0.72 26 0.65 
Northern Ireland 1 156921 6 0.52 31 2.68 1 1 0.95 11 0.95 4 0.35 8 0.69 
Scotland 2243121 9 0.40 112 4.99 21 0.94 37 1.65 21 0.94 17 0.76 
South Central 4 103293 21 0.51 185 4.51 30 0.73 64 1.56 34 0.83 24 0.58 
South East Coast 3425204 14 0.41 150 4.38 45 1.31 71 2.07 19 0.55 29 0.85 
South West 3733229 20 0.54 191 5.12 25 0.67 78 2.09 37 0.99 36 0.96 
Wales 1 909249 12 0.63 78 4.09 30 1.57 25 1.31 12 0.63 16 0.84 
West Midlands 3518793 20 0.57 117 3.32 34 0.97 47 1.34 19 0.54 28 0.80 
Yorkshire & Humber 2 201 022 6 0.27 101 4.59 32 1.45 33 1.50 15 0.68 20 0.91 
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The age at diagnosis of leukaemia by subtype is shown in Figure 4.7. Most 
cases of All are diagnosed in early ch ildhood, while most Cll is diagnosed 
in the elderly. 
Figure 4.7: Age at Diagnosis 
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Age at Diagnosis 
The gender differences in age at diagnosis for the 4 specific subtypes of 
interest are shown in Figure 4.8 to Figure 4.11 . The more dramatic increase 
in incidence in men than women after the age of 40 (noted earlier for 
leukaemia overall (Figure 3.2)) is mostly accounted for by Cll, where this 
trend is most pronounced, and by AMl. 
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Figure 4.8: All Incidence by Age and Gender 
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Figure 4.10: AML Incidence by Age and Gender 
AML Incidence by Age and Gender 
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Figure 4.11: CML Incidence by Age and Gender 
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Results of Poisson regression are shown in Table 4.4 and Table 4.5, in which 
incidence rate ratios are adjusted for all other variables in the table. Women 
have a lower incidence of ell, unspecified lymphocytic leukaemia and 
AMl than men. The incidence of all subtypes increases with increasing age 
at diagnosis (p for trend<0.01 for each subtype). A decreasing incidence of 
All with increasing deprivation is present, but this trend does not reach 
statistical significance (p for trend =0.13). There is no evidence of a 
socioeconomic class trend in incidence in any of the other subtypes. An 
increasing trend in incidence with calendar time is seen for All, ell, AMl 
and unspecified Myeloid leukaemia. Statistically significant regional variation 
in incidence is only seen in unspecified Myeloid leukaemia. 
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Table 4.4: Mutually Adjusted Incidence Rate Ratios (95% Col.) 
All Cll' Unsp. lymph. 
I 
AMl CMl Unsp. Myel. 
Gender 
Males 1 1 1 1 1 1 
Females 1.05(0.78-1.42) p=0.73 0.55(0.49-0.61) p<0.01 0.62(0.50-0.77) p<0.01 0.78(0.66-0.92) p<0.01 0.84(0.66-1.07) p=0.17 0.96(0.75-1.23) p=0.74 
Diagnosis 
Age 
<20 1 } 1 1 1 1 
20-39 0.14(0.09-0.23) } 1 0.40 (0.19-0.85) 1.40(0.89-2.21 ) 3.32(1.25-8.81 ) 2.07(0.87 -4.96) 
40-59 0.11 (0.06-0.18) 74.74 (33.24-168.02) 2.73(1.66-4.50) 3.28(2.18-4.93) 10.34(4.16-25.71 ) 6.86(3.13-15.02) 
60-79 0.16(0.09-0.27) 433.54(194.22-967.72) 11.82(7.44-18.76) 12.34(8.41-18.09) 29.58(12.08-72.44) 20.28(9.44-43.54) 
80+ 0.47(0.25-0.87)*p<0.01 731.00(326.11-1638.61 )*p<0.01 20.15(12.25-33.14 )*p<0.01 16.23(10.67 -24.67)*p<0.01 62.42(25.04-155.60)*p<0.01 41.68(19.00-91.43)*p<0.01 
Townsend 
Score 
1 1 1 1 1 1 1 
2 0.92(0.59-1.45) 1.01 (0.86-1.17) 1.01 (0.75-1.38) 1.15(0.90-1.47) 0.79(0.54-1.15) 1.32(0.92-1.89) 
3 0.90(0.57 -1.42) 0.95(0.81-1.12) 0.88(0.63-1.22) 0.92(0.71-1.20) 1.07(0.75-1.52) 1.02(0.69-1.52) 
4 0.76(0.47-1.23) 1.01 (0.86-1.19) 1.00(0.72-1.39) 1.01 (0.77-1.32) 0.72(0.47-1.09) 1.01 (0.66-1.53) 
5 0.67(0.38-1.18)*p=0.13 0.93(0.77-1.13)*p=0.59 0.74(0.49-1.12)*p=0.25 O. 73(0.52-1.03)*p=0.1 0 0.84(0.54-1.31 )*p=0.32 1.19(0.75-1.87)*p=0.97 
No Record 0.98(0.56-1.71 ) 0.88(0.72-1.09) 0.64(0.40-1.03) 0.86(0.61-1.21 ) 0.82(0.51-1.32) 0.86(0.50-1.49) 
. Baseline age category for ell is age<40. *p=test for trend across ordered categories. 
Records with missing Townsend Scores were not included in trend analysis for Townsend Score. 
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Table 4.5: Mutually Adjusted Incidence Rate Ratios (95% C.I.) (Cont.) 
Diagnosis Year 
1987-1991 1 1 1 1 1 1 
1992-1996 1.15(0.56-2.34 ) 1.34(1.01-1.77) 1.25(0.83-1.89) 1.43(0.88-2.31 ) 1.49(0.86-2.58) 1.35(0.73-2.49) 
1997-2001 1.49(0.76-2.92) 1.96(1.50-2.55) 0.95(0.63-1.44) 2.14(1.36-3.38) 1.27(0.74-2.18) 1.83(1.02-3.28) 
2002-2006 2.02(1.04-3.90)*p<0.01 2.87(2.21-3.72)*p<0.01 0.92(0.61-1.39)*p=0.11 3.49(2.24-5.44)*p<0.01 1.64(0.97-2.78)*p=0.12 1.92(1.08-3.43) *p=0.01 
Health Authority 
London 1 1 1 1 1 1 
East of England 0.72(0.38-1.40) 0.84(0.66-1.07) 1.09(0.66-1.81 ) 0.98(0.67-1.43) 1.14(0.66-1.96) 1.37(0.68-2.75) 
East Midlands 0.57(0.23-1.40) 1.06(0.80-1.39) 1.02(0.56-1.88) 0.79(0.48-1.29) 1.12(0.58-2.16) 2.48(1.23-5.00) 
North East 0.69(0.26-1.82) 0.93(0.68-1.28) 1.56(0.85-2.85) 1.39(0.88-2.19) 1.75(0.93-3.30) 0.80(0.27 -2.43) 
North West 1.03(0.58-1.83) 0.94(0.75-1.72) 1.03(0.63-1.68) 0.97(0.68-1.40) 1.03(0.60-1.75) 1.69(0.89-3.21 ) 
Northern Ireland 0.67(0.25-1.77) 0.72(0.49-1.06) 1.21 (0.59-2.48) 0.66(0.35-1.26) 0.56(0.20-1.62) 1.94(0.82-4.60) 
Scotland 0.69(0.32-1.49) 1 .12(0.87-1.43) 1.28(0.74-2.23) 1.09(0.72-1.65) 1.46(0.83-2.59) 1.90(0.94-3.84) 
South Central 0.81 (0.44-1.50) 0.90(0.72-1.12) 0.77(0.46-1.29) 0.77(0.52-1.12) 1.09(0.65-1.84) 1.27(0.65-2.48) 
South East Coast 0.61 (0.31-1.21) 0.93(0.73-1.17) 1.40(0.88-2.24) 1.20(0.84-1.72) 0.63(0.33-1.18) 2.05(1.09-3.87) 
South West 0.86(0.47-1.59) 0.97(0.78-1.21) 0.71 (0.42-1.21) 1.07(0.75-1.52) 1.27(0.76-2.09) 2.14(1.16-3.95) 
Wales 1.10(0.54-2.21 ) 0.87(0.66-1.15) 1.56(0.92-2.64) 0.72(0.44-1.71 ) 0.88(0.44-1.75) 2.07(1.02-4.21 ) 
West Midlands 0.92(0.50-1.70) 0.79(0.62-1.01 ) 1.16(0.71-1.90) 0.83(0.56-1.23) 0.76(0.41-1.39) 2.11 (1.12-3.99) 
Yorks. & Humber 0.48(0.19-1.17) 0.97(0.75-1.26) 1.55(0.94-2.57) 0.89(0.57 -1.37) 0.81 (0.41-1.57) 2.21 (1.12-4.33) 
*p=test for trend across ordered categories. 
107 
4.5.2 Survival 
The median survival from each subtype is shown in Table 4.6 and Kaplan-
Meier survival curves are plotted by subtype in Figure 4.12. ALL has the best 
prognosis, with more than 50% of cases surviving the end of the follow-up 
period. The 5-year survival for ALL was therefore calculated and is 69%. The 
poorest median survival, of only 9112 months, is seen in AML. 
Table 4.6: Median Survival by Subtype 
Subtype Cases Median Survival (Yrs) Std. Error 95% C.1. 
ALL* 180 - - -
CLL 1 549 9.53 0.30 8.20 - 10.18 
Unspecified Lymphoid 352 10.05 0.54 6.83 -. 
AML 593 0.79 0.03 0.64 - 1.00 
CML 274 5.06 0.19 3.67 - 6.07 
Unspecified Myeloid 250 0.81 0.04 0.59 - 1.39 
OVERALL 3198 6.82 0.37 6.16 - 7.46 
* >50% of ALL cases survived follow-up penod. (5-year mortality IS 69%) 
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Figure 4.12: Kaplan-Meier Survival Plots by Subtype 
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Hazard ratios are presented in Table 4.7 and Table 4.8, and show a lower 
risk of death among women than men with Cll (HR 0.59, p<0.01, 95%, C.I. 
0.49-0.72) and unspecified lymphoid leukaemia (HR 0.58, p=0.01, 95% C.I. 
0.40-0.85), when adjusted for age-category, Townsend Score, year of 
diagnosis and health authority. The relative risk of death increases with 
increasing age at diagnosis in all subtypes (p for trend<0.01). In AMl the risk 
of death increases with increasing deprivation (p for trend=0.01), but no such 
gradient is seen in any of the other subtypes. There has been no statistically 
significant trend in the risk of death over calendar time. The risk of death in 
AMl in the North East was nearly twice that in london even when gender, 
age at diagnosis, Townsend Score and year of diagnosis was adjusted for 
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and also significantly greater in the North West than in London (North East 
HR 1.94, 95% C.1. 1.10-3.42; North West HR 1.66,95% C.1. 1.04-2.65). 
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Table 4.7: Mutually adjusted Hazard Ratios (95% C.I.) 
All Cll' Unsp.lymph. AMl CMl Unsp.Myel. 
Gender 
Males 1 1 1 1 1 1 
Females 1.34(0.71-2.56) p=0.37 0.59(0.49-0.72) p<0.01 0.58(0.40-0.85) p=0.01 0.89(0.72-1 .10) p=0.29 0.89(0.61-1.30) p=0.56 1.02(0.72-1.43) p=0.94 
Diagnosis Age 
<20 1 } 1 1 } 1 
20-39 0.82(0.26-2.61 ) } 1 4.01 (0.35-46.57) 1.63(0.58-4.60) } 1 0.88(0.17-4.54) 
40-59 4.63(1.81-11.86) 0.36(0.08-1.57) 6.20(0.81-47.23) 4.64(1.79-11.16) 0.92(0.35-2.43) 1.38(0.31-6.10) 
60-79 20.82(7.57-57.22) 1.08(0.26-4.48) 10.98(1.51-79.76) 10.02(4.09-24.55) 2.46(1.04-5.83) 3.88(0.91-16.53) 
80+ 4.96(1.43-17.20)*p<0.01 2.85(0.69-11.77)*p<0.01 29.51 (4.00-217.82)*p<0.01 23.80(9.45-59.91 )*p<O.01 6.86(2.74-17.22)*p<0.01 7.22(1.67-31.21 )*p<0.01 
Townsend 
Score 
1 1 1 1 1 1 1 
2 1.05(0.40-2.80) 1.21 (0.84-1.49) 0.75(0.44-1 .29) 1.15(0.84-1.58) 0.60(0.31-1.15) 1.02(0.62-1.69) 
3 1.21 (0.45-3.28) 1.30(0.98-1.74) 1.94(1.16-3.24) 1.38(0.99-1.92) 0.86(0.49-1.50) 0.79(0.46-1.35) 
4 0.89(0.32-2.5) 1.21 (0.89-1.65) 0.67(0.37-1.23) 1.44(1.03-2.02) 0.91 (0.48-1.73) 0.69(0.39-1.21 ) 
5 0.25(0.05-1.17)*p=0.23 1.18(0.82-1.70)*p=0.31 0.76(0.39-1.50)*p=0.40 1.S2(0.99-2.35)*p=0.01 0.73(0.36-1.51 )*p=0.65 0.75(0.40-1.43)*p=0.13 
No Record 0.79(0.23-2.63) 2.07(1.43-2.99) 1 .29(0.59-2.83) 1.06(0.68-1.63) 1.34(0.65-2.75) 0.63(0.27-1 .49) 
. Baseline age category for ell is age<40. *p=test for trend across ordered categones. 
Records with missing Townsend Scores were not included in trend analysis for Townsend Score. 
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Table 4.8: Mutually adjusted Hazard Ratios (95% C.I.) (Cont.) 
Diagnosis Year 
1987-1991 1 1 1 1 1 1 
1992-1996 6.44(0.91-45.71 ) 0.88(0.60-1.27) 0.86(0.47-1.58) 0.60(0.34-1.08) 0.64(0.31-1.35) 1.31 (0.52-3.31) 
1997-2001 6.94(1.03-46.58) 1.02(0.71-1.48) 0.86(0.45-1.64) 0.52(0.30-0.90) 0.72(0.34-1.54) 1.13(0.46-2.78) 
, 
2002-2006 4.57(0.72-28.90)*p=0.83 1.09(0.74-1.61 )*p=0.58 1.25(0.65-2.42)*p=0.77 0.54(0.32-0.93) *p=0.93 0.45(0.20-0.99)*p=0.07 1.10(0.45-2.69)*p=0.19 
Health Authority 
London 1 1 1 1 1 1 
East of England 1.00(0.23-4.38) 1.10(0.69-1.76) 1.14(0.43-3.06) 1.41 (0.86-2.31) 0.85(0.37-1.97) 0.74(0.29-1.89) 
East Midlands 0.37(0.04-3.83) 1 .27(0.77-2.12) 1.89(0.69-5.20) 1.10(0.58-2.09) 0.89(0.33-2.41 ) 0.98(0.38-2.57) 
North East 1.72(0.32-9.22) 1.32(0.74-2.36) 1.39(0.51-3.82) 1.94(1.10-3.42) 0.75(0.30-1.89) 0.95(0.26-3.46) 
North West 0.86(0.27-2.76) 1 .43(0.94-2.19) 1.69(0.74-3.85) 1.66(1.04-2.65) 0.98(0.43-2.19) 1.27(0.55-2.96) 
Northern Ireland 6 cases, no deaths 1.12(0.49-2.54) 1.07(0.35-3.30) 1.12(0.43-2.92) 4 cases, no deaths 1.35(0.39-4.70) 
Scotland 0.33(0.04-2.99) 0.84(0.50-1.42) 0.97(0.33-2.84) 1.21 (0.68-2.14) 0.39(0.14-1.11 ) 0.96(0.36-2.59) 
South Central 0.95(0.26-3.45) 1.21 (0.79-1.86) 1.16(0.45-2.99) 1.14(0.70-1 .85) 0.64(0.28-1.47) 0.90(0.36-2.24) 
South East Coast 1.51 (0.43-5.29) 1.38(0.88-2.15) 1.07(0.47-2.44) 1.43(0.89-2.29) 0.64(0.24-1.74) 0.80(0.31-2.07) 
South West 1.05(0.33-3.35) 1.24(0.81-1.88) 0.87(0.33-2.31 ) 1.17(0.74-1.85) 0.57(0.25-1.32) 1.29(0.56-2.99) 
Wales 1.80(0.41-7.92) 1.30(0.77-2.19) 1.34(0.53-3.41 ) 1.18(0.64-2.19) 0.85(0.28-2.55) 1.45(0.57-3.73) 
West Midlands 2.13(0.65-6.94) 1.26(0.79-2.01 ) 1.87(0.81-4.29) 1.58(0.94-2.66) 0.41 (0.13-1.33) 1.14(0.48-2.75) 
Yorks. & Humber 6 cases, no deaths 1.56(0.97-2.53) 1.61 (0.68-3.79) 1.05(0.59-1.87) 0.77(0.27-2.16) 0.88(0.35-2.21 ) 
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4.6 DISCUSSION 
4.6.1 ALL 
4.6.1.1 Incidence 
No statistically significant difference in incidence between males and females 
was found in this study. Results of previously published studies are 
inconsistent in this regard. A study examining sex ratios in incident leukaemia 
found no gender difference in patients aged under 10 years, but a male 
predominance at older ages7 . Many other studies have, however, found a 
male excess when only children were studied5 8 35 64 67. These differences 
may be explained by the different age ranges studied, different time periods 
covered by the respective studies, as well as the relative proportion of 
children in the respective study populations. Furthermore, studies have 
adjusted for different combinations of potential confounders from each other, 
and from this study. The age at diagnosis of ALL in this study is consistent 
with that published elsewhere, with a peak under the age of 5 years, followed 
by a relatively low incidence until after the ih decade, when incidence 
increases again35 64. Several studies found no socioeconomic class trend in 
incidence, in keeping with findings here9 1035. In terms of trends over time, 
results here are again consistent with those in the literature which show an 
increasing incidence of ALL starting in the 1950 ls through the 1970'S64 , 
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followed by a plateau in incidence rates thereafter67, No significant regional 
variation was found, here in keeping with earlier UK studies9, 
4.6.1.2 Mortality 
The survival patterns seen in ALL in these data are consistent with the 
findings of earlier published research, The 5-year survival has consistently 
been reported at around 70% for those diagnosed in the 1980 ls 13141668, This 
research found no gender differences in mortality in ALL, while others have 
shown better survival in girls68, A review of UK children covering the period 
1911-97 found greater mortality among boys than girls until the 1980s, after 
which mortality rates were similar, until mortality in girls was actually greater 
than in boys by 199711 , Survival was also found to be worse with increasing 
age at diagnosis 1468, Like this research, other studies have also consistently 
reported improvements in survival over the past 3 decades, both across 
Europe and within the UK13 14 1668, No socioeconomic trend in mortality is 
seen in these data, nor are there significant regional differences in mortality, 
These findings are consistent with an earlier study of ALL in the UK 16, 
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4.6.2 ell 
4.6.2.1 Incidence 
ell is known to be the most commonly diagnosed leukaemia in adults in 
western countries317, which concurs with the findings of this research. Again 
the gender and age distribution of incident ell found here is consistent with 
previous studies, which show a male predominance3 7 69, and greater 
incidence rates with increasing age3 1769. An increasing incidence over time 
has also been noted before 11, although it is unclear whether this represents a 
true increase in disease incidence, or increased diagnosis as a result of 
routine blood testing in older patients, for example. This study found regional 
differences in ell incidence, although no region had significantly different 
incidence rates from london. Again, this is consistent with the findings of 
others 17. Socioeconomic class trends in ell have not been published for the 
UK before. 
4.6.2.2 Mortality 
Survival in ell ranges from months to decades, which is consistent with the 
fact that most patients will die from other, unrelated causes. The median 
survival in this study of 9112 years is consistent with the findings of others3 17. 
The finding that mortality increases with increasing age at diagnosis is also 
entirely expected, given that co-morbidity is likely to be greater with 
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increasing age and that patients die of co-morbid conditions more often than 
of ell itself. The gender difference in mortality of about 2: 1 (male: female) 
found here is consistent with previously published research 11 6970. Reasons 
for this phenomenon might include greater co-morbidity among men, better 
response to treatment in women, better tolerance to the adverse effects of 
treatment in women, and/or intrinsic gender differences in the disease at 
biological level. In addition to the combination of factors in play related to 
ell, women also have a longer life expectancy than men in general. 
Mortality is reported to have remained fairly constant over the past 2 
decades, again consistent with the results of this research6 11. No studies 
specifically examining the association of ell mortality with socioeconomic 
class have been published. Given that over half of patients are reported to 
die from other causes 17, it seems that any associations with socioeconomic 
class will reflect the associations between the respective causes of death and 
socioeconomic class. The lack of association of socioeconomic class and 
mortality found in this research is thus not surprising. Regional mortality 
figures for ell have not been published for UK patients, but this research 
showed no statistically significant differences in mortality in any region 
compared to london. 
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4.6.3 AML 
4.6.3.1 Incidence 
AMl incidence is greater in men than women, and increases with increasing 
age at diagnosis in this study. Again this is entirely consistent with previous 
hf· d· 718196470 Th .. .. researc In Ings . ese data show an Increasing Incidence over 
the period of this study. Other reports of time trends in AMl incidence 
produce conflicting results, but are difficult to interpret since they cover 
different age ranges and different time periods63. There is no socioeconomic 
trend in incidence, nor any statistically significant regional difference in 
incidence in these data, which concurs with the findings of others9 10. 
4.6.3.2 Mortality 
As is the case in ell, mortality in AMl is greater in men than in women, and 
increases with increasing age at diagnosis. Both these findings are in 
keeping with the published literature. Survival has previously been shown to 
decline with increasing age218, and survival beyond 1 year is reported to be 
rare in those aged over 702. In a study examining the effect of gender and 
age on survival in European children with AMl, girls had better survival than 
boys overall, but there was no gender difference in survival under the age of 
5 years20. The findings with regard to gender were similar across most of the 
European countries included in the study. A study of 507 adults with AML in 
the south-east of England, however, found no statistically significant 
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difference in 1- and 3-year survival between men and women 18. While 
mortality in AML in the research presented here appears to have declined 
over the past 2 decades, the trend did not reach statistical significance. The 
MRC AML trial data show a consistent improvement in survival over time for 
younger, but not older, patients71 . The fact that data in this study do not show 
a significant improvement in AML survival over time may reflect the overall 
age distribution of AML in this study, i.e. mostly older people, many of whom 
are not entered into clinical trials. 
The statistically significant increase in mortality with increasing 
socioeconomic deprivation found here for AML, but not other subtypes, has 
not been shown before. Given that AML incidence is independent of 
socioeconomic class, the findings with regard to mortality suggest that 
diagnostic services are equally accessible across the spectrum of 
socioeconomic class, but that other factors influence the provision and/or 
uptake of therapeutic services. Furthermore, mortality in AML is worse in the 
North East and North West, even after adjusting for deprivation. Again, this is 
in the absence of regional variation in incidence. This phenomenon has also 
not been demonstrated before. Regional differences in mortality may similarly 
be explained by differences in treatment uptake, but may also reflect regional 
differences in the population's co-morbidity. 
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4.6.4 CML 
4.6.4.1 Incidence 
This research found a greater incidence of CML with increasing age, 
consistent with others' findings2 4. A male excess in incidence was found 
here, but the gender difference was not statistically significant. While the 
published literature mostly shows a male predominance4 718, gender 
differences do not always reach statistical significance and the non-
significant results found here may be due to the small number of CML cases 
in this study (265 cases). Although the incidence of CML in another study 
was found to increase with increasing socioeconomic deprivation among 
teenagers and young adults in England9 , this was not borne out in these 
data. The authors do not state the number of CML cases studied, however, 
so it is not clear whether that study is comparable to the one presented here 
in terms of size. The same study also found statistically significant 
differences in incidence across geographic regions, which is not evident in 
these data. Again, this difference is difficult to interpret due to the lack of 
information on the size of the study population. Differences in the age of the 
study populations and/or differences in study design may also account for the 
difference in results. No other reports were found in the literature describing 
the incidence of CML in the context of socioeconomic class or geographic 
region within the UK. No trend in the incidence of CML over time is seen in 
this study. A review reporting trends in incident CML among adults showed 
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an increase in men between 1970 and 1985, but this was followed by a 
decrease in incidence until the end of the study period in 1990, back to 1970 
levels. In women the incidence rates were fairly similar in 1990 compared to 
what they were in 197011 . Reported CML trends need to be interpreted with 
caution since Chronic Myelomonocytic Leukaemia (CMML), previously 
included within CML, has been reclassified as a myelodysplastic syndrome. 
This reclassification occurred during the time period included in this study, 
and hence case ascertainment in this (and other studies incorporating this 
time period) will vary. 
4.6.4.2 Mortality 
Mortality in CML increases with age in these data, as is the case with the 
other leukaemia subtypes studied. This has been also been demonstrated 
before 18. Mortality tends to be greater in men than women in this study, 
which is also consistent with other published work, which found better 1- and 
5-year survival among women than men with both CML and CMML in a study 
of UK adults 18. Gender differences did not reach statistical significance in the 
aforementioned study, but case numbers were small (180 CML cases, 99 
CMML cases). The downward trend in mortality over the past 2 decades 
found here concurs with data published earlier, covering the period 1968 to 
199711 . No association between mortality and socioeconomic class or 
geographic region is seen in this study. No national data in this regard has 
been published before for the UK. 
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In summary, the age and gender patterns of leukaemia incidence and 
mortality in the subtypes studied here are consistent with the published 
literature. Time trends in incidence and mortality must be interpreted with 
caution due to changes in case ascertainment and classification of subtypes 
over time. The increase in incidence of All, ell and AMl over the past 20 
years has not been accompanied by improvements in mortality with time. 
Whether the increase in incidence over time is real or due to better recording, 
or both, remains unclear. 
There is a paucity of published data examining socioeconomic class and 
regional variations in incidence and mortality for most leukaemia subtypes. 
Similar leukaemia incidence across social strata and geographic regions 
found in this research suggests that diagnostic services are equally 
accessible to all. The concomitant discrepancies in mortality, however, may 
suggest poorer uptake of or response to treatment among people with AMl 
from lower social classes and those residing in the North East and the North 
West. 
The socioeconomic class difference in survival may reflect a class bias in 
treatment offered to people with AMl and/or greater co-morbidity in AMl 
patients from lower socioeconomic classes. A class bias in access to 
treatments such as haemopoetic stem cell transplantation, for example, may 
however itself result from differences in co-morbidity, rather than a true class 
bias in treatment offered. 
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The following chapter examines social class differences in bone marrow 
transplantation and co-morbidity among patients with AML using hospital 
data. 
MAIN FINDINGS 
• Diagnostic validity for leukaemia subtypes in THIN is good. 
• Mortality in AML patients from lower socioeconomic classes is 
worse than among the better off, in the absence of a 
socioeconomic class trend in incidence. This is not seen for 
other leukaemia subtypes. 
QUESTIONS ARISING 
• Are patients from lower socioeconomic classes less likely to 
receive bone marrow transplantation than the better off? 
• If so, is this accounted for by a socioeconomic class gradient in 
co-morbidity among patients with AML? 
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5 Bone Marrow Transplantation and Socioeconomic 
Class in AML 
5.1 ABSTRACT 
Introduction: The previous study has shown that while the incidence of 
Acute Myeloid Leukaemia (AML) in the UK is similar across the spectrum of 
social class, mortality is nearly 50% greater among the most socio-
economically deprived patients than among the most advantaged. Aims and 
Objectives: The aim of this study was to determine whether AML patients 
from lower socioeconomic classes are less likely to receive bone marrow 
transplantation (BMT) than those from higher socioeconomic classes, and 
whether any difference in access to BMT found is due to greater co-morbidity 
among more deprived patients than among the better off. Methods: Using 
Hospital Episode Statistics (HES) data, all incident cases of AML admitted to 
UK hospitals between 1998 and 2007 were identified, including those 
admitted as day-cases, along with all their co-existing medical diagnoses 
recorded in HES. All bone marrow transplants that these patients underwent 
during this period were also identified. The number of bone marrow 
transplantations undertaken in AML patients was calculated. and the results 
stratified by gender, age at diagnosis, year of diagnosis, degree of 
socioeconomic deprivation and co-morbidity. Logistic regression was used to 
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calculate odds ratios for bone marrow transplantation, adjusting for gender, 
age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and 
co-morbidity score. Results: A total of 23 910 incident cases of AML were 
identified over this 1 O-year time period, of whom 1 140 (4.8%) underwent 
BMT. A smaller percentage of patients from lower socioeconomic classes 
had transplants than those from higher socioeconomic classes. Bone marrow 
transplantation declines with increasing socioeconomic deprivation (p for 
trend <0.01). Patients with AML in the most deprived socioeconomic quintile 
are 40% less likely to have a bone marrow transplantation than those in the 
most advantaged socioeconomic class (OR 0.60, p<0.01, 95% C.I. 0.49 -
0.73), even after adjusting for gender, age at diagnosis, year of bone marrow 
transplantation and co-morbidity. Discussion: This large cohort study 
demonstrates that AML patients from lower socioeconomic classes are less 
likely to undergo bone marrow transplantation than their better off counter-
parts and that this phenomenon is independent of co-existing illness. 
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5.2 INTRODUCTION 
The previous study showed that while the incidence of Acute Myeloid 
Leukaemia (AML) in the UK is similar across the spectrum of social class, 
mortality is nearly 50% greater among the most socio-economically deprived 
patients than among the most advantaged72 . One possible reason for this 
difference in survival might be due to a class bias in treatment, such as bone 
marrow transplantation (BMT), and/or the result of greater co-morbidity 
among patients from lower socioeconomic classes. Trends in bone marrow 
transplantation across socioeconomic classes have not been investigated 
before. 
Previous studies have, however, shown a social class bias in the use of 
chemotherapy and radiotherapy. A US study of breast cancer patients, for 
example, found that women with less than a high school education were 3 
times more likely to receive smaller doses of adjunctive chemotherapy than 
those with a high school education, even after adjusting for co-morbidity, age, 
BMI, race and geographic region73. 
A similar phenomenon was found when lung cancer patients in Scotland 
were studied, with the poorest patients being 60% less likely to receive 
74 . . 
chemotherapy than their well-off counterparts . Colorectal cancer patients In 
both the UK and the US are also up to 50% less likely to receive 
chemotherapy if they are from lower socioeconomic classes than if they are 
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better off475. Again, both of these studies were adjusted for a range of 
confounding factors, including co-morbidity. 
5.3 AIMS AND OBJECTIVES 
The aim of this study was to use Hospital Episode Statistics (HES) data to 
determine whether AML patients from lower socioeconomic classes are less 
likely to receive bone marrow transplantation than those from higher 
socioeconomic classes. A further aim was to determine whether any 
differences in BMT found was due to greater co-morbidity among more 
deprived patients than among the better off. 
5.4 METHODS 
Hospital episode statistics (HES) data were used in this study as bone 
marrow transplantation takes place in hospital and is likely to be more reliably 
recorded in HES than in THIN. As discussed earlier, these data include 
patient demographics such as date of birth, gender and region of residence, 
details of diagnoses and treatments received, as well as administrative 
details such as admission and discharge dates, along with the place patients 
were treated (NHS Trust or independent sector hospital, for example)56. 
Lower Super Output Area (LSOA), a measure of socio-economic deprivation 
of the patient is also included in HES data. I mapped the LSOA of patients to 
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Townsend Score for the purposes of this research to ensure consistency in 
the measure of socioeconomic class used. 
Diagnosis dates are not held in HES; this was estimated for the purposes of 
this research. Patients were assumed to have been diagnosed with AML in 
the year they first had a code for AML in HES, provided they had at least one 
year of data in HES without any codes for AML. Patients who had a code for 
AML in HES from the first year they were represented in the data were 
censored. The time period of one year was chosen because the median 
survival of AML is relatively short (9Y2 months in this research 76). 
All incident cases of AML admitted to UK hospitals between 1998 and 2007, 
including those admitted as day-cases were identified. All co-existing medical 
diagnoses recorded in HES for these patients, along with all procedures, 
including bone marrow transplantation, which they underwent during all of 
their admissions over this period were also identified. 
The number of bone marrow transplantations undertaken in AML patients 
was calculated, and the results stratified by gender, age at diagnosis, year of 
diagnosis, degree of socioeconomic deprivation and co-morbidity. Townsend 
Score was again used as the measure of socioeconomic deprivation. 
Recorded data on co-morbid illness were used to assign a co-morbidity score 
to each patient using the Charlson Co-morbidity Index described earlier. 
Logistic regression was used to calculate odds ratios for bone marrow 
transplantation, adjusting for gender, age at diagnosis, year of diagnosis, 
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degree of socioeconomic deprivation and co-morbidity score. All data 
management and statistical analyses were conducted using STAT Av.1 0.0. 
5.5 RESULTS 
A total of 23 910 incident cases of AML were identified over this 1 a-year time 
period, of whom 1 140 (4.8%) underwent BMT. The numbers of bone marrow 
transplants performed across various strata in AML are shown in Table 5.1. 
A similar proportion of men and women, about 5%, underwent BMT. The 
frequency of bone marrow transplantation decreased with increasing age at 
diagnosis, with only 3 transplants recorded in those aged 71 or older. A 
smaller percentage of patients from lower socioeconomic classes had 
transplants than those from higher socioeconomic classes. 
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Table 5.1: Numbers of Bone Marrow Transplants 
BMT TOTAL 
No Yes (%) 
Overall 22770 1 140 (4.8) 23910 
Gender 
Males 12695 614 (4.6) 13309 
Females 10008 525 (5.0) 10533 
Age at Diagnosis 
Up to 30 2909 417 (13.0) 3326 
31 to 40 1 463 213 (13.0) 1 676 
41 to 50 1 912 222 (10.0) 2 134 
51 to 60 2947 237 (7.0) 3 184 
61 to 70 4523 48 (1.0) 4571 
71 and older 9013 3 (0.0) 9016 
Year of Diagnosis 
1997 to 1999 4730 262 (5.2) 4992 
2000 to 2001 4873 290 (5.6) 5 163 
2002 to 2003 4913 266 (5.1) 5 179 
2004 to 2007 8254 322 (3.8) 8576 
Townsend Score 
1 4433 265 (5.6) 4698 
2 4495 226 (5.6) 4721 
3 4179 190 (4.3) 4396 
4 3968 207 (4.9) 4 175 
5 3735 186(4.7) 3921 
No Record 1 960 66 (3.3) 2026 
Charlson Co-morbidity Score 
0 16 174 855 (5.0) 17029 
1 3238 108 (3.2) 3346 
2 or more 3358 177 (5.0) 3535 
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Table 5.2 shows the proportion of patients in each category of Charlson 
Score by socioeconomic class. 
Table 5.2: Charlson Score of AML patients by Social Class 
Charlson Score 
0 1 2 or more 
0/0 950/0 C.1. % 95% C.1. % 95% C.1. 
Townsend Score 
1 70 69 -72 14 13 - 15 16 15 - 17 
2 68 67 -70 16 14 - 17 16 15 - 17 
3 69 68 - 71 15 14 - 16 16 15 - 17 
4 69 68 -70 15 14 - 16 16 15 - 17 
5 68 67 -70 16 15 - 17 16 15 - 17 
No Record 94 93 - 95 3 2-4 2 2 -3 
Between 68 and 70% of AML patients have a Charlson Co-morbidity Score of 
0, 14 -16% have a Score of 1, and 16% have a Score of 2 or more, with no 
significant differences across socioeconomic classes in any of the co-
morbidity categories. 
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Odds Ratios for bone marrow transplantation in AML are shown in Table 5.3, 
where odds ratios are mutually adjusted for all other variables in the table 
(*p = test for trend across Townsend Scores 1 to 5). Bone marrow 
transplantation declines with increasing age at diagnosis after the age of 30 
(p for trend <0.01), as well as with increasing socioeconomic deprivation (p 
for trend <0.01). Patients with AML in the most deprived socioeconomic 
quintile are 40% less likely to have a bone marrow transplantation than those 
in the most advantaged socioeconomic class (OR 0.60, p<0.01, 95% C.I. 
0.49 - 0.73), even after adjusting for gender, age at diagnosis, year of bone 
marrow transplantation and co-morbidity. 
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Table 5.3: Odds Ratios for Bone Marrow Transplantation 
O. R.* Std. Err. p>z 95% C.I. 
Gender 
Males 1 -
-
-
Females 0.91 0.04 0.03 0.83 - 1.99 
Age at Diagnosis 
Up to 30 1 - - -
31 to 40 0.86 0.08 0.10 0.72 - 1.03 
41 to 50 0.65 0.06 <0.01 0.54 - 0.77 
51 to 60 0.40 0.04 <0.01 0.34 - 0.48 
61 to 70 0.05 0.01 <0.01 0.04 - 0.07 
71 and older 0.00 0.00 <0.01 0.00 - 0.00 
Year of Diagnosis 
1997 to 1999 1 - - -
2000 to 2001 1.12 0.10 0.22 0.93 - 1.34 
2002 to 2003 1.11 0.10 0.28 0.92 - 1.33 
2004 to 2007 0.84 0.07 0.05 0.70 - 1.00 
Townsend Score 
1 1 - - -
2 0.85 0.08 0.10 0.70 - 1.03 
3 0.76 0.08 0.01 0.63 - 0.93 
4 0.78 0.08 0.01 0.64 - 0.95 
5 0.60 0.06 <0.01 *p<O.01 0.49 - 0.73 
No Record 0.18 0.03 <0.01 0.14-0.24 
Charlson Score 
0 1 - - -
1 1.03 0.11 0.80 0.83 - 1.27 
2 or more 1.58 0.14 <0.01 1.33 - 1.89 
*AII odds ratios are adjusted for all other vanables In the table. 
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No statistically significant interaction was found between Townsend score 
and age, or year of diagnosis. There was, however, statistically significant 
interaction (p=0.01) between Townsend score and gender, with greater 
differences in odds ratios across the socioeconomic class gradient in women 
than in men. Results of logistic regression (Odds Ratios) stratified by gender 
are shown in Table 5.4. 
Table 5.4: Odds Ratios for Bone Marrow Transplantation by Gender 
o. R.** Std. Err. p>z 
MALES 
Townsend Score 
1 1 - -
2 0.83 0.11 0.16 
3 0.77 0.11 0.07 
4 0.83 0.11 0.17 
5 0.68 0.09 <0.01 *p=O.01 
No Record 0.18 0.03 <0.01 
FEMALES 
Townsend Score 
1 1 - -
2 0.86 0.12 0.29 
3 0.74 0.11 0.04 
4 0.73 0.11 0.03 
5 0.51 0.08 <0.01 *p<O.01 
No Record 0.21 0.05 <0.01 
** Adjusted for Age at diagnosIs, year of diagnosIs and Cha 
*p = test for trend across Townsend Scores 1 to 5. 
95% C.1. 
-
0.63 - 1.08 
0.58 - 1.02 
0.63 - 1.08 
0.52 - 0.88 
0.12 - 0.26 
-
0.65-1.14 
0.56 - 0.98 
0.54 - 0.97 
0.38 - 0.70 
0.14 - 0.34 
rison Score 
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5.6 DISCUSSION 
This study has shown that AML patients from more deprived socioeconomic 
classes are less likely to undergo bone marrow transplantation than their 
counter-parts from more advantaged social classes, even after adjusting for 
the presence of recorded co-existing disease. 
The main strength of this study is the large size of the study population. It has 
been possible to study over 23 000 incident cases of AML in the UK using 
data derived from hospital records. Data also included the co-existing 
medical conditions of AML patients, which made adjusting for co-morbidity 
possible. By using available data rather than questionnaires or interviews, 
any bias in the reporting of socioeconomic class and any social class bias in 
participation in the study has been eliminated. Bone marrow transplantation 
recording is likely to be accurate in hospital records given the highly 
specialised nature of the procedure. 
One potential weakness of this study is that it was not possible to adjust for 
the cytogenetic risk group of AML patients. Based on cytogenetics at 
presentation, AML patients are classified into good, intermediate, and 
adverse risk groups, each with very different long term outcomes77 . Good risk 
patients in their first remission are not transplanted, whereas adverse risk 
patients are almost always transplanted (subject to fitness and donor 
availability). Any bias introduced by this into these results will, however. 
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have applied across all social classes, unless patients from lower social 
classes are more likely to be in the good risk group than those from higher 
socioeconomic classes, for which there is no evidence. Although there is 
evidence that patients from lower social classes present later with disease 
symptoms in general, it is unlikely that late presentation is an important factor 
in AML survival given the acute presentation of the disease and its relatively 
poor prognosis. 
The accuracy of social class classification is imperfect given that Townsend 
Score is not an individual measure of deprivation. This will have introduced a 
non-differential bias into these results, if any, i.e. both patients who had had a 
bone marrow transplant and those who had not will have been similarly 
affected. Such a bias will have moved odds ratios closer to '1 '. It seems then 
that if it had been had been possible to perfectly adjust for socioeconomic 
deprivation, our results will have shown an even greater class bias. 
The validity of co-morbidity recorded in HES data may also be imperfect. Any 
inaccuracies would, however, apply equally across all social class strata and 
so is unlikely to have introduced bias into these results. Furthermore, these 
results showed no difference in recorded co-morbidity across the social 
classes. Residual confounding cannot be ruled out completely, however, 
since only co-morbidity recorded in the hospital episode data has been taken 
into account. Other co-morbidities not related to hospital admission or not 
recorded during admission may have existed which would have resulted in 
incomplete adjustment for co-morbidity. 
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To my knowledge no studies examining the association between bone 
marrow transplantation and socioeconomic class have previously been 
published. Studies have, however, examined the associations between social 
class and chemotherapy in a number of cancers. Several studies found that 
lower socioeconomic class predicted under-use of chemotherapy in 
colorectal cancer (CRC) 7475, breast cancer73 and lung cancer74. Two North 
American studies found that low socioeconomic status was associated with 
under-use of adjuvant chemotherapy in both breasf3 and colorectal 
cancers75, and postulated that this was in part due to a combination of poor 
access to care, financial barriers and physicians' assumptions and biases 
regarding patients from lower socioeconomic classes. Examples of the latter 
include assumptions that adequate social and monetary support may not be 
available, that patients from lower socioeconomic classes have lower 
expectations of treatment, and that they are less likely to comply with 
treatment. A further study concluded that lower incomes, absent or limited 
insurance cover and poorer education reduced access to high-quality 
adjuvant chemotherapy, which in turn reduced survival in breast cancer78 . 
In the UK, a Scottish study showed that patients from the poorest deprivation 
quintile were less likely to receive chemotherapy for lung cancer and 
colorectal cancer than the most advantaged patients even after adjusting for 
age, tumour stage at diagnosis, health authority and distance from oncology 
centre74 . Delay between referral and treatment was similar across all social 
classes and so did not explain the findings. Although this study did not adjust 
for co-morbidity, another Scottish study which had done so also found poorer 
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survival in colorectal cancer patients from the most deprived socioeconomic 
quintiles, in a study population which showed no correlation between 
socioeconomic deprivation and co-morbidity79. The findings of these studies, 
in the UK healthcare setting where access to treatment is equal and free, 
suggest that decision-making (by both physicians and patients) regarding 
chemotherapy may be influenced by non-clinical factors. 
This large cohort study demonstrates that AML patients from lower 
socioeconomic classes are less likely to undergo bone marrow 
transplantation than their better off counter-parts and that this phenomenon is 
independent of co-existing illness. It is very likely that a similar gradient for 
BMT exists in other leukaemia subtypes, which have not been explored here. 
While this apparent gradient may be the result of incomplete adjustment for 
co-morbidity, non-clinical factors such as those discussed above offer 
possible alternative explanations for this phenomenon. Bone marrow 
transplantation is widely available across the UK, at transplant centres in 
both district general hospitals and tertiary care hospitals80 , and so regional 
variation in availability seems an unlikely explanation for these findings. (See 
Appendix C) 
Furthermore, a socio-economic class gradient in chemotherapy uptake in 
leukaemia is also likely. While such a gradient has been found for other 
cancers as discussed above, it was not possible to investigate this as part of 
this research, given that details of in-patient prescriptions (such as those for 
chemotherapy) are not held in THIN or HES data. 
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MAIN FINDING 
• AML patients from lower socioeconomic classes are less likely to 
undergo bone marrow transplantation than their better off 
counter-parts, even when co-morbidity is accounted for. 
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6 Non-steroidal Anti-inflammatory Drugs and 
Leukaemia Risk 
6.1 ABSTRACT 
Introduction: The use of non-steroidal anti-inflammatory drugs (NSAIDs) is 
associated with a reduced risk of developing colorectal and lung cancer. 
While there is some evidence that similar associations exist in leukaemia, 
studies have thus far been small and underpowered. Aims and Objectives: 
The aim of this large population-based case-control study, using general 
practice data, was to determine whether the use of NSAIDs is associated 
with a reduced risk of acute and chronic leukaemias, and whether their use 
has any impact on survival in these patients. Methods: The incident cases of 
leukaemia identified in the previous studies were used as the cases in this 
study. In addition at least 4 controls per case, matched by age, gender and 
general practice, were randomly selected from the same dataset, at the same 
time. Conditional logistic regression was used to determine odds ratios for 
NSAID prescription rates and the risk of developing several leukaemia 
subtypes. Cox regression was then used to determine the association 
between NSAI D prescription rate and risk of death in leukaemia. Hazard 
ratios were adjusted for gender, age at diagnosis, smoking status and 
Townsend Score. Results: The risk of leukaemia overall appears to increase 
with increased use of NSAIDs prior to diagnosis. This is not seen when 
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individual leukaemia subtypes are examined, however, except perhaps in 
Cll where patients who had received 2-5 prescriptions/year are 290/0 more 
likely to be diagnosed with Cll than those who had not had any NSAI D 
prescriptions (G.R. 1.29, p=0.05, 95% C.1. 1.00-1.67). There was no 
statistically significant association between exposure to NSAIDs prior to 
leukaemia diagnosis and survival. Discussion: This study provides strong 
evidence that the use of NSAI Ds does not reduce the risk of developing 
leukaemia, nor do they improve survival. 
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6.2 INTRODUCTION 
Observational studies have suggested that the use of non-steroidal anti-
inflammatory drugs (NSAIDs) is associated with a reduced risk of developing 
and/or dying from a number cancers including gastrointestinal and lung 
cancers81 -86. 
A UK population-based case-control study published in 2000, for example, 
found a significant inverse relationship between the incidence of 
oesophageal, gastric and colon cancer, and the number NSAID prescriptions 
patients received in the 2 to 3 years prior to their cancer diagnosis81 . The 
size of the protective effects in that study ranged from a 26% reduction in the 
risk of colon cancer to a 50% reduction in risk of gastric cancer when patients 
received at least 7 NSAI D prescriptions per year. US studies had earlier 
reported a 22% reduction in the risk of colon cancer when aspirin was used 
at least twice per week in a cohort of men82 , and a reduction in the risk of 
fatal gastric and colon cancers of over 40% in patients who had aspirin more 
than 16 times per month compared to those who took no aspirin83 . 
Subsequent randomised control trials have confirmed that NSAIDs have a 
protective effect in the risk of developing colorectal cancer, with quoted risk 
reductions of between 26 and 42% 8788 . 
In terms of lung cancer, a Danish study found a 50% reduction in risk in 
people who had at least 4 NSAID prescriptions/year in the 3 years prior to 
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their diagnosis84. A meta-analysis found risk reductions in lung cancer of 
between 21 and 32% in people who used NSAIDs compared to those who 
did not, with greater effects seen with increased duration of use85. 
While there is some provisional evidence that the use of NSAIDs may also 
reduce the risk of developing certain leukaemias3738, these studies have 
been hampered by small numbers of cases. A case-control study of 412 
cases of AMl appeared to show a risk reduction of 50% in those who used 
NSAI Ds for at least 4 weeks in the 8 to 10 years prior to diagnosis, but 
results did not reach statistical significance37. A cohort study of 81 leukaemia 
cases found a 55% reduction in incidence when aspirin was taken at least 
twice/week38. The reported risk reduction was 70% in AMl, and 62% in Cll, 
but there were only 5 AMl cases and 8 Cll cases in that study. Others 
reported finding no association between NSAID use and risk of leukaemias83, 
or a protective effect with aspirin, but not non-aspirin NSAIDs38. 
NSAIDs have the potential to protect against malignancy in a number of 
possible ways. The mechanism of action in colorectal cancer is believed to 
be through cyclo-oxygenase (COX) inhibition, which in turn inhibits 
prostaglandin synthesis and prostaglandin-induced cellular immunity38 88. 
Inhibition of angiogenesis, induction of apoptosis, disruption of signal-
transduction pathways, and inhibition of oxidative DNA damage have also 
been suggested as mechanisms whereby NSAI Ds may playa chemo-
protective role any malignancy38. 
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6.3 AIMS AND OBJECTIVES 
This large population-based case-control study utilised general practice data 
to determine whether the use of NSAIDs is associated with a reduced risk of 
acute and chronic leukaemias, and whether their use has any impact on 
survival in these patients. 
6.4 METHODS 
'The Health Improvement Network' (THIN) dataset was used as before. Data 
held include patient demographic data, Townsend score of socioeconomic 
deprivation, as well as patients' medical and prescribed-drug histories43. 
The incident cases of leukaemia identified in the dataset for the previous 
studies were used as the cases in this study. At least 4 controls for each 
case were randomly selected from the same dataset at the same time, and 
were matched to controls by age (to within 1 year), gender and general 
practice. Controls had to be alive on the date the index case was diagnosed 
with leukaemia, and had to have been contributing data for at least 12 
months prior to that date. 
The NSAI D prescription rate in the period prior to diagnosis (or index date for 
controls) was calculated as the number of NSAID prescriptions per year of 
follow-up. Prescriptions within the 12 months prior to diagnosis (or index date 
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for controls) were excluded from the analysis to minimize any potential bias 
introduced by those NSAIOs prescribed for symptoms of leukaemia, such as 
bone pain, for example. Exposure to NSAIOs was then categorised into 4 
groups for analyses: No NSAIO prescriptions, less than 2 prescriptions per 
year, 2 to 5 prescriptions per year, and more than 5 prescriptions per year. 
Smoking status was included as a potential confounder given that the 
literature on its association with leukaemia remains inconclusive. Smoking 
status was categorised into 2 groups: those who had never smoked, and 
those who were current or ex-smokers. The reason for this categorisation 
relates to the recording of smoking status in THIN, which is discussed in 
greater detail in the next chapter. 
Townsend Score was again used as the measure of socioeconomic 
deprivation. 
Co-morbidity was also adjusted for, as the use of NSAIOs may be associated 
with co-morbid conditions. As THIN data include the medical histories of 
patients, it was possible to identify co-morbidity in all cases and controls. I 
used the Charlson Co-morbidity Index to assign a co-morbidity score to each 
case and control. Co-morbidity was then categorized into 4 ordered groups 
and included in the analysis as a categorical variable. 
Conditional logistic regression was used to determine odds ratios for NSAIO 
prescription rates and the risk of leukaemia overall, as well as for 4 subtypes 
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of interest. Odds ratios were adjusted for Townsend Score, smoking status 
and Charlson Co-morbidity Index. 
Cox regression was then used to determine the association between NSAID 
prescription rate and risk of death in people with leukaemia overall, and in 
those diagnosed with one of the leukaemia subtypes of interest. Hazard 
ratios were adjusted for gender, age at diagnosis, smoking status and 
Townsend Score. 
Ethical approval was obtained from the Nottingham Research Ethics 
Committee. 
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6.5 RESULTS 
3 226 patients had been identified as having one of the following diagnoses: 
Acute Lymphocytic Leukaemia (ALL); Chronic Lymphocytic Leukaemia; 
Unspecified Lymphocytic Leukaemia; Acute Myeloid Leukaemia; Chronic 
Myeloid Leukaemia; and Unspecified Myeloid Leukaemia, which accounted 
for 78% of all leukaemias identified in the dataset. The number of NSAI D 
prescriptions prior to leukaemia diagnosis (or index date for controls) is 
shown in Figure 6.1 for these 3 226 patients. 
Figure 6.1: NSAID Prescriptions Prior to Leukaemia Diagnosis 
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NSAID prescription rates prior to leukaemia diagnoses are shown in Table 
6.1 for cases and controls. 
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Table 6.1: NSAIO Prescription Rates in Leukaemia 
Overall All Cll AMl CMl 
Prescription 
Rate· 
Controls Cases Total Controls Cases Total Controls Cases Total Controls Cases Total Controls Cases Total 
No NSAIDs 5915 1 436 7351 506 127 633 2713 630 3343 1 058 288 1 346 510 129 639 
< 2/year 4228 1 153 5381 105 34 139 2201 587 2788 846 225 1 070 338 90 428 
2-5/year 577 175 752 8 1 9 310 95 405 107 36 143 43 1 1 54 
> 5/year 462 117 579 6 3 9 227 55 282 88 20 108 47 11 58 
Total 11 182 2881 14063 625 165 790 5451 1 367 6818 2099 568 2667 938 241 1 179 
*Number of prescriptions per year. 
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Odds ratios for leukaemia adjusted for Townsend Score, smoking status and 
Charlson Score are shown in Table 6.2 for leukaemias overall, Table 6.3 for 
All, Table 6.4 for Cll, Table 6.S for AMl and Table 6.6 for CML. The risk of 
leukaemia overall appears to increase with increased use of NSAIDs, up to S 
prescriptions per year prior to diagnosis. This is not seen at higher 
prescription rates, however. In bi-variate analyses, Townsend Score and 
smoking do not alter odds ratios, but the inclusion of co-morbidity tends to 
decrease ORs toward 1. Multi-variate analysis shows that the risk of 
leukaemia overall appears to increase with increased use of NSAIDs, up to 5 
prescriptions per year prior to diagnosis. Townsend Score, smoking and 
Charlson Score were all included in the multi-variate analysis in order to be 
consistent with subtype analyses. 
The use of NSAIDs is not associated with incident leukaemia in any of the 
subtypes studied here, except perhaps in Cll where patients who had 
received 2-S prescriptions/year are 29% more likely to be diagnosed with 
Cll than those who had not had any NSAID prescriptions (O.R. 1.29, 
p=O.OS, 9So/0 C.1. 1.00-1.67). No association is seen at higher NSAID 
prescription rates though. As is seen in these tables, the association of 
incident leukaemia with Townsend Score, smoking and Charlson Score 
varies between level of NSAID exposure, and by leukaemia subtype. For this 
reason all 3 these variables were in included in all the multivariate analyses 
to ensure consistency. 
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Table 6.2: Odds Ratios for Leukaemias Overall 
Odds Ratio P>z 95 % C.I. 
Uni-variate Analyses 
Number of Prescriptions 
No NSAIDS 1 
<2/year 1.15 0.00 1.05-1.27 
2-5/year 1.28 0.01 1.06-1.55 
>5/year 1.06 0.59 0.85-1.33 
Townsend Score 
1 1 
2 1.10 0.14 0.97-1.25 
3 1.01 0.88 0.88-1.16 
4 0.99 0.92 0.86-1.15 
5 0.90 0.25 0.76-1.07 
No Record 1.06 0.67 0.80-1.42 
Smoking 
Never Smoked 1 
Current/Ex 0.95 0.25 0.86-1.04 
No Record 0.93 0.36 0.79-1.09 
Charlson Score 
0 1 
1 1.17 0.01 1.04-1.31 
2-5 1.51 <0.001 1.36-1.69 
6+ 1.49 0.00 1.17-1.92 
Bi-variate Analyses 
Adjusted for Townsend Score: 
No NSAIDS 1 
<2/year 1.15 0.00 1.05-1.27 
2-5/year 1.28 0.01 1.06-1.55 
>5/year 1.06 0.59 0.85-1.33 
Adjusted for smoking: 
No NSAIDS 1 
<2/year 1.15 0.00 1.05-1.27 
2-5/year 1.28 0.01 1.06-1.55 
>5/year 1.06 0.58 0.85-1.33 
Adjusted for Char/son Score: 
No NSAIDS 1 
<2/year 1.12 0.03 1.01-1.23 
2-5/year 1.23 0.03 1.02-1.48 
>5/year 1.00 0.99 0.80-1.25 
Multi-variate Analyses* 
No NSAIDS 1 
<2/year 1.13 0.02 1.02-1.24 
2-5/year 1.23 0.03 1.02-1.49 
>5/year 1.00 0.97 0.80-1.25 
*Adjusted for Townsend Score, smoking and Charlson Score. 
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Table 6.3: Odds Ratios for ALL 
Odds Ratio P>z 95%C.I. 
Uni-variate Analyses 
Number of Prescriptions 
No NSAIDS 1 
<2/year 1.36 0.26 0.80-2.31 
2-5/year 0.44 0.46 0.05-3.82 
>5/year 2.55 0.22 0.57-11.35 
Townsend Score 
1 1 
2 0.81 0.44 0.47-1.39 
3 0.98 0.93 0.54-1.75 
4 0.58 0.08 0.31-1.07 
5 0.82 0.59 0.40-1.69 
No Record 1.13 0.83 0.37-3.46 
Smoking 
Never Smoked 1 
Current/Ex 0.68 0.18 0.38-1.20 
No Record 1.35 0.29 0.78-2.28 
Charlson Score 
0 1 
1 0.86 0.59 0.51-1.47 
2-5 3.84 <0.001 2.00-7.38 
6+ 3.80 0.16 0.58-24.70 
Bi-variate Analyses 
Adjusted for Townsend Score: 
No NSAIDS 1 
<2/year 1.33 0.30 0.78-2.26 
2-5/year 0.45 0.47 0.05-3.92 
>5/year 2.30 0.28 0.51-10.39 
Adjusted for smoking: 
No NSAIDS 1 
<2/year 1.51 0.13 0.88-2.60 
2-5/year 0.45 0.48 0.05-4.00 
>5/year 2.65 0.20 0.59-11.84 
Adjusted for Charlson Score: 
No NSAIDS 1 
<2/year 1.26 0.43 0.72-2.20 
2-5/year 0.73 0.77 0.08-6.24 
>5/year 2.54 0.26 0.50-12.87 
Multi-variate Analyses· 
No NSAIDS 1 
<2/year 1.39 0.25 0.79-2.45 
2-5/year 0.72 0.77 0.08-6.42 
>5/year 2.18 0.36 0.42-11.28 
*Adjusted for Townsend Score, smoking and Charlson Score. 
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Table 6.4: Odds Ratios for Cll 
Odds Ratio P>z 95 % Col. 
Uni-variate Analyses 
Number of Prescriptions 
No NSAIOS 1 -
-
<2/year 1.18 0.02 1.02-1.35 
2-5/year 1.40 0.01 1.09-1.82 
>5/year 1.10 0.57 0.80-1.51 
Townsend Score 
1 1 - -
2 1.08 0.45 0.89-1.30 
3 1.04 0.73 0.85-1.26 
4 1.05 0.66 0.85-1.30 
5 0.99 0.95 0.78-1.27 
No Record 0.87 0.52 0.57-1.33 
Smoking 
Never Smoked 1 - -
Current/Ex 0.99 0.91 0.87-1.13 
No Record 0.64 0.00 0.49-0.84 
Charlson Score 
0 1 - -
1 1.26 0.01 1.06-1.49 
2-5 1.74 <0.001 1.49-2.02 
6+ 2.13 <0.001 1.54-2.94 
Bi-variate Analyses 
Adjusted for Townsend Score: 
No NSAIOS 1 - -
<2/year 1.18 0.02 1.02-1.35 
2-5/year 1.40 0.01 1.08-1.81 
>5/year 1.10 0.57 0.80-1.51 
Adjusted for smoking: 
No NSAIOS 1 - -
<2/year 1.15 0.05 1.00-1.32 
2-5/year 1.38 0.02 1.06-1.78 
>5/year 1.08 0.65 0.79-1.49 
Adjusted for Char/son Score: 
No NSAIOS 1 - -
<2/year 1.13 0.09 0.98-1.30 
2-5/year 1.31 0.04 1.01-1.70 
>5/year 1.02 0.96 0.74-1.41 
Multi-variate Analyses* 
No NSAIOS 1 - -
<2/year 1.12 0.13 0.97-1.28 
2-5/year 1.29 0.05 1.00-1.67 
>5/year 1.01 0.96 0.73-1.39 
* Adjusted for Townsend Score, smoking and Charlson Score. 
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Table 6.5: Odds Ratios for AML 
Odds Ratio P>z 95 % Col. 
Uni-variate Analyses 
Number of Prescriptions 
No NSAIDS 1 
<2/year 0.99 0.89 0.80-1.22 
2-5/year 1.22 0.36 0.80-1.84 
>5/year 0.84 0.52 0.50-1.43 
Townsend Score 
1 1 
2 1.21 0.19 0.91-1.60 
3 0.93 0.63 0.69-1.26 
4 0.99 0.96 0.71-1.38 
5 0.70 0.08 0.47-1.04 
No Record 1.58 0.15 0.84-2.97 
Smoking 
Never Smoked 1 
Current/Ex 0.90 0.31 0.73-1.11 
No Record 1.30 0.13 0.92-1.84 
Charlson Score 
0 1 
1 0.96 0.75 0.74-1.24 
2-5 0.91 0.43 0.71-1.16 
6+ 0.40 0.03 0.18-0.90 
Bi-variate Analyses 
Adjusted for Townsend Score: 
No NSAIOS 1 
<2/year 1.00 0.96 0.80-1.23 
2-5/year 1.25 0.30 0.82-1.90 
>5/year 0.84 0.51 0.49-1.42 
Adjusted for smoking: 
No NSAIOS 1 
<2/year 1.02 0.87 0.82-1.26 
2-5/year 1.27 0.27 0.83-1.93 
>5/year 0.88 0.64 0.53-1.50 
Adjusted for Charlson Score: 
No NSAIDS 1 
<2/year 1.00 0.99 0.81-1.24 
2-5/year 1.24 0.31 0.82-1.89 
>5/year 0.86 0.58 0.50-1.46 
Multi-variate Analyses* 
No NSAIOS 1 
<2/year 1.04 0.73 0.84-1.29 
2-5/year 1.32 0.20 0.86-2.01 
>5/year 0.88 0.64 0.51-1.51 
*Adjusted for Townsend Score, smoking and Charlson Score. 
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Table 6.6: Odds Ratios fro CML 
Odds Ratio P>z 95 % Col. 
Uni-variate Analyses 
Number of Prescriptions 
No NSAIDS 1 
<2/year 1.0S 0.76 0.76-1.46 
2-S/year 1.03 0.94 0.S1-2.07 
>S/year 0.83 0.61 0.41-1.68 
Townsend Score 
1 1 
2 0.71 0.16 0.44-1.1S 
3 1.22 0.40 0.77-1.96 
4 0.83 0.47 0.SO-1.38 
S 0.81 0.S1 0.44-1.S1 
No Record 1.96 0.18 0.74-S.23 
Smoking 
Never Smoked 1 
Current/Ex 0.69 0.02 0.SO-0.9S 
No Record 0.64 0.10 0.37-1.09 
Charlson Score 
0 1 
1 1.41 0.09 0.9S-2.10 
2-S 1.86 0.00 1.27-2.72 
6+ 1.30 0.S9 0.SO-3.42 
Bi-variate Analyses 
Adjusted for Townsend Score: 
No NSAIDS 1 
<2/year 1.0S 0.79 0.7S-1.46 
2-S/year 1.01 0.99 0.SO-2.04 
>S/year 0.90 0.77 0.44-1.83 
Adjusted for smoking: 
No NSAIDS 1 
<2/year 1.04 0.82 0.74-1.46 
2-S/year 0.96 0.92 0.48-1.96 
>S/year 0.84 0.63 0.41-1.71 
Adjusted for Charlson Score: 
No NSAIDS 1 
<2/year 1.01 0.96 0.72-1.40 
2-S/year 1.00 1.00 0.49-2.03 
>S/year 0.73 0.40 0.36-1.S0 
Multi-variate Analyses* 
No NSAIDS 1 
<2/year 0.99 0.96 0.70-1.40 
2-S/year 0.91 0.81 0.4S-1.88 
>S/year 0.82 0.S9 0.39-1.69 
*Adjusted for Townsend Score, smoking and Charlson Score. 
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The number of deaths in the study population is shown by leukaemia subtype 
in Table 6.7. These figures exclude those for whom smoking status was not 
recorded, as these patients were excluded in the subsequent calculations of 
hazard ratios (which are adjusted for smoking status). 
Table 6.7: Number of Deaths by Leukaemia Sub-type 
Number of Cases* Number of Deaths 
ALL 78 29 
Cll 1277 349 
Unspecified Lymphoid Leukaemia 249 93 
AMl 493 301 
CMl 216 99 
Unspecified Myeloid leukaemia 201 128 
* Excludes people for whom smoking status is not known. 
Hazard ratios for death in leukaemia, adjusted for gender, age at diagnosis, 
Townsend Score and smoking status, are shown in Table 6.8. There is no 
statistically significant association between exposure to NSAIDs prior to 
leukaemia diagnosis and survival, except in Cll where people who had up to 
2 prescriptions per year had a 25% lower mortality than those who were not 
prescribed any NSAIDs (H.R. 0.75, p=0.01, 95% C.1. 0.60-0.94). 
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Table 6.8: Adjusted Hazard Ratios for Risk of Death in Leukaemia 
Overall All Cll AMl 
Prescription 
Rate*** H.R.* P>z 95% C. I. H.R.* P>z 95% C.1. H.R.* P>z 95% C. I. H.R.* P>z 
No NSAIDs 1 - - 1 - - 1 - - 1 -
< 2/year 0.96 0.58 0.84-1.10 2.63 0.07 0.92-7.54 0.75 0.01 0.60-0.94 1.17 0.21 
2-5/year 0.95 0.73 0.73-1.25 n/a** - - 0.74 0.21 0.46-1.18 1.54 0.07 
> 5/year 1.02 0.88 0.77-1.35 2.83 0.23 0.52-15.49 0.97 0.89 0.63-1.50 1.37 0.26 
*Hazard Ratios are adjusted for gender, age at diagnosis, Townsend Score and smoking status. 
**There were no deaths in this group. 
***Number of prescriptions per year. 
CML 
95% C. I. H.R.* P>z 95% C. I. 
- 1 - -
0.91-1.50 1.00 0.99 0.64-1.56 
0.96-2.47 1.68 0.21 0.75-3.78 
0.79-2.38 0.81 0.73 0.25-2.61 
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6.6 DISCUSSION 
This study demonstrates that the use of NSAIOs is not associated with a 
reduced risk of developing leukaemia and is, if anything, associated with a 
small increased risk of leukaemia overall and Cll specifically. Furthermore, 
NSAIOs have no survival benefit in the acute and chronic leukaemias 
studied, except in Cll, where low prescription rates appear to be beneficial. 
The main strength of this study is that the large number of incident leukaemia 
cases for whom there are data has facilitated a statistically powerful study. 
The preceding studies suggest that the leukaemia diagnoses in THIN are 
valid in terms of age, incidence and survival. THIN data are also a good 
source of population controls from which matched controls for this study 
could be selected. Obtaining prescription information directly from THIN, 
rather than relying on self-reporting by study subjects, has avoided recall bias 
with respect to NSAIO use. 
One potential weakness of this study may be inaccuracies in prescription 
information held within THIN. This has not had an important impact on these 
results given that the validity of general practice data, including that of 
prescription data, has been demonstrated elsewhere44 51 . A further potential 
weakness of this study is that the use of over-the-counter NSAIOs has not 
been taken into account. This is unlikely to have biased these results since 
cases and controls are equally likely to have used over-the-counter NSAIOs 
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prior to diagnosis (or index date for controls). Furthermore, since people over 
the age of 60 are entitled to free prescriptions, their general practice 
prescription records are likely to accurately reflect their NSAID use. 
Few studies have explored the association of NSAID use and risk of 
leukaemia. A case-control study of 412 AMl cases found NSAIDs had a 
protective effect on the risk of one AMl subtype (M2), but results did not 
reach statistical significance37• Another study of 81 post-menopausal women 
with leukaemia (including 35 cases of Cll, 28 of AMl and 5 of CMl) found a 
statistically significant protective effect with NSAID use in leukaemia overall, 
as well as with aspirin use in leukaemia overall, AMl and Cll38. However, 
both these studies relied on self-reported drug histories (in the former 
subjects were required to recall their drug intake up to 10 years prior to their 
diagnosis) subjecting results to recall bias. 
The small positive association of NSAID prescriptions and incident Cll found 
here is likely to be due to reverse causation, i.e. where NSAIDs have been 
prescribed for symptoms of leukaemia. The reason this is apparent in Cll, 
but not other subtypes studied, may be because Cll progresses more slowly 
than the other subtypes, and so excluding prescriptions during the 12 months 
prior to diagnosis (or index date for controls) may not have sufficiently 
eliminated the problem of reverse causation in the Cll cases. 
In a secondary analysis, examining only aspirin prescription rates, no 
association with the incidence of and mortality from leukaemia overall was 
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found (results not shown), which contrasts with the findings of others38 . 
Aspirin prescription rates among the cases in this study are too low to allow 
similar analyses by leukaemia subtype (see Table 6.9 and Figure 6.2). 
Table 6.9: Aspirin Prescription Rates in Leukaemias Overall 
Controls Cases Total 
Prescription Rate 
No Aspirin 12614 3164 15778 
< 2 prescriptions/year 90 24 114 
2-5 prescriptions/year 27 10 37 
> 5 prescriptions/year 39 4 43 
Total 12770 3202 15972 
Figure 6.2: Aspirin Prescriptions Prior to Leukaemia Diagnosis 
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This study provides strong evidence that NSAIDs do not reduce the risk of 
leukaemia, and in all probability do not offer any survival benefit in these 
cancers. In addition, no statistically significant association with aspirin use 
and the incidence or mortality from leukaemia overall was found in this study. 
MAIN FINDING 
• NSAID use is not associated with a reduced risk of Leukaemia, 
nor do they offer any survival benefit. 
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7 Alcohol Consumption and Risk of Leukaemia 
7.1 ABSTRACT 
Introduction: Alcohol consumption may produce chemo-protective effects in 
leukaemia via several mechanisms. The relationship between alcohol 
consumption and the risk of leukaemia has been explored in a number of 
studies, but results thus far have been inconsistent. Aims and Objectives: 
This population-based case-control study investigates the association 
between alcohol consumption and the incidence of and mortality from the 
acute and chronic leukaemias. Methods: The incident cases of leukaemia 
and the matched controls identified in THIN in the previous studies were 
used for this study. Conditional logistic regression was used to determine 
odds ratios for alcohol consumption and risk of developing leukaemia and 
several leukaemia subtypes. Cox regression was then used to determine the 
association between alcohol consumption and the risk of death in leukaemia. 
Hazard ratios were adjusted for gender, age at diagnosis, smoking status, 
Townsend Score and co-morbidity. Results: There is no statistically 
significant association between alcohol consumption and risk of developing 
leukaemia overall, nor with any of the leukaemia subtypes studied here. 
Alcohol consumption is associated with a lower risk of death in leukaemia 
overall (HR 0.83, p=0.04, 95% C.1. 0.69 - 0.99), as well as in All (HR 0.14, 
p<0.01, 95% C.1. 0.04 - 0.44) and Cll (HR 0.71, p=0.02, 95% C.1. 0.53 -
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0.96), when compared to those who had not consumed any alcohol. 
Discussion: Alcohol consumption is positively associated with survival from 
leukaemia even after adjusting for co-morbid illness. Better recording of 
alcohol consumption in THIN will enhance its value in investigating 
associations of alcohol consumption and disease, or other outcomes. 
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7.2 INTRODUCTION 
A number of studies have examined the relationship between alcohol 
consumption and the risk of leukaemia, but results have thus far been 
inconsistene4-27 . Several of these studies have found inverse associations 
with low or moderate alcohol intake and positive associations with high 
alcohol intake and leukaemia incidence, but results were often not 
statistically significane4 26 27. When individual leukaemia subtypes were 
investigated, studies tended to be underpowered, and again showed 
insignificant results24 25 27. To my knowledge, the impact of alcohol 
consumption on mortality in leukaemia has not been investigated. 
Alcohol has the potential to exert its effects, both protective and damaging, 
via several mechanisms. There is evidence, for example, of its 
immunomodulatory effects whereby moderate consumption elicits an 
improved cellular and humoral response while heavy drinking impairs 
immune function89 . Anti-oxidants contained in wine and beer, as well as the 
improvements in insulin sensitivity ascribed to moderate alcohol consumption 
may be further mechanisms through which alcohol potentially exerts anti-
carcinogenic effects. 
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7.3 AIMS AND OBJECTIVES 
This population-based case-control study investigates the association 
between alcohol consumption and the incidence of and mortality from the 
acute and chronic leukaemias. 
7.4 METHODS 
The incident cases of leukaemia and the controls identified in the THIN 
dataset for the previous study were used for this study. 
Alcohol consumption was categorised into 2 groups: those who never 
consumed alcohol and those who were recorded as being current or ex-
drinkers prior to their diagnosis of leukaemia (or index date for controls). The 
reason for this relatively simplistic classification is due to the incomplete 
recording of alcohol in THIN, which will be discussed later. 
As in the previous study, smoking status was categorised into those who 
never smoked and those who were current or ex-smokers, again because of 
incomplete recording. Cases and controls were assigned the most recent 
smoking and alcohol status in their records prior to their diagnosis (or index 
date for controls). Townsend Score was also adjusted for as before. 
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Conditional logistic regression was used to determine odds ratios for alcohol 
consumption and the risk of leukaemia overall, as well as for 4 subtypes of 
interest. Odds ratios were adjusted for smoking status, Townsend Score as 
well as co-morbidity. 
Cox regression was then used to determine the association between alcohol 
consumption and risk of death in people with leukaemia overall and in those 
diagnosed with one of the leukaemia subtypes of interest. Hazard ratios were 
adjusted for gender, age at diagnosis, smoking status, Townsend Score 
smoking and co-morbidity. 
A secondary analysis was then conducted to quantify any bias introduced 
into the initial results by co-existing illness among study participants. As THIN 
data include the medical histories of patients, it was possible to identify co-
morbidity in all cases and controls. The Charlson Co-morbidity Index90 was 
used to assign a co-morbidity score to each case and control. Co-morbidity 
was then categorized into 4 ordered groups and included in the analysis as a 
categorical variable. Conditional logistic regression and Cox regression was 
then performed as before, but additionally adjusting for co-morbidity. 
Ethical approval was obtained from the Nottingham Research Ethics 
Committee. 
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7.5 RESULTS 
7.5.1 Primary Analysis 
Alcohol consumption was recorded in THIN for 8 735 out of 11 182 controls 
(78%), and for 2 227 out of 2 881 cases (77%). The alcohol intake of cases 
and controls are shown in Table 7.1. 
Table 7.1: Alcohol Records 
Controls Cases Total 
Alcohol 
Never 1 295 346 1 641 
Ex 95 24 119 
Current 7345 1 857 9202 
No Data 2447 654 3 101 
Total 11 182 2881 14063 
, 
Alcohol consumption is not associated with an increased risk of leukaemia 
overall, nor with any of the subtypes studied here, when adjusted for smoking 
status and Townsend Score (Table 7.2). 
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Table 7.2: Odds Ratios for Leukaemia 
OVERAll All Cll AMl CMl 
O.R. p 95% Col. O.R. P 95% C.1. O.R. P 95% Col O.R. P 95% Col O.R. P 95% Col 
Alcohol 
Never 1 - - 1 - - 1 - - 1 - - 1 - -
Ever 0.95 0.49 0.83 - 1.09 1.46 0.38 0.62 - 3.44 1.05 0.65 0.86 - 1.27 0.84 0.28 0.62-1.15 0.79 0.33 0.49 - 1.27 
No Record 1.05 0.61 0.87 - 1.26 1.16 0.75 0.45 - 3.01 1.22 0.15 0.93 - 1.59 1.13 0.53 0.76 - 1.69 0.77 0.44 0.40 - 1.49 
Smoking 
Status 
Never 1 - - 1 - - 1 - - 1 - - 1 - -
Ever 0.96 0.35 0.87 - 1.05 0.68 0.20 0.38 - 1.22 0.99 0.88 0.87 - 1.13 0.94 0.58 0.76 - 1.17 0.70 0.03 0.51 - 0.97 
No Record 0.87 0.17 0.72 - 1.06 1.40 0.28 0.76 - 2.57 0.57 0.00 0.41 - 0.78 1.07 0.75 0.71 - 1.62 0.65 0.21 0.33 - 1.28 
Townsend 
Score 
1 1 - - 1 - - 1 - - 1 - - 1 - -
2 1.10 0.14 0.97 - 1.26 0.82 0.49 0.48 - 1.43 1.08 0.43 0.89 - 1.30 1.22 0.17 0.92 - 1.62 0.70 0.16 0.43 - 1.14 
3 1.01 0.86 0.88 - 1.16 1.00 0.99 0.56 - 1.79 1.05 0.66 0.86 - 1.28 0.94 0.68 0.69 - 1.27 1.23 0.40 0.76 - 1.97 
4 0.99 0.94 0.86 -1.15 0.60 0.12 0.32-1.13 1.05 0.63 0.85 - 1.30 1.00 0.99 0.72 - 1.39 0.85 0.52 0.51 - 1.41 
5 0.91 0.27 0.76-1.08 0.86 0.69 0.42 - 1.78 1.00 0.97 0.78 - 1.29 0.71 0.09 0.47 - 1.05 0.80 0.49 0.43 - 1.50 
No Record 1.07 0.66 0.80 - 1.42 1.07 0.91 0.34 - 3.32 0.90 0.64 0.59 - 1.39 1.51 0.20 0.80 - 2.84 2.13 0.14 0.78 - 5.76 
--
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Hazard Ratios for death in leukaemia adjusted for gender, age at diagnosis, 
Townsend Score and smoking status are shown in Table 7.3. These data 
show that alcohol consumption is associated with a lower risk of death in 
leukaemia overall (HR 0.83, p=0.04, 95% C.I. 0.69 - 0.99), as well as in All 
(HR 0.14, p<0.01, 95% C.I. 0.04 - 0.44) and Cll (HR 0.71, p=0.02, 95% C.I. 
0.53 - 0.96), when compared to those who had not consumed any alcohol. 
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Table 7.3: Hazard Ratios for death in Leukaemia 
OVERALL ALL Cll AML CML 
H.R.* p 95% Col. H.R.* P 95% C.1. H.R.* P 95% C.1. H.R.* P 95% Col. H.R.* P 95% Col. 
Alcohol 
Never 1 - - 1 - - 1 - - 1 - - 1 - -
Ever 0.83 0.04 0.69 - 0.99 0.14 <0.01 0.04 - 0.44 0.71 0.02 0.53 - 0.96 1.17 0.38 0.82 - 1.67 0.63 0.09 0.37 - 1.07 
No Record 1.11 0.39 0.88 - 1.39 0.12 <0.01 0.03 - 0.50 0.98 0.93 0.67 - 1.43 1.30 0.24 0.84 - 2.01 1.39 0.37 0.68 - 2.85 
*Hazard ratios are adjusted for gender, age at diagnosis, Townsend Score, smoking status and co-morbidity. 
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7.5.2 Secondary Analysis 
The relationships between Charlson Co-morbidity Index and alcohol 
consumption patterns among cases and controls are shown in Table 7.4 and 
Table 7.5, respectively, and graphically in Figure 7.1. 
Table 7.4: Alcohol Consumption and Charlson Scores for Cases 
Charlson Score 
Cases Alcohol Consumption 
No Data Never Ex Current Total 
0 337 110 4 675 1 126 
1 128 83 9 394 614 
2-5 176 141 11 717 1 045 
6+ 13 12 0 71 96 
Total 654 346 24 1 857 2881 
Table 7.5: Alcohol consumption and Charlson Score for Controls 
Control Alcohol Consumption 
Charlson Score 
No Data Never Ex Current Total 
0 1 463 493 22 3075 5053 
1 483 311 16 1 684 2494 
2-5 459 439 47 2372 3317 
6+ 47 52 10 214 318 
Total 2447 1 295 95 7345 11 182 
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Figure 7.1: Charlson Co-morbidity Profiles of Cases and Controls 
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The hazard ratios defining the associations between alcohol consumption 
and survival by leukaemia subtype are shown in Table 7.6. This shows the 
positive association between alcohol consumption and survival persisted in 
leukaemia overall, All and ell, when co-morbidity is adjusted fo r. 
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Table 7.6: Hazard Ratios for death in Leukaemia (adjusted for CCI) 
OVERALL ALL Cll AMl CML 
H.R.* p 95% C.1. H.R.* P 95% C.1. H.R.* P 95% Col. H.R.* P 95% C.1. H.R.* P 95% C.1. 
Alcohol 
Never 1 - - 1 - - 1 - - 1 - - 1 - -
Ever 0.83 0.04 0.69 - 0.99 0.16 <0.01 0.05 - 0.53 0.72 0.03 0.54 - 0.97 1.20 0.33 0.84 - 1.71 0.65 0.12 0.37 - 1.12 
, 
No Record 1.12 0.32 0.89 - 1.41 0.12 <0.01 0.03 - 0.51 1.03 0.87 0.71 - 1.51 1.37 0.16 0.88 - 2.13 1.46 0.33 0.69 - 3.09 
Charlson 
Score 
0 1 - - 1 - - 1 - - 1 - - 1 - -
1 1.07 0.44 0.91 - 1.26 0.68 0.45 0.25 - 1.83 1.91 <0.01 1.37 - 2.66 1.01 0.97 0.76 - 1.34 1.24 0.45 0.71 -2.19 
2-5 1.06 0.44 0.92 - 1.22 0.45 0.10 0.17 -1.18 1.81 <0.01 1.35 - 2.42 1.31 0.03 1.02 - 1.69 1.21 0.47 0.72 - 2.05 
6+ 1.45 0.01 1.11 - 1.90 1.69 0.64 0.19 - 15.13 3.09 <0.01 2.04 - 4.66 1.90 0.11 0.86 - 4.20 1.51 0.45 0.52 - 4.38 
-
*Hazard ratios are also adjusted for gender, age at diagnosis, Townsend Score and smoking status. 
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7.6 DISCUSSION 
This study found no statistically significant association between alcohol 
consumption and the risk of developing leukaemia. Interestingly though, 
alcohol consumption was found to be positively associated with a reduced 
risk of death from leukaemia overall, All and elL. 
The main strength of this study lies in the large size of the dataset from which 
cases were derived. Greater numbers of cases allowed leukaemia subtypes 
to be examined with greater statistical power than in previous studies. THIN 
data are also a source of general population controls, which makes large 
case-control studies easier and cheaper to conduct than studies that require 
interviews and/or questionnaires. The scope of data held within THIN, for 
example, age, gender and general practice, allows matching of controls to 
cases thus reducing potential bias. Furthermore, the availability of 
information on socioeconomic class, medical and smoking histories makes 
adjusting for these potential confounders possible. As these data are 
extracted directly from THIN, rather than via interviews and questionnaires, 
recall bias in terms of exposures is also avoided. 
The greatest weakness of this study is the number of patients for whom 
alcohol consumption is incompletely and/or unreliably recorded. Alcohol is 
recorded in 2 ways in THIN: The status of patients' alcohol consumption is 
recorded as current, ex, or never, at various points in time within the dataset. 
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In addition, the number of units of alcohol consumed per week is also 
recorded. These both represented sources of weakness in this study. 
Firstly, inconsistencies were noted in the classification of patients' alcohol 
consumption status, whereby people who were recorded as being drinkers or 
ex-drinkers at one point in time were, for example, recorded as 'never 
drinkers' at a later date. There were also people who were recorded as being 
current drinkers, when they had earlier been recorded as being ex-drinkers, 
with no way of knowing whether these records were erroneous or whether 
patients had given up alcohol and then resumed its consumption. It is for 
these reasons that current drinkers and ex-drinkers were grouped together 
into a single category for the purposes of this study. Smoking records in 
THIN have similar inaccuracies and hence a similar, relatively simplistic 
categorisation was adopted for these studies. Only people who were 
consistently recorded as being 'never drinkers' were classified as such. While 
this approach improved the reliability of the classification of patients' alcohol 
consumption status, it meant that 'current' exposure to alcohol could not be 
distinguished from 'previous' exposure to alcohol in the analyses. This is an 
important consideration as any influence alcohol may have aetiologically or 
with respect to survival, may differ between current and ex-drinkers. 
Incomplete recording of the number of units of alcohol consumed per week 
further weakened this study. While 2 443 out of 11 182 controls, i.e. 22% of 
controls have no record of alcohol consumption status and no record of the 
number of units of alcohol consumed, an additional 2 673 of the 7 349 
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controls i.e. 36% of controls recorded as being current drinkers, also have no 
record of the number of units consumed per week. Records are similarly 
incomplete for cases with 654 out of 2 881 cases, i.e. 23% having no record 
of alcohol consumption status and no record of the number of units of alcohol 
consumed, and a further 672 out of 1 857 cases i.e. 36% of cases recorded 
as being current drinkers, also having no record of the number of units 
consumed per week. One can conclude that since records are equally 
incomplete for cases and controls, bias in terms of whether or not the amount 
of alcohol consumed is recorded for cases versus controls is not likely to be 
an important issue. The paucity of these data does, however, mean that 
investigating the existence of a dose-response relationship between alcohol 
consumption and leukaemia incidence and/or survival reliably is difficult. 
The relationship between alcohol consumption and leukaemia has been 
examined previously, but results have been inconsistent. In a case-control 
study of 578 white men with leukaemia, alcohol consumption was positively 
associated with ALL, but not leukaemia overall or CML 24. Odds ratios did not 
reach statistical significance, however, nor did investigators find a dose 
response gradient with the quantity of alcohol consumed, a pattern which 
may have suggested causality, had it been found. 
In another case-control study of 164 case-control pairs, Pogoda et al. found 
that alcohol consumption was associated with a decreased risk of AML in 
adults, but results did not reach statistical significance25 . The authors 
acknowledge that alcohol consumption in their study population was related 
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to higher socioeconomic class, and that their controls were also of higher 
socioeconomic class than their cases. As only education was controlled for in 
the analysis, this combination of factors may have resulted in residual 
confounding with respect to socioeconomic class and consequently produced 
spuriously low odds ratios. 
In another case-control study of 765 incident cases of acute de novo 
leukaemia in adults and 618 controls, regular drinkers had a reduced relative 
risk of leukaemia compared to non-drinkers26 . When consumption patterns 
and different types of alcohol were examined, light and moderate beer intake 
was associated with a reduced risk of leukaemia that was statistically 
significant, while moderate or heavy wine intake was associated with an 
increased relative risk of leukaemia, although results for the latter did not 
reach statistical significance. As in the study by Pagoda et a1. 25, alcohol 
consumption was more prevalent among controls than cases and education 
was the only marker of socioeconomic class adjusted for. Again this may 
have resulted in downwardly biased odds ratios if the controls were of higher 
socioeconomic class than the cases in this study. Unfortunately, the similarity 
or otherwise of cases and controls with respect to socioeconomic class is not 
reported in the paper. Selection bias related to social class may also explain 
the inverse association found with beer if, for example, beer intake is 
inversely associated with socioeconomic class and controls were of lower 
socioeconomic class than cases. 
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A more recent multi-centre case-control study exploring the associations of 
alcohol intake with a number of leukaemia subtypes was also inconclusive27. 
In this study of 649 cases and 1 771 controls, any alcohol intake was found 
to be associated with a reduced risk of leukaemia overall, All and Cll, 
compared to those who never drank alcohol. The contrary was true for AMl 
and CML. None of these odds ratios reached statistical significance, 
however. This study also examined the type and quantity of alcohol 
consumed and found an inverse association with leukaemia overall and 
moderate intake of all alcohol, wine, beer and spirits. Similar inverse 
associations were seen in All, Cll and AMl with all alcohol. A positive 
association with leukaemia overall was found for high-level consumption of 
all alcohol, wine and beer. Again, results did not reach statistical significance. 
CMl was positively associated with alcohol consumption at all levels, but 
odds ratios again did not reach statistical significance. 
While the finding that survival from leukaemia overall is better in those who 
currently consume or have previously consumed alcohol, than in those who 
never did may be a true phenomenon, it may also be due to bias or 
confounding. Recall bias has been avoided in this study by utilising alcohol 
consumption records held in the dataset, rather than conducting interviews or 
questionnaires retrospectively, as was the case in many of the studies 
reported above. The study design has minimized reporting bias with respect 
to alcohol consumption by using alcohol consumption records that pre-date 
patients' leukaemia diagnosis. Potential confounding by gender, age at 
diagnosis, Townsend Score and smoking status have been adjusted for in 
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the analyses. Better survival among current and ex-drinkers may be 
explained by the 'healthy drinker' effect, whereby patients with less 
debilitating or less symptomatic co-morbid illness may be more likely to 
continue to drink alcohol. 
A secondary analysis was therefore conducted adjusting for confounding by 
co-morbidity (using the Charlson Co-morbidity Score as before), which 
demonstrated that the positive association between alcohol consumption and 
survival persisted in leukaemia overall, All and ClL. 
This adjustment for confounding by co-morbid disease does not, of course, 
take into account the stage of leukaemia or the severity of leukaemia 
symptoms. The negative association of alcohol with mortality may still, 
therefore, be explained by the 'healthy drinker' effect. 
The alternative explanation, that alcohol really is protective, has some 
biological plausibility in that alcohol is known to be toxic to bone marrow and 
white blood cells91 92, with the latter study showing that although alcohol was 
toxic to both leukaemic and non-leukaemic lymphocytes, its toxic effect was 
greater on leukaemic lymphocytes. 
In summary, this study has shown that incident leukaemia is independent of 
alcohol consumption, but that the latter is associated with a lower risk of 
death in leukaemia overall, All and ClL. There is under-recording of the 
amount of alcohol patients consume in this dataset, in which over a third of 
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current drinkers have no record of the number of units of alcohol they 
consume. This is an important consideration as any influence alcohol may 
have aetiologically or with respect to survival, may differ between current and 
ex-drinkers. Improving this will facilitate the investigation of any dose-
response relationship with incidence and mortality in leukaemia, as well as 
other diseases, at population level. 
MAIN FINDINGS 
• Alcohol consumption is not associated with incident leukaemia, 
but it is associated with reduced mortality in leukaemia overall, 
ALL and ell. 
• The amount of alcohol patients consume is under-recorded in 
THIN, and improvements in this will further enhance THIN as 
resource for epidemiology research. 
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8 CONCLUSIONS 
8.1 SUMMARY OF FINDINGS 
• THIN data is a valuable resource for leukaemia research with diagnostic 
validity comparable to cancer registries. 
• Mortality in leukaemia patients overall from lower socioeconomic classes is 
worse than among the better off, despite no class gradient in incidence. 
• Mortality in AMl patients from lower socioeconomic classes is worse than 
among the better off, in the absence of a socioeconomic class trend in 
incidence. This is not seen for other leukaemia subtypes. 
• AMl patients from lower socioeconomic classes are less likely to undergo 
bone marrow transplantation than their better off counter-parts, even after 
adjusting for co-morbidity. 
• NSAID use is not associated with a reduced risk of leukaemia, nor do they 
offer any survival benefit. 
• Alcohol consumption is not associated with incident leukaemia, but it is 
associated with reduced mortality in leukaemia overall, All and elL. 
• The amount of alcohol patients consume is under-recorded in THIN, and 
improvements in this will further enhance THIN as resource for epidemiology 
research. 
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8.2 CLINICAL IMPLICATIONS AND FUTURE RESEARCH 
This research firstly provides reassurance that diagnostic services for 
leukaemia in the UK are accessible to all patients regardless of 
socioeconomic class and geographic region. Mortality, however, is greater 
among socio-economically disadvantaged leukaemia patients, specifically 
those with AM L. 
While greater mortality among patients from lower socioeconomic classes is 
by no means unique to leukaemia, the reasons for lower bone marrow 
transplantation rates among poorer patients with AML does warrant further 
investigation. Lower bone marrow transplantation rates in this group do not 
necessarily explain the greater mortality seen, since mortality is influenced by 
multiple factors, including cytogenetic profile as discussed earlier, and the 
use of and response to chemotherapy, as well as other risk factors that were 
able to be investigated here. Cytogenic information is not held in THIN, nor 
are details of in-patient prescriptions, such as chemotherapy, hence neither 
of these factors could be studied in this project. 
The fact that lower uptake of bone marrow transplantation appears to be 
related to non-clinical factors rather than reflecting greater co-morbidity in 
patients from lower socioeconomic classes is of concern. While a social class 
gradient in uptake of bone marrow transplantation has not been shown 
before, others have found such gradients in the uptake of chemotherapy, as 
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discussed in Chapter 5. Possible reasons suggested by these investigators 
include: lower incomes, absent or limited insurance cover and poorer 
education result in reduced access to these therapies; and that health 
professionals' assumptions that adequate social and monetary support may 
not be available; that patients from lower socioeconomic classes have lower 
expectations of treatment; and that they are less likely to comply with 
treatment. 
While factors such as health insurance do not apply in the UK setting, the 
other factors that may influence uptake of bone marrow transplants (and 
chemotherapy) mentioned above are relevant in the UK and can and should 
be investigated. One way of doing this would be for transplant centres to 
conduct audits to assess local patterns of bone marrow transplantation. 
Centres should establish whether these social class trends in bone marrow 
transplantation are apparent locally. If so, an examination into their own 
practice would be justified to establish the reasons for any such trend. Local 
audits could also examine whether there are social class trends in 
chemotherapy uptake, as they will have access to in-patient prescription 
data. Only once in-patient prescription data are linked to other databases will 
it be possible to examine this issue efficiently at a national level. 
This work has also demonstrated that THIN data provide a valuable resource 
for conducting epidemiological research. While the diagnostic validity in THIN 
has been demonstrated for many acute and chronic diseases, the additional 
health-related data, such as co-morbidity, prescription data, and information 
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on smoking and alcohol consumption, held in the dataset also allow a range 
of variables to be included in study designs and analyses. This represents a 
distinct advantage over registry data as a resource for epidemiological 
research, at least until such time as linkage of these data sources has been 
completed. 
The impact of several lifestyle factors, such as alcohol consumption, smoking 
and obesity is easier, quicker and cheaper to investigate in these data 
without the need for questionnaires and interviews. Using routinely collected 
data rather than the latter methods reduces reporting bias and excludes 
recall bias, both of which improve the quality of epidemiological studies. This 
research has shown that any dose-response effects of alcohol and/or 
smoking consumption will be more accurately ascertained if these data were 
more completely recorded, and represents an area of current weakness in 
general practice datasets, although with improvements in recording of these 
additional health data, the range and quality of studies possible using these 
data will be enhanced. 
THIN data are also a valuable resource for studies of pharmacoepidemiology 
given the robustness of prescription data held. This is an area where this 
dataset is under-utilized despite its huge potential. In terms of patient safety, 
for example, these data represent 'real-world' use of medications in an 
unselected population compared to clinical trial data. These data are not only 
useful for calculating background incidence rates of disease or symptoms in 
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the general population, but is also invaluable in determining these rates in 
sub-populations of patients taking specific treatments, for example. 
While this research only presents one such example, the potential protective 
effects of a range of drugs can be investigated with relative ease using these 
data. Similarly, where there is speculation surrounding the safety of a 
particular drug or drug class, this can be addressed by 
pharmacoepidemiology studies demonstrating its safety retrospectively in 
large numbers of exposed patients. 
Another potential area of pharmacoepidemiology research that is of public 
health importance is in demonstrating the safety of medicines retrospectively. 
Women of childbearing potential and children, for example, are excluded 
from most clinical trials of new medicines. This results in a lack of safety data 
for these populations and they are consequently not prescribed potentially 
beneficial medication. Where such medication is prescribed 'off licence', this 
exposure will be captured in these data and safety in these populations can 
then be demonstrated retrospectively. Examples include the use of steroids 
in pregnancy for exacerbations of asthma and inflammatory bowel disease, 
amongst others. 
A range of fairly complex research questions can therefore be answered by 
using general practice data such as THIN. Furthermore, these studies can be 
conducted relatively quickly and cheaply using these data, and more 
resources should be made available to facilitate this. 
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Appendix B. Leukaemia READ Codes 
READ CODE DESCRIPTION 
864 .. 00 Lymphoid leukaemia 
864 .. 11 Lymphatic leukaemia 
8640.00 Acute lymphoid leukaemia 
8641.00 Chronic lymphoid leukaemia 
8641.11 Chronic lymphatic leukaemia 
8642.00 Subacute lymphoid leukaemia 
864y.00 Other lymphoid leukaemia 
864yOOO Aleukaemic lymphoid leukaemia 
864y100 Prolymphocytic leukaemia 
864y200 Adult T-cell leukaemia 
864yzOO Other lymphoid leukaemia NOS 
864z.00 Lymphoid leukaemia NOS 
865 .. 00 Myeloid leukaemia 
8650.00 Acute myeloid leukaemia 
8651.00 Chronic myeloid leukaemia 
8651.11 Chronic granulocytic leukaemia 
8651000 Chronic eosinophilic leukaemia 
8651200 Chronic neutrophilic leukaemia 
8651 zOO Chronic myeloid leukaemia NOS 
8652.00 Subacute myeloid leukaemia 
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865y.00 Other myeloid leukaemia 
865yOOO Aleukaemic myeloid leukaemia 
865y100 Acute promyelocytic leukaemia 
865yzOO Other myeloid leukaemia NOS 
865z.00 Myeloid leukaemia NOS 
866 .. 00 Monocytic leukaemia 
866 .. 11 Histiocytic leukaemia 
866 .. 12 Monoblastic leukaemia 
8660.00 Acute monocytic leukaemia 
8661.00 Chronic monocytic leukaemia 
8662.00 Subacute monocytic leukaemia 
866y.00 Other monocytic leukaemia 
866yOOO Aleukaemic monocytic leukaemia 
866yzOO Other monocytic leukaemia NOS 
866z.00 Monocytic leukaemia NOS 
867 .. 00 Other specified leukaemia 
8670.00 Acute erythraemia and erythroleukaemia 
8671.00 Chronic erythraemia 
8672.00 Megakaryocytic leukaemia 
8672.11 Thrombocytic leukaemia 
8673.00 Mast cell leukaemia 
867y.00 Other and unspecified leukaemia 
867yOOO Lymphosarcoma cell leukaemia 
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B67yzOO Other and unspecified leukaemia NOS 
B67z.00 Other specified leukaemia NOS 
B68 .. 00 Leukaemia of unspecified cell type 
B680.00 Acute leukaemia NOS 
B681.00 Chronic leukaemia NOS 
B682.00 Subacute leukaemia NOS 
B68y.00 Other leukaemia of unspecified cell type 
B68z.00 Leukaemia NOS 
B69 .. 00 Myelomonocytic leukaemia 
B690.00 Acute myelomonocytic leukaemia 
B691.00 Chronic myelomonocytic leukaemia 
B692.00 Subacute myelomonocytic leukaemia 
BBr..OO [M]Leukaemias 
BBrO.OO [M]Leukaemias unspecified 
BBrOOOO [M]Leukaemia NOS 
BBr0100 [M]Acute leukaemia NOS 
BBr0111 [M]Blast cell leukaemia 
BBr0112 [M]Blastic leukaemia 
BBr0113 [M]Stem cell leukaemia 
BBr0200 [M]Subacute leukaemia NOS 
BBr0300 [M]Chronic leukaemia NOS 
BBr0400 [M]Aleukaemic leukaemia NOS 
BBrOzOO [M]Leukaemia unspecified, NOS 
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BBr1.00 [M]Compound leukaemias 
BBr1000 [M]Compound leukaemia 
BBr1011 [M]Mixed leukaemia 
BBr1z00 [M]Compound leukaemia NOS 
BBr2.00 [M]Lymphoid leukaemias 
BBr2000 [M]Lymphoid leukaemia NOS 
BBr2011 [M]Lymphatic leukaemia 
BBr2100 [M]Acute lymphoid leukaemia 
BBr2200 [M]Subacute lymphoid leukaemia 
BBr2300 [M]Chronic lymphoid leukaemia 
BBr2400 [M]Aleukaemic lymphoid leukaemia 
BBr2S00 [M]Prolymphocytic leukaemia 
BBr2600 [M]Burkitt's cell leukaemia 
BBr2700 [M]Adult T-cell leukaemia/lymphoma 
BBr2z00 [M]Other lymphoid leukaemia NOS 
BBr3.00 [M]Plasma cell leukaemias 
BBr3000 [M]Plasma cell leukaemia 
BBr3z00 [M]Plasma cell leukaemia NOS 
BBr4.00 [M]Erythroleukaemias 
BBr4000 [M]Erythroleukaemia 
BBr4200 [M]Chronic erythraemia 
BBr4z00 [M]Erythroleukaemia NOS 
BBrS.OO [M]Lymphosarcoma cell leukaemias 
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BBr5000 [M]Lymphosarcoma cell leukaemia 
BBr5z00 [M]Lymphosarcoma cell leukaemia NOS 
BBr6.00 [M]Myeloid leukaemias 
BBr6000 [M]Myeloid leukaemia NOS 
BBr6011 [M]Granulocytic leukaemia NOS 
BBr6100 [M]Acute myeloid leukaemia 
BBr6200 [M]Subacute myeloid leukaemia 
BBr6300 [M]Chronic myeloid leukaemia 
BBr6311 [M]Naegeli-type monocytic leukaemia 
BBr6400 [M]Aleukaemic myeloid leukaemia 
BBr6500 [M]Neutrophilic leukaemia 
BBr6600 [M]Acute promyelocytic leukaemia 
BBr6700 [M]Acute myelomonocytic leukaemia 
BBr6BOO [M]Chronic myelomonocytic leukaemia 
BBr6z00 [M]Other myeloid leukaemia NOS 
BBr7.00 [M]Basophilic leukaemias 
BBr7000 [M]Basophilic leukaemia 
BBr7z00 [M]Basophilic leukaemia NOS 
BBrB.OO [M]Eosinophilic leukaemias 
BBrBOOO [M]Eosinophilic leukaemia 
BBrBzOO [M]Eosinophilic leukaemia NOS 
BBr9.00 [M]Monocytic leukaemias 
BBr9000 [M]Monocytic leukaemia NOS 
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BBr9011 [M]Histiocytic leukaemia 
BBr9012 [M]Schilling-type monocytic leukaemia 
BBr9100 [M]Acute monocytic leukaemia 
BBr9200 [M]Subacute monocytic leukaemia 
BBr9300 [M]Chronic monocytic leukaemia 
BBr9400 [M]Aleukaemic monocytic leukaemia 
BBr9z00 [M]Other monocytic leukaemia NOS 
BBrA.OO [M]Miscellaneous leukaemias 
BBrAOOO [M]Mast cell leukaemia 
BBrA100 [M]Megakaryocytic leukaemia 
BBrA111 [M]Thrombocytic leukaemia 
BBrA400 [M]Hairy cell leukaemia 
BBrASOO [M]Acute megakaryoblastic leukaemia 
BBrAzOO [M]Miscellaneous leukaemia NOS 
BBrz.OO [M]Leukaemia NOS 
ByuDSOO [X]Other lymphoid leukaemia 
ByuD600 [X]Other myeloid leukaemia 
ByuD700 [X]Other monocytic leukaemia 
ByuD800 [X]Other specified leukaemias 
ByuD900 [X]Other leukaemia of unspecified cell type 
ZV10600 [V]Personal history of leukaemia 
ZV10611 [V]Personal history of lymphoid leukaemia 
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Appendix C: UK Bone Marrow Transplant Centres 
Royal Dr Dominic Auto 344 ABERDEEN Infirmary, and Adult Culligan Aberdeen Allograft 
Ysbyty 
736 BANGOR Gwynned Dr David Auto Adult Hospital, Edwards only 
Bangor 
619 BATH Royal United Dr Christopher Auto Adult Hospital, Bath Knechtli only 
Belfast City Auto 
268 BELFAST Hospital, Dr Mary Frances and Adult 
Belfast McMullin Allograft 
Children's Dr Sarah Auto 781 BIRMINGHAM Hospital, and Paediatric Lawson Birmingham Allograft 
Dudley Dr Auto 405 BIRMINGHAM Hospital, Adult Savio. Fernandes only Birmingham 
Heartlands Auto 
284 BIRMINGHAM Hospital, Dr Don Milligan and Adult 
Birmingham Allograft 
Queen Auto Elizabeth Prof. Charles 387 BIRMINGHAM and Adult Hospital, Craddock Allograft Birmingham 
Blackpool 
832 BLACKPOOL Victoria Dr M Macheta 
Auto Adult 
Hospital, only 
Blackpool 
Royal 
765 BOURNEMOUTH B o u r ~ e m o u t h h Dr Sally Killick Auto Adult 
Hospital, only 
Bournemouth 
Avon Auto 
386 BRISTOL Haematology Dr Jenny Bird and Adult 
Unit, Bristol Allograft 
Bristol Auto 
386 BRISTOL Children's 
Prof. David and Adult 
Hospital, Marks Allograft 
Bristol 
386 BRISTOL Bristol Dr Jacaueline Auto Paediatric 
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Children's Cornish OBE and 
Hospital, Allograft 
Bristol 
Addenbrookes Dr Charles Auto 566 CAMBRIDGE Hospital, and Both Crawley Cambridge Allograft 
University Auto 
303 CARDIFF Hospital of Dr Keith Wilson and Adult 
Wales, Cardiff Allograft 
Cheltenham 
398 CHEL TENHAM General Dr Eve Blundell Auto Adult Hospital, only 
Cheltenham 
University Dr Waqas Auto 322 COVENTRY Hospital, Adult Bokhari only Coventry 
Our Lady's Auto 
774 DUBLIN Hospital, Dr Anne and Paediatric Dublin. Rep. O'Meara Allograft Ireland 
Ninewells Dr David Auto 719 DUNDEE Hospital, Adult Meiklejohn only Dundee 
Western Auto 
228 EDINBURGH General Dr Peter and Adult Hospital, Johnson Allograft Edinburgh 
Royal Devon 
and Exeter Dr Claudius Auto Adult 571 EXETER Hospital, Rudin only 
Exeter 
University 
College 
Hospital Dr Patrick Auto Adult 408 GALWAY Galway, Hayden only 
Galway, Rep 
Ireland 
Royal Dr Grant Auto and Adult 244 GLASGOW Infirmary, McQuaker Glasgow Allograft 
Yorkhill Auto 
Children's Dr Brenda and Paediatric 707 GLASGOW Hospital, Gibson Allograft 
Glasgow 
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128 IPSWICH 
254 LEEDS 
713 LEICESTER 
773 LIVERPOOL 
501 LIVERPOOL 
243 LONDON 
721 LONDON 
205 LONDON 
763 LONDON 
216 LONDON 
218 LONDON 
768 LONDON 
539 LONDON 
866 LONDON 
Ipswich 
Hospital, 
Ipswich 
Dr Nick Dodds 
St James' 0 M . 
U ·· r ana nlverslty G.II 
Hospital, Leeds I eece 
Leicester Royal 
Infirmary, Dr Ann Hunter 
Leicester 
Auto 
only 
Auto 
Adult 
and Both 
Allograft 
Auto 
and Adult 
Allograft 
Auto Alder Hey 
Children's, 
Liverpool 
Dr Mark Caswell and Paediatric 
Allograft 
Auto 
Royal Hospital, Dr Richard Clark and Adult 
Liverpool Allograft 
Great 0 rmond 
Street 
Children's Dr Paul Veys 
Hospital, 
London 
Guy's Hospital, Dr Majid Kamzi 
London 
Hammersmith 
Hospital, 
London 
King's College 
Hospital, 
London 
Royal Free 
Hospital, 
London 
Royal 
Marsden, 
London 
St 
Bartholomew's 
Hospital 
London 
St Georges 
Hospital, 
London 
St Mary's 
Hosoital. 
Prof. Jane 
Apperley 
Dr Tony 
Pagliuca 
Prof. Stephen 
Mackinnon 
Dr Mike Potter 
Prof. John 
Gribben 
Dr Mickey Koh 
Dr Josu de la 
Fuente 
Auto 
and Paediatric 
Allograft 
Auto 
and Adult 
Allograft 
Auto 
and Adult 
Allograft 
Auto 
and Adult 
Allograft 
Auto 
and Both 
Allograft 
Auto 
and Both 
Allograft 
Auto 
and Adult 
Allograft 
Auto 
and Both 
Allograft 
Auto 
and Paediatric 
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London Allograft 
The London 
263 LONDON Clinic, Harley Dr Mike Potter Auto Adult 
Street, London only 
Parkside 
Auto 450 LONDON Hospital, Prof Ray Powels Adult 
London only 
University Auto College Dr Kirsty 224 LONDON and Both Hospital, Thomson Allograft London 
Christie Auto 
780 MANCHESTER Hospital, Dr Adrian Bloor and Adult 
Manchester Allograft 
Manchester Auto Children's 521 MANCHESTER Dr Robert Wynn and Paediatric Hosp, Allograft Manchester 
Manchester Auto Royal 601 MANCHESTER Prof. John Yin and Adult Infirmary, Allograft Manchester 
Royal Victoria Dr Graham Auto 276 NEWCASTLE Infirmary, Jackson and Adult Newcastle Allograft 
Royal Victoria Dr Roderick Auto 
276 NEWCASTLE Infirmary, Skinner and Paediatric Newcastle Allograft 
Norfolk and 
391 NORWICH Norwich 
Dr Matthew Auto Adult 
Hospital, Lawes only 
Norfolk 
Nottingham Prof Nigel Auto 
717 NOTTINGHAM City Hospital, and Adult Russell Nottingham Allograft 
John Radcliffe DrTim Auto 
255 OXFORD Hospital, and Adult Littlewood Oxford Allograft 
Derriford Hosp, Dr Simon Rule 
Auto 
823 PLYMOUTH and Adult Plymouth Allograft 
Dorset Cancer Dr Andrew Bell Auto Adult 765 POOLE only Centre, Poole 
757 SALISBURY District General Dr Jonathan Auto Adult 
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Hospital, 
Salisbury 
Cullis only 
Auto 
778 SHEFFIELD 
Children's 
Hospital, 
Sheffield 
Dr Ajay Vora and Paediatric 
Allograft 
Sheffield 
Auto 
778 SHEFFIELD 
Teaching Dr John 
Hospitals NHS Snowden 
Foundation 
and Adult 
Allograft 
Trust 
Southampton Auto 
704 SOUTHAMPTON Gene,ral 
Hospital, Dr Kim Orchard and Both 
394 STOKE 
554 SWANSEA 
608 SWINDON 
708 TAUNTON 
Southampton Allograft 
North , 
St ff d h' Dr Richard Auto 
only a or sire Ch t Hospital, Staffs as y 
Singleton 
Hospital, 
Swansea 
Great Western 
Hospital, 
Swindon 
Taunton and 
Somerset 
Hospital, 
Taunton 
Dr Saad AI- Auto 
Ismail only 
Dr Norbert Auto 
Blesing only 
Auto 
Dr Simon Bolam only 
http://www,bsbmt.org/pages/42-Transplant_Centre_List 
Adult 
Adult 
Adult 
Adult 
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